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Abstract  
This thesis investigated five key areas, which are each presented as a chapter, 
with the major aims and findings summarized below: 
1. The dose enhancement (DE) levels caused by secondary electron emissions from 
gold nanoparticles (AuNPs) were investigated by impregnating spherical AuNPs 
of varying sizes (1.9, 5 & 15 nm) and concentrations (3, 2 and 1 %) within the 
dosimeter alanine. The AuNP/alanine composites were irradiated alongside 
control pellets (alanine) with different quality beams (kV and MV X-rays, 
electrons and protons) and the yield of alanine radicals quantified by Electron 
Paramagnetic Resonance (EPR) spectroscopy. For X-rays (kV and MV) 
increasing AuNP concentration yielded increased DE, and was greatest for kV X-
rays overall (55 % DE for 3 %, 5nm AuNP /alanine composites, which decreased 
to 15 % DE for the 1 %-composites). Similarly, the effects of AuNP size on DE 
levels was clearer for kV X-ray irradiations with a preference for the smaller 1.9 
nm sized AuNPs. Whilst MV X-ray irradiations did show the same AuNP size 
preference, the effects of concentration were more noticeable on DE, which was 
consistent with the literature. Irradiations with charged particles; electrons (6 
MeV) and protons (150 MeV) showed no such dependence on either AuNP 
concentration or size and consistently yielded DE levels of  9 % (electrons) and 
 5 % (protons). These results agree well with recent Monte Carlo simulations, 
(which report little to no secondary electron production) and support cell and 
animal studies for AuNPs irradiated with protons that suggest the higher DE seen 
(ca.15 to 20 %) is due to other processes, such as; the production of reactive 
oxygen species (ROS) generated from the aqueous media in cells.  
Abstract 
2 
2. The suitability of IRGANOX®1076 as a near-tissue equivalent radiation 
dosimeter was investigated for various radiotherapy beam types; kV and MV X-
rays, electrons and protons over clinically-relevant doses. Pellets consisting of 
solid solutions of IRGANOX®1076  in wax (IWSS) were manufactured, which 
yielded a single EPR peak after exposure to ionising radiations, and was attributed 
to the phenoxyl radical obtained by net loss of H•.  Whilst, irradiation of solid 
IRGANOX®1076 produced a doublet signal, consistent with the formation of the 
phenol cation radical, obtained by electron loss. The IWSS pellets gave reliable 
dose measurements for exposures as low as 2 Gy, and a linear dose response for 
all types of radiations examined. Post- measurements for proton irradiations (up 
to 77 days) indicate good signal stability with minimal signal fading (between 1.6 
to 3.8 %), and no significant change with the orientation of the sample. Overall, 
IWSS pellets are ideal for applications in radiotherapy dosimetry, and can easily 
be prepared in wax and moulded to different shapes.
3. Alanine is well known to have an EPR angular dependant response which alters 
its peak amplitudes. It is understood that water bound within alanine affects the 
EPR cavities resonance and promotes radical transformations causing signal 
variation. Means to overcome this include; averaging several measurements at 
different angles within the cavity, and using an internal EPR standard. This work 
examined an alternative method using alanine pellets manufactured with the 
binder (paraffin wax) as the bulk material (approximately 90 %) with alanine 
dispersed within (approximately 10 %). The sensitivity of the amplitude EPR 
signal when rotated within the cylindrical axis of the EPR cavity was investigated, 
with alanine-wax pellets showing a deviation range of; 1.14 to 2.06 % (3 days 
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post-irradiation), which was comparable to commercial alanine pellets; 0.95 to 
1.91 %. After approximately 30 days post-irradiation, the wax-alanine pellets 
remained stable, without being stored in a controlled environment; 1.56 to 1.93 
%, whilst the commercial pellets deviation range had increased; 2.04 to 3.18 % 
despite being kept in a controlled environment. This simple method offers an 
alternative means to overcome EPR signal variation, without having to store the 
wax-samples in a highly controlled environment. 
4. Currently alanine dosimeters are limited in their potential use in radiotherapy, 
mainly by poor sensitivity at low radiation doses (< 5 Gy), which was addressed 
in this work by implementation of a new protocol called ‘spiking’. A set of 
alanine dosimeters were ‘spiked’ with a large dose of radiation, (approximately 
30 Gy of 6 MV X-rays) then subjected to additional doses ranging between 0.5 
and 10 Gy. The radical yield obtained following exposure to ionising radiation 
was measured by EPR spectroscopy and quantified using the central peak of the 
alanine radical species. After subtraction of the contribution from the "spike" 
dose, a linear correlation between both the dose and the area of the central EPR 
signal was obtained for doses of 0.5 Gy (regression value of 0.9890), and for the 
central peak’s amplitude (regression value of 0.9895). Overall, this method 
allowed quantification of doses as low as 0.5 Gy, and offers many advantages as a 
technique; it is easy to perform, requires no complex EPR signal analysis, and (by 
the addition of a large spike dose) is not susceptible to baseline distortions at low 
doses (<10 Gy), and may extend the current usage of alanine dosimeters in 
radiotherapy. 
Abstract 
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5. Finally, the novel formation of the bimetallic nanoparticle (BiMetNP); AuHgNP 
by neutron capture was investigated. Neutron bombardment of AuNPs was 
completed at ANSTO, with gamma spectrum analysis confirming the formation 
of the unstable 198Au isotope. After a sufficient decay time, inductively coupled 
plasma mass spectroscopy (ICP-MS) positively identified the stable 198Hg 
isotope, thus confirming the formation of the BiMetNP product. Analysis of the Ȗ-
decay of the unstable 198Au isotope was perfumed and quantified over time (1 to 
10 hours) using thermo luminescent dosimeters (TLD100s), OSL (optically 
stimulated luminescence) nanoDots® and Gafchromic films (EBT3 and RTQA2-
1010), with good agreement between all techniques. These confirm that neutron 
bombardment of a mono-metallic-nanoparticle offers an alternative means to 
synthesize alloy-type BiMetNP products, which are not readily formed using 
current wet-chemistry methods (which favour a core and layer BiMetNP product). 
Furthermore, the Ȗ- decay of the 198Au isotope has potential as a theranostics 
agent, capable of emitting a localised radiation dose at a tumour site, whilst 
simultaneously allowing real time imaging. 
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Chapter 1: Background, theory and 
literature review
1.1  Overview 
This chapter aims to explain the fundamentals of radiotherapy and how it results 
in cancer cell death. Recent literature on the use of metallic-nanoparticles (MetNPs) 
with external beam radiotherapy was examined, and the physics behind these 
interactions leading to enhanced cancer cell death was investigated. The interactions of 
matter with varying types of radiation were also reviewed. 
Reports of DE caused by AuNPs was reviewed and discrepancies in the 
literature between cell and animal studies compared to computer modelling for AuNPs 
irradiated with protons examined. Advantages and limitations of current dosimeters 
used in radiotherapy were also investigated, with particular focus on the well-studied 
EPR dosimeter alanine, including its current limitations for use in clinical applications. 
Finally, the role of AuNPs and their therapeutic benefit in radiotherapy, and the 
potential advantages of BiMetNPs in this area are also studied.  
1.2  Radiotherapy 
It was estimated by the International Agency for Research on Cancer (IARC) 
that in 2012 there were 7.6 million deaths worldwide due to cancer [1]. In 2015 this had 
increased to 8.7 million deaths worldwide and an additional 
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17.5 million new cancer cases diagnoses [2].  Today radiotherapy is one of the most 
common forms of treatment available to cancer sufferers, with over 50% of people 
diagnosed undergoing radiotherapy at some point in their treatment [1].  
1.2.1  How does radiotherapy work  
Radiotherapy aims to target and destroy cancerous tumours within the body, 
with high precision, whilst minimizing radiation damage to the adjacent healthy tissues 
[3]. To achieve this more personalised modalities capable of accurately targeting the 
cancer have been sought, as well as, agents called radio-sensitizers, which can readily 
enter a cancer tumour and be retained, whilst simultaneously sensitizing the tumour to 
the incoming radiation. Such agents promote greater cell damage and death to the target 
cancerous cells, and minimise damage to the surrounding healthy tissue.  
Radiotherapy is based on ionizing radiation, which is of sufficient energy to 
remove an electron from an atom at the target site, and generate an ion (i.e. causes 
ionisation). The ejected electron, plus the excess energy discharged by the ion as it 
returns to a ground energy state, both act to damage the surrounding target cells. The 
radiation dose delivered to the cells acts in two different ways; either directly damaging 
the cell’s DNA (single or double strand breakage which is more lethal) or indirectly by 
forming radicals from the surrounding water, which also act to damage the cell’s DNA 
[4, 5] (Figure 1-1). Therefore, cancer cell death is not instantaneous but rather can take 
several hours or days to occur [1]. 
The irradiation damage inflicted on a cancer cell results in the inability to divide 
and metastasize, ultimately causing cell death and tumour reduction [4]. Whilst the 
exact mechanism is not completely understood, three known processes are involved: 
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1. Apoptosis- the cells undergo programmed death rather than repair [6].  
2. Mitotic death- the cells fail to segregate correctly, resulting in abnormal 
morphology and multiple nuclei. For solid tumours this is the most common 
means of cell death [1].  
3. Senescence- the cells permanently lose the ability to proliferate, and apoptosis 
follows [1]. 
Figure 1-1. Radiation is either direct or indirect in how it damages cancer cell DNA. 
The incoming photon ejects an electron, which acts directly to damage cancer cells 
DNA or indirectly to form radicals that go on to damage the cancer cells DNA [7].
1.2.2  Photon radiotherapy 
Radiotherapy is administered to a patient either externally using beams 
(electrons, photons etc.) or internally using a radioactive material implanted within the 
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tumour (brachytherapy), which as it decays, delivers a highly localised dose of radiation 
to the tumour [8].  
External delivery utilizes two beam types; photons or particles. Photons (X-ray 
and gamma rays) are the energy quanta with no mass and low linear energy transfer 
(LET) [9]. Since the discovery of X-rays by Wilhelm Konrad Roentgen in 1895 [1, 10], 
their use to treat cancer has revolutionized medicine and provided hope to sufferers for 
over 100 years, thus making photon based radiotherapy the most common form of 
treatment used in the world today. X-rays are generated by a X-ray tube (with an energy 
range of 25-150 kV) [10] or electron linear accelerators (LINAC), which produces high 
energy X-rays and electron beams in the megavolt range (2-25 MV) [11]. The X-rays/ 
photons produced are delivered to the patient during treatment in accordance with a 
treatment plan, which is determined using the known interactions between photons and 
matter (the patient’s tissue), and are described below. Other interaction processes, such 
coherent scattering, are negligible over the range of energies employed in this research 
and are not described. 
1.2.2.1  How photons interact with matter  
The three main processes of how photons interact with matter are; the 
photoelectric effect, Compton scattering and pair-production, and are all descried 
below. In all three processes energy is deposited by the incoming photon, and is 
dependent on; the energy of the incoming photon (beam energy), and the atomic 
number (Z) and electron density (ı) of the target material [4]. The electron that is then 
consequently ejected from an atom within the target material goes on to interact with 
another nearby atom, resulting in further ionisation and excitation events [12]. 
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1.2.2.1.1 The photoelectric effect 
The photoelectric effect occurs when the incident photon collides and transfers 
all of its energy to an inner shell electron. The energy gained by the electron is greater 
than the orbital binding energy of the electron shell it occupies, so the electron is 
ejected from the atom. The newly formed ion is both excited and chemically reactive, 
so to stabilize itself an outer shell electron is moved to the newly vacant inner shell 
position (Figure 1-2), and in doing so releases energy as an X-ray (called a 
characteristic X-ray as it is related to the energy difference between the electron shell 
levels that the electron moves between). This characteristic X-ray may then interact 
with a neighbouring outer shell electron, in a process referred to as a secondary 
photoelectric effect [4], which in turn causes the electron to be ejected and is known as 
an Auger electron (Figure 1-2). 
Photoelectric interactions are dominant for matter of high atomic mass (Z) when 
interacting with photons of energies (E) < 100 keV, [12] and causes the greatest 
damage to cancer cells. The probability of the photoelectric effect occurring is 
therefore dependent on approximately: Z3 / E3 [12]. 
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Figure 1- 2. A diagram of the photoelectric effect. An incident photon removes an inner 
shell electron, whose vacant space is filled by an outer shell electron. The subsequent 
characteristic X-ray is released causing the emission of a second outer shell electron.
1.2.2.1.2 Compton interactions 
Compton interactions are dominant for photon energies between 100 keV to 20 
MeV [8]. The incoming photon only interacts with an atom’s outer shell electrons, and 
only part of its total energy is transferred to the electron. The outer shell electron is 
ejected, whilst the remaining energy is emitted as a scattered photon (Figure 1-3). The 
likelihood of Compton interactions occurring is dependent on a materials electron and 
physical density (as only low energy outer shell electrons are involved) and not its 
atomic number (Z).  
Auger electron
Characteristic X-rays
Incident photon
Photoelectron
K
L
M
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Figure 1-3. The Compton interaction showing the incoming photon interacting with an 
outer shell electron, and the subsequent scattered photon.
1.2.2.1.3 Pair-Production 
Pair-production occurs when the incoming photon gets close to the atomic 
nuclei and interacts with its Coulomb field (or electromagnetic field); resulting in the 
formation of an electron (e-) and positron (e+) pair (Figure 1-4). The electron and 
positron interact with surrounding electrons and rapidly lose energy until the positron 
comes to rest and is annihilated, releasing two photons in opposite directions (which is 
the basis for Positron Emission Tomography (PET) imaging). Whilst, pair-production 
generally requires high energies > 1.02 MeV, high Z materials increase the likelihood 
of pair-production occurring at lower energies [8].  
Compton  
electron
Incident 
photon
K
L
M

ೂವ
Scattered  
photon
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Figure 1-4. Pair-production occurs when the incident photon interacts with the nucleus, 
and results in the production of an electron and a positron pair. 
In the three processes described the transfer of energy from the incoming 
photons causes emissions from the target material in the form of; photoelectrons, Auger 
electrons, characteristic X-rays, Compton electrons, scattered photons and positrons. In 
targeted radiotherapy it is these secondary emissions from photon-atom interactions that 
are utilized to kill cancer cells, particularly low-energy electrons, which deposit their 
energy as radiation dose within the surrounding medium, causing biological damage. 
The amount of radiation that is absorbed or attenuated by a medium (tissue) is 
defined by the equation (1-1), which describes the attenuation of number of 
monoenergetic photons in a well collimated beam.
ܫሺݔሻ ൌ  ܫ௢݁ିఓ௫      (1-1) 
Where: 
I(x) = the intensity of the photons after passing through a material 
Io = the initial intensity of the photons prior to passing through the material  
Incident photon
> 1.02 MeV
K
L
M
+
-
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ȝ = linear attenuation coefficient of the material/medium (cm-1)  
x = the distance travelled by the photons (material thickness)  
Attenuation occurs when the incoming photon intensity (Io) is reduced (I) after passing 
through a material of a given thickness (x). Each material has a linear attenuation 
coefficient (ȝ), which is the probability of an incoming photon being scattered or 
absorbed by the atoms within one cubic centimetre (cm3) of the material [12], and is 
therefore dependent on its density.  
The linear attenuation coefficient is often divided by a material’s density, to yield the 
mass attenuation coefficient (ȝ/ȡ), which is dependent only on the materials atomic 
composition, and is indicative of the photons ‘lost’ when passing through a material [13]. It is 
this process which is used in radiotherapy to determine the amount of radiation dose 
(energy) absorbed by tissue during treatment, and what the likely biological effects are 
for a patient undergoing treatment [12]. 
1.2.3 Particle radiotherapy 
Particle therapies are an important treatment modality and include; electrons, 
protons, neutrons and heavy ions such as carbon ions. Whilst electron beams, which are 
regularly used in the treatment of superficial lesions [14], are easily produced using 
LINACs, other forms of high-mass particle therapy are not as prevalent, with only 29 
particle accelerators worldwide, compared to 7,500 LINACs listed in 2009 [10]. This is 
mainly due to the expensive set-up costs associated with construction and shielding, and 
large areas of land need to house the facility. 
Despite this high-mass particles, particularly protons and heavy ions, are 
advantageous as they deposit more energy deeper within tissue [10], and have very 
different energy profiles compared to X-rays. Unlike photons, particles release minimal 
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energy upon entry into tissue, and instead deposit their energy completely at a point of 
depth called the “Bragg peak”, before exiting with no further energy release (Figure 1-
5). This energy deposition profile is extremely useful in radiotherapy as damage to 
healthy tissue above and below the target site is reduced. Therefore, by selecting the 
particle’s energy, one can control the depth at which the energy is deposited, so that 
maximal damage is inflicted only at the tumour site.  
Figure 1-5. The energy deposition profiles of X-rays (blue), protons (red) and carbon 
ions (green), showing the dose deposition with increasing depth within tissue and the 
Bragg peak at the site of the tumour [15].
Unlike protons and ions, neutrons have no charge and are therefore not as 
predictable in their interactions with matter. Whilst, neutron beams are not commonly 
used in radiotherapy treatments they have shown promise with cancers of the head, 
neck and prostate [16-18], but are generally used as last line treatment, as the risks 
outweigh the potential benefit. 
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1.2.3.1  Neutron interactions with matter
When a collision between a neutron and atomic nuclei occurs one of three 
interactions result: scattering (elastic or inelastic), capture/absorption or fission [19]
(Figure 1-6). For thermal neutrons with energies < 0.5 eV any of these three 
interactions can occur [19], and are described below. 
       
            Absorption           Fission    Scattering 
Figure 1-6. The three main interactions of neutrons: absorption, fission and scattering. 
The neutron is represented as a bullet interacting with a bullseye (matter) [19].
1.2.3.1.1 Neutron scattering
Elastic scattering
Also termed neutron moderation, the collision between the nucleus and matter 
alters the neutron’s direction and energy, so that after multiple collisions the neutron 
has lost all its kinetic energy and stops. In this interaction the nucleus of the atoms 
involved do not become excited and remain in the ground state [20]. 
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Inelastic Scattering 
In this interaction the neutron loses part of its kinetic energy to the target 
nucleus, and if enough energy is transferred the nucleus can become excited, and emit 
secondary radiation (gamma radiation) as it returns to its ground state. 
1.2.3.1.2 Neutron absorption/capture 
In neutron capture the incoming neutron is absorbed into the target nucleus, 
to form the next higher isotope (Atomic mass +1). The nucleus is in an excited state and 
emits gamma rays, and even a proton or alpha particle to stabilize itself [20], and it is 
this process which is utilized in neutron capture therapy [17]. 
1.2.3.1.3 Neutron fission 
Fission occurs when an incoming neutron collides with a large nucleus and 
splits it into smaller nuclei, releasing large amounts of energy. Typically the fission 
products are unequal in mass [20], with neutrons, photons and other products also being 
generated, and it is this process that can result in chain reactions (Figure 1-7). 
Figure 1-7. The fission process showing the incoming neutron colliding with a nucleus 
and forming smaller nuclei and two neutrons for further reaction [21].
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1.2.3.2  Proton interactions with matter 
 Protons interact with the electrons and nucleus of atoms in matter via three main 
processes, as shown in Figure 1-8.  
Figure 1-8. The three interaction of protons with atoms in matter (where p is a proton, e
an electron, n a neutron and p’ a proton from the nucleus): (1) Inelastic Coulombic 
interactions, where small energy losses occur (2) Elastic Coulomb interactions, where 
the proton is deflected from the nucleus by repulsive forces (3) Non-elastic nuclear 
interactions, where the incoming proton is absorbed into the nucleus and other nuclei 
particles are ejected (adapted from [22]).
The energy loss rate of a proton or heavy charged particle as it moves through a 
material is called the linear stopping power (S), and is defined as the quotient of dE and 
dx; where E is the mean energy loss and x is the distance traversed through a 
material/absorber. It should be noted that dx is reflective of only a small part of the total 
 

5HFRLO
Chapter 1: Background, theory and literature review
18 
length travelled by a particle, which deviates from a linear path due to scattering, 
particularly as energy decreases.
Often the rate of energy loss is expressed without reference to the mass density 
of the incident particle, so that the mass stopping power for a beam is more simply 
expressed as is shown in equation (1-2) [22]. 
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ఘǤௗ௫                 (1-2)
   
 Where: 
ȡ = the mass density of the material/absorber.  
However, the Bethe-Bloch equation is most commonly used to describe the 
average energy loss for a heavy charged particle (whose mass is greater than that of an 
electron) as it is absorbed by a material, and is shown in equation (1-3). 
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Where: 
NA = Avogadro’s number 
re = the classical electron radius or the Thomson scattering length  
me = the electron mass  
Chapter 1: Background, theory and literature review
19 
z = the charge of the particle (for a proton z =1) 
Z = the atomic number of the material/absorber 
A = the atomic mass of the material/absorber 
c = the speed of light 
ȕ = v/c where v is the velocity of the incoming particle 
Ȗ = ሺͳ െ ߚଶሻିభమ            
I = a constant that is the mean excitation (ionization) potential of the material/absorber 
į = a density correction used to account for electron shielding by distant electrons, 
which reduces the energy loss 
C = a correction factor that is only needed for low energy particles whose velocity is 
less than or similar to that of the orbital velocity of the bound electrons within a shell. 
The interactions of protons in matter (Figure 1-8) are described in more detail 
below.
1.2.3.2.1 Inelastic Coulombic interactions 
Protons have a much larger mass [23] and energy, relative to the electron’s 
binding energy within an atom. Therefore, when a proton collides with an outer shell 
electron, energy is transferred and excitation and ionization of the atoms occurs 
(number 1 in Figure 1-8), and the electron can travel macroscopic distances if the 
energy transferred is sufficient [23]. Although, the collisions do not significantly alter 
the protons direction, many such collisions result in a total loss of energy, bringing the 
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proton to rest. The distance travelled by the proton in a medium during this process is 
referred to as its range [23].
1.2.3.2.2 Elastic Coulombic interactions 
 In matter, the proton’s path is only significantly changed when it encounters the 
nucleus of the atom (number 2 in Figure 1-8). The repulsive Coulombic elastic 
interaction between the much larger nucleus and proton deflects it from its path and can 
completely alter its trajectory [22].  
1.2.3.2.3 Non-elastic nuclear interactions 
Non-elastic nuclear interactions occur less frequently and require the incoming 
proton to have sufficient energy to overcome the Coulomb force of the nucleus (number 
3 in Figure 1-8). The incoming proton enters the nucleus and irreversibly changes the 
composition of the nucleus by emitting a neutron, proton, deuteron, triton or heavier ion 
[22]. 
1.3 Dosimeters in radiotherapy  
As stated earlier, radiotherapy aims to deliver a highly tailored dose deposition 
to cancerous targets, whilst minimizing the damage to normal healthy surrounding 
tissues [3, 24]. As treatment plans increase in complexity, often involving multiple 
radiation fields that utilize image guided 4D-CT, PET and MRI, so too has the need to 
more accurately measure the radiation dose actually being given, to validate the 
treatment planning outcomes.  
There are many different types of dosimeters currently available for use in 
radiotherapy centres [25], with each possessing its own set of advantages and 
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disadvantages that warrant and limit its use. Radiotherapy centres typically use three 
sets of dosimeters; ionisation chambers (parallel plate and Farmer type) for calibration 
and quality assurance, and TLDs and diodes for in vivo patient dosimetry.  
1. 3.1 The ‘ideal’ dosimeter 
The ideal dosimeter for use in clinical radiotherapy would possess the following 
qualities:  
 small in size (allowing for small-field dosimetry use [26]), 
 independent to the beam energy (so that no correction factors have to be 
applied), 
 immune to changes in the angle of radiation delivery, and the dose rate of 
administration [26], 
 malleable (so custom geometrical forms can be made),  
 accurate at low doses (0.5 to 2 Gy) [27],  
 tissue equivalent in composition (for more reliable dose estimation in humans) 
[25],  
 have long term post-irradiation signal stability that is not destroyed during the 
read-out process, 
 can be read onsite (where the patient is treated), 
 is unaffected by temperature changes during irradiation [25],  
 inexpensive (making it disposable), and  
 easy to read and interpret [25]. 
Whilst many dosimeters are available, one that fulfils the majority of these 
requirements is still sought. In Sections 1.3.1.1 to 1.3.1.5 some of the most commonly 
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used radiotherapy dosimeters are described and their advantages and disadvantages 
presented. 
1.3.1.1  Thermo-luminescent dosimeters (TLDs) 
TLDs usually consist of lithium fluoride doped with a combination of metal 
impurities; typically magnesium and titanium. When irradiated, electrons absorb energy 
and transition from the low-energy ‘Valance band’ to the higher-energy ‘Conduction 
band’ (Figure 1-9). However, when the electrons release their excess energy in an 
attempt to return to their original band they become trapped in an ‘electron trap’ formed 
by the metal impurities present [25]. During the read-out process, when the TLDs are 
heated, the electrons escape the trap and emit light as they return to the Valance band 
(Figure 1-9), which is directly related to the amount of radiation received.  
Figure 1-9. The process that occurs for electrons within a TLD; energy is absorbed and 
the electrons become trapped (after de-excitation from the Conduction band. The read-
out process returns the electrons to the lowest-energy state by creating a visually 
detectable measurement indicative of the radiation dose received.
Ionising 
radiation
e- e-
Valence band
Conduction band
Electron 
trap
Visible light
Heating during read-out
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TLDs are favoured due to their small size (which can be as small as 1mm3), no 
cables are needed, reusable after annealing, are independent to the direction of radiation 
received and the dose rate used, making them popular for in vivo dosimetry [25, 28]. 
However, TLDs suffer from post- irradiation fading, delayed read-out (approximately 
one hour), non-tissue equivalence, higher sensitivity to low energy photons (which must 
be corrected for), require high temperature annealing before use, have poor 
reproducibility (±2%) [25, 26, 28] and UV/visible light exposure can elicit both an 
increase in energy absorption, as well as signal reduction within the dosimeter [26].  
1.3.1.2  Diodes 
Diodes are often employed in specialized dosimetry roles, such as the 
verification of modulated beams and in vivo dosimetry. Typically, the diodes used in 
radiotherapy are either a diamond or silicon [26] semi-conductor that consist of three 
different zones (Figure 1-10). The first zone is the ‘p-type’ zone, which is doped with 
group 13 elements (within the p-block of the periodic table), and includes the elements; 
boron and gallium. On the other side of the diode is the ‘n-type’ zone, which is doped 
with group 15 elements (within the n-block of the periodic table), and include; 
phosphorous and arsenic. The p-type and n-type areas are separated within the diode by 
an area called the ‘depletion zone’ (Figure 1-10) where under steady state conditions 
few free electrons exist within this region [25]. When irradiated, electrons are excited 
into the conduction band; however, those in the p-type and n-type areas have an 
extremely short lifetime and recombine or relax very quickly, so that only the electrons 
in the depletion areas contribute to the measured current. Therefore, the more radiation 
dose received, the greater the number of electrons produced, and the stronger the 
current detected [25, 28]. 
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Figure 1-10. The irradiation of a diode produces electrons in the depletion zone, which 
cross to the n-type zone and generate a current. 
Diodes are advantageous as they are highly sensitive, small in size, can be read-
out instantly and have excellent reproducibility [25, 28]. However, like TLDS, diodes 
suffer from non-tissue equivalence, as well as, energy dependence, a narrow range of 
temperature usage (although this can be corrected for), need cables, pertubates the 
treatment beam [28] and requires ongoing recalibration due to radiation damage. 
1.3.1.3  Fricke dosimeters and PRESAGE® 
Radiotherapy has also widely employed chemical detectors, which utilize a 
reporter chemical to signal an interaction with ionizing radiation. Examples include; 
Fricke dosimeters and gels, which undergo changes in their optical density and 
magnetic properties when aqueous Fe2+ is converted to Fe3+. Another example is 
PRESAGE®, which undergoes a visible colour change, from which the absorbance 
p-type n-type
Depletion
zone
Incident ionising radiation









-
-
-
-
-
-
--
-- -
-
-
-
Ion current
ve-ve
- -
Chapter 1: Background, theory and literature review
25 
difference can be linearly related to the amount of absorbed radiation dose received 
[29]. PRESAGE® contains a halogenated carbon species (usually chloroform or 
bromoform) that when irradiated cleaves the halogen-carbon bond to form a radical 
species, which then reacts with a reporter dye (usually leucomalachite green (LMG) 
[29] to produce an observable colour change. However, both these types of dosimeters 
are affected by UV light and temperature, which can alter the signal, producing large 
uncertainties in measurements. 
1.3.1.4  Ionisation chambers 
The most commonly used detector in radiotherapy centres worldwide is the 
ionisation chamber, and is employed as a calibration standard for determining the 
absorbed dose delivered by an external beam [25]. Typically, the chamber is open to air 
or filled with a noble gas; such as helium, neon, or argon [28], with a voltage applied 
across two electrodes; the anode (positive) and cathode (negative), to create an electric 
field [28] (Figure 1-11).  
Often the electrode plates are positioned parallel to one another, which is a 
design feature of the commonly used ‘parallel plate ionisation chamber’[28]. The other 
type often used is the cylindrical chamber designed by Farmer, also known as the 
‘thimble’ due to the chamber shape, which ranges in volume size from 0.1 and 1 cm3
[30]. Incoming ionising radiation (photons, electrons, charged particle etc.) enters the 
chamber and ionises the air or gas molecules within, producing an ion pair (typically a 
positive ion and an electron), which migrate to the oppositely charged electrode and 
produce a current or an electrical pulse depending on the design.   
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Figure 1-11. A schematic of the ionisation chamber showing the migration of the 
positive ions (red) to the negative cathode and the electrons (black) to the positive 
anode after an ionisation event within the chamber.
As the charge detected is related to the number of ion pairs formed, the dose 
deposited by the incoming ionising radiation can be determined according to the 
equation (1-4) [25]: 
ܳ ൌ ௉೔೚೙௘ఘ௩஽ௐ            (1-4)
Where: 
Q = the charge collected 
D = the mean dose deposited  
v = the volume of air within the chamber 
Pion = the correction factor for ion recombination 
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e = the electron charge  
ȡ = the air density 
W = the mean energy needed in air to produce an electron-ion pair 
A correction factor for ion recombination (Pion) is needed for instances when the 
ions formed do not migrate to the electrode plates fast enough and recombine. This 
occurs when the voltage applied to the chamber is too low or the dose rate is too high, 
such that the electric field is unable to collect all the ions formed, and underestimates 
the dose deposited. Similarly, if the voltage applied is too high; secondary ionisation 
events can occur, causing an overestimate of the energy deposited [25]. Correction 
factors for standard environmental conditions are also applied and include; temperature 
(at T0 22 °C) and pressure (at P0 101.33 kPa) but are not required for relative humidity 
over the range 20 to 80 % [31]. 
1.3.1.5  Radiochromic films 
The use of radiochromic films in medical radiation dosimetry has increased 
greatly since their introduction in the early 1990s [25], with current commercial films 
having usable dose ranges from less than 1 Gy and up to many kGy [32]. Because of 
their high sensitivity radiochromic films are often employed in radiotherapy for two 
dimensional (2D) imaging of dose distribution and can provide high spatial resolution. 
Whilst film is sensitivity to visible light, energy dependent and non- tissue 
equivalence[25], this can reduced by storing exposed films in darkness and applying 
correction factors. 
The films consist of an active layer; a poly-diacetylene based crystalline solid 
material, [25] positioned in-between two polyester layers. When exposed to ionising 
Chapter 1: Background, theory and literature review
28 
radiation polymerisation of the crystalline solid material (active layer) occurs to 
produce a permanent, visible colour change, without the need for film development [25, 
33]. The films are typically scanned in transmission mode, and the amount of light 
transmitted through the film is relatable to dose. However, as polymerisation is a slow 
process, the films must be left for a minimum of 6 hours and maximum of 24 hours before 
being scanned and quantified [33]. 
As stated earlier, each dosimeter type listed has advantages and disadvantages 
associated with its use in clinical radiotherapy. Another class of dosimeters are the EPR 
based dosimeters, of which alanine is probably the best known and studied, and its 
limits and advantages are examined below.   
1.3.2 EPR dosimeters 
In 1944 Soviet Russian scientist Evgeny Zaviosky first observed EPR in 
paramagnetic samples [34], allowing for the identification and quantification of free 
radical species present within a sample. EPR is based on the fact that every electron has 
a magnetic moment and spin state (ms), which when present in a magnetic field will 
either align itself parallel (lower energy state ms= െͳȀʹ) or anti-parallel (higher energy 
state (ms= ൅ͳȀʹ) with the field [35]. As a radical species has a single unpaired 
electron, it is able to move between the energy states when exposed to an increasing 
magnetic field and constant microwave energy and fixed frequency. Therefore, when 
the energy difference between the two energy states (parallel and anti-parallel) matches 
that of the applied microwave power (Figure 1-12), the unpaired electron is able to 
transition either by absorbing (lower to higher) or emitting (higher to lower) energy as a 
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photon. As more electrons are found in the lower energy state [35] an overall absorption 
of energy occurs, which generates the EPR spectrum.
Figure 1-12. The change in energy states between parallel and non-parallel alignment 
electron spin occur when an increasing magnetic field is applied at a constant 
microwave power and frequency [35].
Today EPR based detectors (Figure 1-13) are used for both industrial and 
clinical radiation applications, and rely on a chemically reactive species forming a 
stable radical when irradiated, which is directly related to the radiation dose received. It 
is also very important that the radical species does not undergo further reactions post-
irradiation. 
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Figure 1-13. A Bruker EPR spectrometer indicating the main features shown.
1.3.2.1  How an EPR spectrum is formed 
A material can only be considered useful for EPR dosimetry if after exposure to 
ionising radiation a large amount of stable unpaired electron radical species are formed, 
which do not regenerate or form other species over time. Such a radical species will 
produce a detectable EPR signal, and the amount or concentration of which is directly 
related to the absorbed dose received, which allows for quantification.  
Each radical species formed has its own unique EPR spectrum, which is defined 
by the following characteristics; shape, line width and resonance field (Figure 1-14). 
Electromagnets 
Sample cavity 
Modulation coils 
Microwave generator 
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Figure 1-14. The main characteristics of an EPR spectrum used to quantify the radical 
species (adapted from [36]).
Five types of EPR spectrometers are used routinely worldwide (Table 1-1). An 
increase in sensitivity comes with an increase in frequency, resulting in a smaller EPR 
resonance cavity, and consequently smaller useable sample size. Furthermore, increased 
sensitivity also increases the cavities sensitivity to water present within a sample, due to 
microwave absorption, which adversely affects the resonance and spectrum produced 
[37].  The X-band is the most commonly used EPR spectrometer worldwide [36] as it 
has a good balance between sensitivity and allowable sample size. Whilst it does not 
have the sensitivity of the W and Q bands the effects of water content within the sample 
are not as large, and it is more sensitive than the lower frequency bands; L and S.  
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Table 1-1 The frequency (GHz) and corresponding resonance magnetic fields (mT) for 
various EPR spectrometers in use [36].
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1.3.2.2  Alanine/EPR dosimeters  
Historically alanine dosimeters have been used for high dose (kGy scale) food 
irradiation and medical equipment sterilisation. More recently alanine has been 
successfully used in radiotherapy [38-43] to doses of approximately 5 Gy, and 
extensively reviewed for this application [25, 44]. Alanine dosimeters are an attractive 
option for clinical radiotherapy as they have many of the ‘ideal’ dosimeter properties: 
tissue equivalency, good stability post-irradiation (when stored correctly), as EPR is 
non-destructive they can be repeatedly scanned without degradation, are independent of 
the energy of radiation used [41], dose rate, angle of irradiation, and are commercially 
available and relatively inexpensive.  
Alanine dosimeters also show promise for use with high LET radiation in 
radiotherapy, such as protons and heavy ions [42, 45], which is a high growth area in 
radiotherapy. Onori et al. [45] reported good linearity, reliability, and sensitivity down 
to 5 Gy for a 62 MeV proton beam (within the therapeutic range) for alanine 
dosimeters. Additionally, Michalec et al. [42] more recently documented the full 
dosimetry characteristics of alanine for 60 MeV proton beams.  
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1.3.2.2.1. The alanine EPR spectrum  
When alanine is irradiated three radical species are formed; denoted as R1, R2 
and R3 (Figure 1-15).  
Figure 1-15. The three alanine radicals R1, R2 and R3 formed following irradiation of 
alanine; R1 is the main stable radical species formed [46].
The resultant alanine EPR spectrum consists of five peaks in a 1:4:6:4:1 ratio 
[47] (Figure 1-16). The large central peak is due to the unpaired electron on the central 
carbon, formed by deamination, which is the R1 radical [46] (Figure 1-15), whilst the 
remaining peaks are due to hyperfine interactions between the R1 radical and the 
surrounding four hydrogens, according to the structure CH3-C·H-COO [41]. 
Measurements of the central peak’s amplitude, are directly related to the amount of 
radiation received [48]. 
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Figure 1-16. The EPR signal for alanine, showing the large central peak, from which 
amplitude measurements are made.
Heydari et al. [46] showed that at room temperature R1 contributes 
approximately 55% of the EPR spectrum, R2 approximately 35% and R3 the remaining 
10% [46] (Figure 1-15). Whilst, increasing the temperature was shown to change this 
composition and the EPR spectrum formed. Work by Dolo and Feaugas [49] also 
showed that water diffusion in and out of alanine, plus interactions between the three 
radicals formed all act to affect the resultant spectrum and most importantly, the 
amplitude of the central peak (Figure 1-16).  
1.3.2.2.2 Limits of alanine dosimeters 
Currently, alanine dosimeters are limited by poor sensitivity at doses below 5 
Gy [26, 50], and much effort has been made to remedy this. Simply increasing the mass 
of alanine is not preferable [48], as this increases the dosimeter size, which limits its use 
in radiosurgery and intensity-modulated radiation therapy, where narrow photon beams 
are used [26, 39],. The inclusion of additives such as; metal-nanoparticles (MetNPs) 
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[39, 51], gadolinium [50] and potassium iodide [51] to increase the amount of 
secondary electrons generated (thus increasing the amplitude of the resultant EPR 
spectra) is also limited by the energy of radiation used and therefore its usefulness. As 
materials with high atomic numbers have increased physical density this increases the 
probability of photoelectric interactions (and the production of Auger electrons) for low 
energies (kV), whilst for higher energy X-rays (MV) and charged particles the Compton 
Effect dominates. As well, the addition of foreign materials alters the alanine 
composition and hence tissue equivalence, making it non-comparable to human tissue 
[41]. 
An alternative approach to improving the sensitivity of alanine dosimeters is to 
concentrate on the protocols used for measurement of the EPR spectrum and 
quantifying the signal due to the radical species. Haskell et al. [52] and Hayes et al. 
[48] have successfully measured approximately 100 mGy doses using commercial 
alanine dosimeters using a complex multi-step EPR procedure that requires several days 
to complete. Later work by Nagy et al. [53] reduced the procedure to a single day with 
an overall uncertainty of 1.5 to 4.0 % (1 standard deviation) for doses between 1 to 5 
Gy, however, this adaptation requires modification of the EPR spectrometer. Higher 
sensitivity can be obtained by the use of EPR spectrometers with a higher microwave 
frequency where Chen et al. [54] demonstrated  measurement of 5 Gy doses for 
miniature alanine pellets (1.5 mm diameter x 2.5 mm length) containing approximately 
2 mg DL-alanine using a K band (24 GHz) spectrometer. Later Chen et al. [55] 
manufactured L-alanine/2-methylalanine blended dosimeters (approximately 2.4 to 3.2 
mg) and measured doses as low as 0.5 Gy [47]. While this approach is attractive, there 
is a significant increase in cost and maintenance of the EPR spectrometer in moving 
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from conventional X-band (9.5 GHz) to K-band and the use of higher frequency 
microwave sources is currently not practicable in clinical applications.
1.3.2.2.3 Alanine dosimetry in the future? 
For alanine to become a realistic alternative to current dosimeters used in 
radiotherapy (ionisation chambers, TLDs, diodes), it needs to gain sensitivity for low-
dose measurements (approximately 0.2 to 10 Gy), and be read using the more 
commonly available X-band EPR spectrometer. 
1.4 Nanoparticles in radiotherapy  
The ability to synthesise materials on the nanometre scale has greatly changed 
the direction of many areas of research and development in recent times (Figure 1-17). 
The unique properties of materials when present in the nanoscale, such as electrical 
conductivity, magnetic properties and optical changes has led to increased research in 
fields such as; material technologies, biological applications, and electronics [56].  
Figure 1-17. The nanometre scale showing size comparisons relative to other items 
(adapted from [57]) 
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Today the investigation of potential applications of MetNPs as imaging and 
therapeutic agents in radiotherapy is ever growing and well investigated [58-61]. 
Nanoparticles often possess unique properties, which are not present in the bulk 
material. Given that they have a larger surface-to-volume ratio, which increases with 
decreasing particle size [62], more surface atoms can partake in a given interaction. 
This differs to the bulk material as the majority of its atoms are locked within the inner-
central framework and unable to participate. 
1.4.1 Gold-nanoparticles (AuNPs) 
The interactions of AuNPs have been well studied in medical-radiation 
applications [24, 39, 63-67] mainly with photons, and are of interest as they possess 
several properties that make them attractive: 
 High atomic number (Z=79), which increases the probability of 
photoelectric interactions occurring (the main process by which cancer 
tumours are damaged). 
 A naturally high affinity and retention within the leaky microvasculature 
system of tumour cells [68] due to strong binding affinities for thiol (-SH) 
and amine groups (-NH2) [61, 69, 70]. As tumour blood vessels have poorly 
aligned endothelial cells, the AuNPs can readily enter and are retained due to 
poor lymphatic drainage [71], making them a useful target for external beam 
radiotherapy [71, 72] (Figure 1-18).  
 AuNPs  are highly biocompatible and typically less toxic [73]  than their 
chemical counterparts used in cancer treatment [58]. 
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Figure 1-18. A depiction of the entry of nanoparticles into the leaky microvascular 
system of tumours and retention within the tumour cells (adapted from [74]).
The use of gold and AuNPs as radiosensitizers was first identified by Hainfeld 
et al. [4], during in vivo computed tomography (CT) studies, which showed at  energies 
between 10 to 100 keV gold absorbed approximately 100 times more X-rays than soft 
tissue. Therefore, it was realized that if gold was present at the tumour site, one could 
significantly increase the localised dose received by the tumour without any adverse 
effects to the healthy surrounding tissue. Similarly, Monte Carlo simulations suggest 
that when AuNPs are uniformly distributed in a tumour they can increase the 
production of secondary electrons (that damage cells) using a 50 kV X-ray by a factor 
of 2000 when compared to an equivalent volume of water [24, 75]. 
However, the DE levels caused by AuNPs when irradiated with ions and protons 
are still under investigation. Differences in the reported benefit between cell and animal 
studies [24, 76, 77] and computer simulations [59, 78] suggests that the processes 
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occurring are not completely understood, and the actual benefits of proton and ion 
radiotherapy are not clear [79]. Whilst photon ionization is homogeneous and the 
interactions with nanoparticles are highly probable this is not the case for particle 
beams, as the likelihood of interactions occurring are reduced, and therefore, the 
production of Auger electrons [79]. 
Kim et al [80] reported approximately 20 % DE for 14 nm AuNPs in in vivo
when irradiated with 40 MeV protons, and suggested that the increase is due to a 
cascade effect of Auger electrons being released, and the generation of ROS as shown 
in Figure 1-19.  
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Figure 1-19. The first diagram shows the proposed mechanism for proton-irradiated AuNPs 
generating ROS. Protons interact with AuNPs and produce Auger electrons, which generate 
water radicals in the aqueous media. The lower diagram depicts how gold atoms eject 
electrons and emit X-rays after proton irradiation, which may cause other gold atoms 
in close proximity to release more secondary electrons [80].
Whilst Monte Carlo simulations by Walzlein et al. [79] found for proton 
energies of 2, 80 and 300 MeV that the radial dose contributions were low 
(enhancement factor of two), occurred within nanometre distances from the MetNP, and 
could only be partially attributed to Auger electron production. Similarly, Jeynes et al. 
[81] used simulations and cell studies to compare the production of secondary electron 
emissions by AuNPs (50 nm diameter) when irradiated with protons ranging in energy 
from 1 to 250 MeV and kV X-rays (maximum of 250 kV). Whilst enhancement was 
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seen for kV X-rays, AuNPs only produced modest amounts of secondary electrons 
when irradiated with protons. 
Based on these reports the DE by AuNPs irradiated with protons is of interest, 
and warrants further investigations to accurately assess the relative contribution of a 
radical based mechanism for the enhanced efficacy of combined AuNP proton beam 
irradiation. 
1.4.2  Bimetallic-nanoparticles (BiMetNPs) 
The study of BiMetNPs in many fields has increased in recent times due to their 
unique physiochemical properties, interactions and composition [73, 82, 83], which is 
often greater than the properties of the individual MetNPs they consist of [73, 84]. For 
this reason BiMetNPs are of interest for use in radiotherapy as they could increase the 
dose deposition to a target, and have greater uptake and retention properties. Current 
wet-chemistry methods to synthesize BiMetNPs are limited by the type of BiMetNPs 
produced; which either consist of two metals present in a NP as an alloy or one-metal 
present at the NP core with a second-metal layered on top. The latter method is 
favoured as it is easier to separate the BiMetNP product from the reaction mixture. 
Overall, the main wet-chemistry methods used to produce BiMetNPs are:  
 A one-pot reduction of two different metal salts with a reducing agent, typically 
sodium borohydride [73, 85], followed by the addition of a protective capping 
agent like PVP.  
 The layered addition of a secondary metal by deposition onto a MetNP core 
[86].  
 The generation of metal ions using high-energy lasers or electron beams, which 
are then added to a solution of soluble MetNPs [82, 83, 87].  
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However, these methods are limited by the following issues: 
 Time consuming- requiring long preparation and reaction times. 
 Require large amounts of reducing agents and solvents - which have an 
economic and environmental impact. 
 Often produce metal salt by-products- making separation of the products 
difficult [88]. 
Due to these limitations alternative methods for BiMetNP production have been 
sought, which ideally favour BiMetNPs of an alloy composition rather than the layered 
composition. As well, a method that does not use harmful solvents or reducing agents 
(which form salts and by-products) is preferred.  
1.5 Thesis objectives  
The objectives of this thesis are to provide greater insight into key areas of 
radiotherapy research that is both novel and innovative. The five main areas 
investigated are divided into chapters with the objectives of each summarised below: 
1.5.1 Chapter 2- Dose enhancement due to AuNP size, concentration 
and beam quality 
This chapter aimed to quantify and fully investigate the levels of radiation DE 
caused by the presence of AuNPs using alanine as a phantom and dosimeter. As DE 
depends on various factors related to the AuNP, such as; size, concentration, beam 
energy etc. it was decided to systematically investigate each parameter. AuNPs are 
advantageous as they have been well studied in the literature. Recent discrepancies 
between the levels of DE attributed to AuNPs when irradiated with protons as reported 
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by Monte Carlo simulated algorithms- which are fully physics based- are in stark 
contrast to high DE reported for in vitro and in vivo studies. Therefore, it was this 
discrepancy that was investigated and an area of focus for this chapter.  
By incorporating AuNPs within an alanine dosimeter, such that the alanine acts 
as a reporter for the generation of extra secondary electrons due to the presence of the 
AuNPs, a direct comparison to alanine (without AuNPs present), when irradiated under 
the same conditions, would allow for differences in DE to be quantified. Specifically 
this method allowed the following objectives to be investigated: 
 The effects of beam quality/ LET (as used within clinical radiotherapy) on the 
generation of secondary electrons when irradiating AuNPs over clinically 
relevant doses (2 to 20 Gy). 
 The effects of AuNP concentration on the amount of DE observed when 
irradiating with different radiotherapy beam types over clinically relevant doses.  
 The effects of different sized AuNPs (manly smaller sizes which are not well 
studied) on levels of DE, again when irradiating with different radiotherapy 
beam types over clinically relevant doses. 
1.5.2 Chapter 3- Examination of the novel dosimeter 
IRGANOX®1076 
The novel dosimeter IRGANOX®1076 has shown potential for use as a 
radiotherapy dosimeter due to its simple EPR spectrum, good long term post-irradiation 
signal stability, near tissue equivalence, low toxicity and low cost.  Therefore, this work 
examined the following objectives to assess its suitability as a radiotherapy dosimeter: 
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 The response of IRGANOX®1076 to clinical beams; including kV and MV X-
rays, protons and electrons over clinical doses (2 to 20 Gy). 
 The stability of the IRGANOX®1076 radical and resultant EPR signal produced 
over time. 
 The deviation in EPR angular response of the signal produced when rotated 
around the central axis of the EPR cavity, and hence its orientation dependence. 
As IRGANOX®1076 forms only a single radical species and is hydrophobic; it 
is less likely to be affected by water content and radical transformations as 
alanine.  
 Comparisons of the IRGANOX®1076 EPR signal with alanine samples 
irradiated under the same conditions and clinical doses. 
1.5.3 Chapter 4- A comparison of the EPR angular response of 
alanine and IRGANOX®1076 
Means to reduce the EPR angular response of alanine when rotated within the 
EPR cavity are to be investigated. As alanine is highly hygroscopic, exposure to air 
moisture is thought to both promote post-irradiation radical transformations, and affect 
the samples water content, which alters the EPR cavity resonance. Together these 
effects change the EPR spectrum and the amplitude of the central peak, and reduce 
measurement reliability. Therefore, by encasing alanine within wax, such that the wax 
acts as a barrier between alanine and the environment, water absorption is limited, and 
may reduce the EPR angular response. This chapter investigated the following 
objectives: 
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 The orientation dependence (angular response) of alanine-wax pellets, 
commercial alanine pellets and alanine powder samples when rotated around the 
central axis of the EPR cavity. 
 Compare the EPR angular response of the alanine-wax samples to that of the 
novel dosimeter IRGANOX®1076 (also encased in wax).
 The stability of all samples (alanine-wax pellets, commercial alanine pellets, 
alanine powder and IRGANOX®1076-wax pellets) over time.f 
 Determination of suitable storage conditions for the wax pellet samples to 
maintain signal reproducibility. 
1.5.4 Chapter 5- Investigation of the novel method ‘spiking’ to 
determine low doses (<2 Gy) using alanine dosimeters 
A novel method to improve alanine’s usage as a clinical dosimeter in 
radiotherapy centres was evaluated. Alanine has been used extensively in industries 
requiring high dose radiation monitoring (kilo-Grey scale) such as medical equipment 
and food sterilization. However, more recently attempts to use alanine as a routine low-
dose dosimeter in clinical environments or as a secondary standard have been 
examined, mainly because of its unique properties; such as near tissue equivalence and 
low-cost. Currently, its application was limited by the distortion of the EPR signal 
produced at doses below 5 Gy, preventing an accurate measurement of the central 
peak’s (P1) amplitude. To overcome this issue the following objectives were examined: 
 Assessment of the novel method ‘spiking’; whereby a large spike dose is given 
to a set of alanine dosimeters prior to a smaller dose (ranging from 0.5 Gy to 10 
Gy) for determining low doses of radiation as used in a clinical environment. 
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 Quantification of the EPR signals produced following each set of irradiations, 
such that suitable EPR conditions are determined to allow for detectable 
differences in the alanine radical species produced.  
 Establishment of a reliable spiking protocol that does not require complex EPR 
post-analysis to be conducted. 
1.5.5 Chapter 6- The formation of bimetallic-nanoparticles by neutron 
capture  
Finally, this chapter investigated the novel synthesis of BiMetNPs by neutron 
bombardment, and the formation of an alloy-type product. AuNPs underwent long and 
short neutron exposures and the following objectives were investigated: 
 Determination of the 198Au atoms formation following neutron bombardment 
using gamma spectrum analysis to confirm neutron capture had occurred. 
 Identification of the mercury isotope (198Hg) using ICP-MS after sufficient 
decay times to confirm the formation of the BiMetNP product. 
 Detection of the gamma-decay process of the unstable 198Au isotope to 198Hg 
using different detectors available, to confirm its potential usage as an imaging 
agent. 
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Chapter 2: Dose enhancement due to 
AuNP size, concentration and beam 
quality 
The majority of the contents of this chapter has been published in two publications. 
Refer to Appendices i and ii for permission to reproduce published materials.
2.1 Introduction 
The chief aim of this research was to measure the effects of spherical AuNPs of 
different concentrations and sizes on the delivered dose by various radiations with 
emphasis on protons. In this study AuNPs/alanine composites were prepared based on 
previous work by Guidella and Baffa [47] which gave a qualitative estimate of the DE 
of alanine resulting from the inclusion of MetNPs when exposed to low energy X-rays. 
In addition to the more limited energy range of this study, the experimental conditions 
did not meet the requirements needed to allow quantification of the dose, and are 
addressed in this work. 
The DE levels caused by the AuNPs are estimated by comparison of the EPR 
spectroscopy signal’s amplitude for alanine, to alanine impregnated with AuNPs and 
radiated with the same exposure “dose”, and the experimental conditions satisfy full 
scatter conditions.  
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2.1.1 Alanine dosimetry 
Alanine dosimeters and their use as dosimeters are discussed in Section 1.3.2.2, 
including properties that make them an attractive option for clinical radiotherapy, and 
current limitations at low dose ranges. Given that alanine dosimeters have also been 
tested for high LET radiations, such as protons and heavy ions [42, 45], alanine is a 
suitable dosimeter for the investigations proposed, showing good linearity, reliability, 
and sensitivity down to 5 Gy for a 62 MeV proton beam [45].  
2.1.2 AuNP DE size and concentration: kV and MV X-rays
The mechanisms responsible for DE when irradiating AuNPs with kV and MV 
energy range X-rays are well known [47, 77] and presented in Section 1.2.2.1. In brief; 
low energy X-rays (kV range) when interacting with gold, which has a high atomic 
number (Z =79), favour the photoelectric effect, resulting in increased production of 
secondary electrons; photoelectrons (high energy) and Auger electrons (low energy) 
[89]. The emitted electrons deposit energy, which either directly damages DNA; via 
single or double stranded breakages [4] or indirectly by generating aqueous radicals 
(ROS), which also damage DNA and cause cell death [81, 90, 91]. At higher energies 
(6 to 10 MV range) DE for AuNPs decreases [4, 56, 77, 92] as Compton interactions 
dominant, and are not dependent on the atomic number.  
Whilst, this process is well studied for both in vitro and in vivo using kV and 
MV energy ranges, conflicting results for the role of AuNP size and concentration are 
evident due to differing cell lines, tumour permeability (how easily the AuNPs can enter), 
retention factors (how long the AuNPs are retained within the tumour cells) (Section 1.4.1), 
AuNP capping agents and the irradiation beam energy used [93-97]. Likewise, 
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numerous Monte Carlo simulations have also investigated DE levels due to AuNP 
concentration for kV energies.  
However, four recent studies have focused on both AuNP concentration and 
size, when irradiated with kV and/or MV X-ray beams [89, 92, 98-100]. The findings 
for kV energy X-ray irradiations show that DE increases with increasing AuNP 
concentration, and decreasing AuNP size, whilst for MV energy X-rays; DE increases 
with increasing AuNP concentration, however, AuNP size is not as important and the 
effects are less than that for concentration. Lechtman et al. [99] examined AuNPs of 
1.9, 5, 30 and 100 nm sizes, which were irradiated with various brachytherapy seeds, 
300 kV and 6 MV X-rays. As expected 6 MV X-rays showed the lowest DE, but for 
lower energy photons the smallest AuNP (1.9 nm) yielded the highest DE levels.  
Similarly, Hossain and Su [101] used 50, 110 and 300 kV X-rays to irradiate 
AuNPs (also bismuth and platinum-nanoparticles) ranging in size from 2 to 400 nm, 
and found that DE levels increased with decreasing MetNP size or increasing 
concentration (DE for 7 mg/g of BiNP was 1.3 when irradiated with a 50 kVp source, 
which increased to 9.99 for 350 mg/g concentrations). Similarly, Mesbahi et al. [92] 
reported in 2013 comparable findings for kV energy irradiations of AuNPs (30, 50 and 
100 nm). AuNPs (30 nm, 7 mg/g) irradiated with a 70 keV source yielded DE of 1.5, 
which increased to 2.3 for 18 mg/g AuNP concentrations. However, for MV X-rays, 
whilst a small increase in DE was evident for increasing AuNP concentrations, no such 
relationship was found for AuNP size (DE was 1.01 for 30 nm AuNPs irradiated with 6 
MV X-rays, and remained unchanged for 50 nm and 100 nm AuNPs) [92]. The same 
results were seen by Hwang et al. [98] for MV X-rays (4, 6, 10 and 15 MV) used to 
irradiate AuNPs gadolinium and iodine nanoparticles, ranging from 25, 50, 75, 100 and 
125 nm in size at concentrations of 7, 18 and 30 mg/ g (of water), with an increase in 
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nanoparticle size affording only a modest increase in DE (DE for 6 MV X-ray 
irradiations were 1.017 for 25 nm AuNPs, and increased to 1.029 for 125 nm AuNPs), 
whilst increasing MetNP concentrations had a much greater effect (DE was 1.017 for 7 
mg/g of 25 nm AuNPs irradiated with 6 MV X-rays, and increased to 1.032 for 30 
mg/g) [98].  
2.1.3 AuNP DE size and concentration: charged particles (electrons 
and protons)
The DE that occurs when irradiating AuNPs (and other high Z elements in 
metallic-nanoparticles) with charged particles, such as electron and proton beams, is not 
as well understood as for photons [79]. Limited studies are reported for electron 
irradiations, but Rahman et al. [24] reported approximately 4 % DE for 1.9 nm AuNPs 
measured using cells, which is similar to in vivo measurements by Chang et al [102] 
who reported 5 to 10% DE in tumour bearing mice containing AuNPs, irradiated with 
electrons.  
However, significant DE for proton irradiations of AuNPs has been reported for 
cell/animal studies; Kim et al [80] measured a ca. 20% DE for 14 nm AuNPs with 40 
MeV proton beams in in vivo studies, which was attributed to an increase in the levels 
of ROS generated by the interaction of the AuNPs with the added protons. Earlier work 
by Polf et al [103] yielded similar DE levels (ca. 15 to 20 %) for in vitro studies using 
AuNPs irradiated with 160 MeV protons. This is in direct contrast to recent Monte 
Carlo simulations reported by Jeynes et al [81] and Walzlein et al [79] which reported 
insignificant amounts of secondary electrons being emitted and subsequently little to no 
DE. 
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Recent works have focused on the biological effects within cells as the source of 
this difference in DE levels between cell/animal studies to computer simulations, and in 
particular on the production of ROS in the presence of metallic-nanoparticles [104-
106]. Notably, Lee et al [91] analysed the DNA fragments of tumour cells after 
irradiation with protons, and from the cleavage patterns produced identified ROS as the 
key mediator for inducing cell death for proton irradiations. Further work [90] showed 
an increase in ROS production when AuNPs were present in cells and irradiated with 
kV X-rays, and was also observed by Kim et al [80] who reported a 12 to 36 % increase 
in ROS when irradiating cells containing AuNPs with protons. More recently, Sicard-
Roselli et al [107] observed a similar result and concluded that the AuNPs played a 
catalytic role in the formation of ROS, which required a more inclusive protocol in 
radiotherapy to better model the DNA damage and cell death that occurred. 
Therefore, the aim of this research was to further examine the levels of DE due 
to AuNPs by using alanine to measure the production of secondary electrons when 
varying AuNP concentration (3, 2 and 1 %), size (1.9, 5 and 15 nm) and beam quality. 
The information gained from this work will further the current understanding of the 
mechanisms involved in DE, and in particular for charged particles (protons) which are 
less understood [81]. To do this; AuNP/alanine composites were manufactured and 
placed as a uniform layer within a wax pellet, and irradiated simultaneously with 
control wax pellets containing only alanine. By direct comparison with the control 
pellets of the EPR signal of the alanine radical formed (due to deamination of the 
alanine molecule) the levels of DE for all AuNP concentrations was determined and 
attributed to the formation of secondary electrons formed due to the presence of AuNPs.  
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2.2  Methods 
2.2.1 Preparation of AuNP/alanine composites
All chemicals used if this work were of analytical grade, and used without 
further purification. L-Alanine ( 98 %) was purchased from Sigma Aldrich, and all 
references to alanine within this work pertain to L-Alanine. The AuNPs used within 
were of three sizes, as shown and purchased from Nanoprobes as capped nanoparticles:  
 1-mercapto-(triethylene Gycol) methyl ether functionalized AuNPs (5nm)  
 AuroVistTM 15 nm AuNPs   
 AuroVistTM 1.9 nm AuNPs   
2.2.1.1  5 nm AuNP/alanine composites (3, 2 and 1 % AuNP content) 
Composites of 5 nm- AuNP/alanine were produced by dissolving 80 mg (mass 
of Au) of 5 nm 1-mercapto-(triethylene gycol) methyl ether functionalized AuNPs in 4 
mL of Milli Q water in a small beaker. The mixture was sonicated to disperse the 
crystals uniformly yielding a dark purple solution, and added at room temperature to a 
stirred solution of L-alanine in Milli Q water. Composites were prepared as follows; 3 
%: 4 mL of the purple solution added to 2.587 g of alanine, 2 %: 2 mL of the purple 
solution added to 1.960 g of alanine, 1 %: 1 mL of the purple solution added to 1.980 g 
alanine. The resulting solutions were stirred for approximately 5 minutes, then placed in 
an oven overnight at approximately 60 to 65 °C to remove all water and yield the dried 
L alanine/AuNP composite (Figure 2-1) as a purple/grey solid (3 %: 2.693 g, 2 %: 
2.043 g, 1 %: 2.059 g). 
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Figure 2-1. The dried purple/grey solid; L-alanine/AuNP (5 nm, 1 %) composite.
2.2.1.2  15 nm AuNP/alanine composites (3, 2 and 1 % AuNP content) 
Composites of 15 nm- AuNP/alanine were produced by adding 40 mg (mass of 
Au content) AuroVistTM 15 nm AuNPs in 0.2 mL phosphate buffered saline solution 
(pH 7.4) to Milli Q water (3.8 mL). The solution was filtered through a 0.22 mm 
hydrophilic polysulphonic membrane syringe bacterial filter (supplied by Nanoprobes) 
and the dark red/purple filtrate was collected (4 mL). The solution was added at room 
temperature to a stirred solution of L-alanine in Milli Q water. Composites were 
prepared as follows; 3 %: 3 mL of the red/purple solution was added to 0.970 g of 
alanine, 2 %: 4 mL of the red/purple solution added to 1.960 g of alanine, 1 %: 1 mL of 
the red/purple solution added to 0.990 g alanine. The resulting solutions were stirred for 
approximately 5 minutes, then placed in an oven overnight at approximately 60 to 65 
°C to remove all water and yield the dried L alanine/AuNP composite (Figure 2-2) as a 
purple solid (3 %: 0.968g, 2 %: 1.899 g,  1 %: 0.990 g). 
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Figure 2-2. The dried purple solid; L-alanine/AuNP (15 nm, 3 %) composite.
2.2.1.3  1.9 nm AuNP/alanine composites (3, 2 and 1 % AuNP content) 
Composites of 1.9 nm- AuNP/alanine were produced by dissolving 40 mg (mass 
of Au) of AuroVistTM 1.9 nm AuNPs in 4 mL of Milli Q water in a small beaker. The 
mixture was sonicated to disperse the crystals uniformly yielding a dark brown solution, 
and added at room temperature to a stirred solution of L-alanine in Milli Q water. 
Composites were prepared as follows; 3 %: 3 mL of the purple solution added to 0.970 
g of alanine, 2 %: 2 mL of the purple solution added to 0.980 g of alanine, 1 %: 1 mL of 
the purple solution added to 0.990 g alanine. The resulting solutions were stirred for 
approximately 5 minutes, then placed in an oven overnight at approximately 60 to 65 
°C to remove all water and yield the dried L alanine/AuNP composite (Figure 2-3) as a 
purple/grey solid (3 %: 0.926 g, 2 %: 0.956 g, 1 %: 0.971 g). 
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Figure 2-3. The dried grey/purple solid; L-alanine/AuNP (1.9 nm, 2 %) composite.
2.2.2  TEM of alanine/AuNP composites 
Nanoparticle morphology, size and distribution was examined using the JEOL 
1010 transmission electron microscope with Gatan Orius SC600 CCD Camera, by 
dissolving the solid in a small amount of isopropanol and drying a drop of the colloidal 
suspension on a strong carbon grid (GSCu 200C-50) or mesh copper holey carbon grid. 
The nanoparticles were spherical and well dispersed, with an average size of 2.9 
± 1.1 nm (1.9 nm AuNPs),  8.2 ± 1.7 nm (5 nm AuNPs) and 18.6 ± 1.2 nm (15 nm 
AuNPs). 
A typical TEM scan of the AuNP/alanine composite samples is shown in Figure 
2-4 for 5 nm AuNPs, and Figure 2-5 for 1.9 nm AuNPs and Figure 2-6 for 15 nm 
AuNPs. 
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Figure 2-4. TEM scan of alanine with AuNPs (5 nm) dispersed (black circles) on 
strong carbon grid. 
Figure 2-5. TEM scan of alanine with AuNPs (15 nm) dispersed (black circles) on 
holey carbon grid.  
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Figure 2-6. TEM scan of alanine with AuNPs (1.9 nm) on holey carbon grid.
2.2.3  FTIR of alanine/AuNP composites 
Fourier transfer infrared (FTIR) spectrum was recorded using a Bruker Tensor 
27 spectrometer using a KBr pellet, in the region between 4000 and 40 cm-1, and 
spectra obtained is shown in Figure 2-7. 
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Figure 2-7. The FTIR spectrum for 1.9, 5 and 15 nm Au/alanine composites with the 
major bands present in all three spectra.  
The major bands evident in all three AuNP sizes are in agreement with those 
reported in the literature (Table 2-1) [38] and include the band at 2113 cm-1 due to NH3+
bending, the band at 1621 cm-1 due to NH3+asymmetric stretching, the bands at 1413 
1.9 nm 
Au/alanine 
5 nm 
Au/alanine 
15 nm 
Au/alanine 
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and 1307 cm-1 due to symmetric stretching of the COO- group, and lastly the band at 
1362 cm-1 due to CH2 wagging and CH3 asymmetric stretching. 
Table 2-1. A summary of the major bands in the FTIR spectrum recorded for the 
Au/alanine composites containing AuNPs of 1.9, 5 and 15 nm (adapted from [38]).
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2.2.4 Preparation of AuNP/alanine and alanine-wax pellets 
Paraffin wax was obtained from Leica Biosystems as Paraplast Tissue 
Embedding Medium. All work within this section was completed in the RMIT 
Bundoora Histology teaching laboratories using the Leica® embedding stations to 
dispense the molten wax into the moulds, this allowed for the rate of flow of the 
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warmed liquid wax to be controlled and for uniform and consistent wax pellets to be 
produced. 
A set of silica moulds were manufactured with multiple rectangular inserts cut 
out, each measuring 10 x 5 x 5 mm (Figure 2-8). The silica moulds were warmed so 
that the molten paraffin wax did not harden upon contact, which ensured the pellets 
were of good construction and prevented sheering as the wax was added in two stages.  
Figure 2-8. The silica moulds used to fabricate the wax pellets (left) and the moulds 
being filled with molten wax to form the top layer (right).   
Approximately two drops of molten paraffin wax was added to the bottom of the 
warmed mould then a uniform layer of either AuNP/alanine composite (30 mg) or L-
Alanine (30 mg) was added. The powder was placed on top of the molten wax, and an 
additional 3 to 4 drops of molten wax was then added over the solid powder to fill the 
mould. The mould was then cooled and the wax pellet removed, excess wax was 
trimmed to yield uniform wax pellets (measuring 10 x 5 x 5 mm) of L-Alanine/AuNP 
(dark in colour) or L-Alanine (white). Only pellets with an even distribution of solid 
through the wax at approximately 2 mm depth were used (Figure 2-9). 
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Figure 2-9. Production of wax pellets with alanine crystals of two formats; with AuNPs 
(upper) and without (lower).
2.2.5  Irradiation conditions of AuNP/alanine composites and control 
alanine-wax pellets 
All x-ray (kV and MV) and electron irradiations were completed at the William 
Buckland Radiotherapy Centre, Alfred Hospital, Melbourne, Australia, and proton 
irradiations were completed at the Hyogo Ion Beam facility in Japan.   
Nominal doses of 2, 5, 10, 15 and 20 Gy were given, and administered as 
accumulative doses. This was done by initially irradiating all samples with a 2 Gy dose, 
from which the first set of samples were removed (total dose of 2 Gy received). A 
second dose of 3 Gy was then administered to the remaining samples, and a second set 
removed (total dose of 5 Gy received). A third irradiation of 5 Gy dose was given to the 
remaining samples, and a third set removed (total dose of 10 Gy received). The process 
was continued until all samples had been irradiated with the correct total dose, and is 
summarized in Table 2-2. 
Chapter 2: Dose enhancement due to AuNP size, concentration and beam quality 
62 
Table 2-2. Showing the accumulative dose method used to irradiate samples, so that all 
receive 2, 5, 10, 15 and 20 Gy dose, for this work three independent samples were used 
per nominal dose received.
3HOOHW 'RVHJLYHQ
$FFXPXODWLYHGRVH
UHFHLYHG
 *\ *\
  
  
  
  
  
Prior to irradiation, all wax pellets were placed within a silica holder of the same 
dimensions such that there were no air gaps between the pellets (Figure 2-10). 
‘Dummy’ wax pellets were fabricated which were colourful and designed to be easily 
distinguished from the ‘real’ wax pellet samples. The dummy pellets were used to fill 
any gaps within the moulds, and maintain full scatter conditions when irradiating. After 
receiving the required dose, wax pellet samples were removed and replaced with 
‘dummy’ wax pellets, again to prevent any air gaps being present during irradiation. 
Figure 2-10. Showing the wax pellet samples positioned in the moulds prior to 
irradiation, with the colourful dummy pellets.  
Sample pellets
Dummy pellets
Chapter 2: Dose enhancement due to AuNP size, concentration and beam quality 
63 
The wax composites were placed on top of the back-scatter medium and 
irradiated using different types of radiations. Conditions for each irradiation setup are 
shown in Table 2-3 and Figure 2-11. For all irradiations (X-rays and charged particles) 
the alanine-wax pellets were then scanned by EPR and the peak intensity was plotted 
against their depth in the phantom. 
Table 2-3. Irradiation conditions used for the different types of radiations measured.
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Figure 2-11 a-d. The set-up and irradiation of the AuNP/alanine-wax pellets for all 
beam types used; (a) kV X-rays, (b) MV X-rays, (c) electrons and (d) protons.  
2.2.6 Spread out proton beam (SOPB) depth-dose-curve using alanine  
Alanine-wax pellets were prepared as for the L-Alanine-wax pellets (Section 
2.2.4), so that each pellet measured 10 x 5 x 5 mm and contained 30 mg of alanine 
uniformly embedded within paraffin wax. In a solid-water block, a pre-cut channel 
(depth 5 mm and width 5 mm) was filled with the alanine-wax pellets so that there was 
no gaps in-between each pellet. The solid-water block and pellets were positioned 
a. kV X-rays b. MV X-rays 
c. Electrons d. Protons 
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vertically with supports on either side (Figure 2-12) and irradiated with a 150 MeV 
proton beam to a nominal dose of 8 Gy.   
Figure 2-12. The solid-water slab with channel containing alanine pellets was placed 
between supports (for full scatter conditions) and irradiated with protons (direction of 
beam and pellet orientation is shown).
The relation of dose and monitor count (Gy/count) was determined by an 
ionization chamber (Semiflex chamber Type-31013 volume 0.03 cm2) at the centre of 
Spread-Out Bragg Peak (SOBP) in a water phantom under the same conditions as the 
irradiated samples. The required physical dose (Gy) is delivered by the multiple beam 
pulse method. 
Alanine 
pellet 
Solid 
water 
Supports 
Direction of  
proton beam and  
alanine-wax 
pellets 
Chapter 2: Dose enhancement due to AuNP size, concentration and beam quality 
66 
2.2.7  EPR spectroscopy conditions and uncertainties 
The EPR spectra of all the irradiated samples were recorded on a BRUKER 
Elexsys 9.5 GHz. After irradiation all samples were stored in controlled conditions as 
stated previously for a minimum of 24 hours before EPR analysis, unless stated here. 
All wax pellet samples were placed vertically in a quartz tube (internal diameter 
= 7 mm), and positioned in the centre of the cylindrical cavity. An o-ring was fitted to 
the outside of the tube to ensure the pellet was consistently positioned in the centre of 
the cylindrical cavity (Figure 2-13). The spectrometer settings for all measurements 
were: number of scans, 5; centre field, 3400 G; microwave power, 0.5024 mW; sweep 
time, 10.50 s; sweep width 150 G; modulation amplitude, 4.0 G; time constant, 10.24 
ms; modulation frequency, 100 kHz;  receiver gain, 75 dB. 
Figure 2-13. The wax pellet sample within the quartz tube and O-ring used to maintain 
the position within the EPR cavity.  
Quartz tube 
O-ring 
Wax- pellet 
Collar 
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The response of the pellets to the nominal doses delivered by X-ray sources, 
electron and the proton beams is quantified by the concentration of the R1 alanine 
radical generated (Figure 1-15). The uncertainty in the determination of the EPR signal 
amplitude depends on the signal intensity, and is estimated to be between 1.5 % and 4 
% for alanine dosimetry [53], this being consistent with repeated measurements from 
the same sample. The errors associated with the data presented in this chapter represent 
the average of at least three independent samples. 
2.2.8 Irradiation standards and uncertainty 
The kV unit is calibrated with ionisation chambers calibrated at Australian 
Radiation Protection and Nuclear Safety Agency (ARPANSA), using the IPEMB 
protocol. The MV X-rays and MeV electron irradiations were performed on clinically 
used medical LINACs, calibrated to 1cGy/monitor unit (MU) in accordance with 
international protocols TRS398. The dose/ MU was calibrated with an ionisation 
chamber that has been calibrated at (ARPANSA), which is a secondary standards 
laboratory. The uncertainty for kV X-rays is less than 3 % and less than 2 % for MV X-
rays and MeV electron doses*. 
For proton beams; prior to irradiation of the samples, the ionization chamber 
setting with a water equivalent phantom was irradiated to determine the prescribed dose 
and dose rate at the monoenergetic Bragg peak and also at the centre of the spread-out 
Bragg peak (SOBP). Both the monoenergetic and 3 cm spread-out depth dose in water 
were then measured by the ionization chamber for reference. The uncertainty of the 
given dose is 2 %. The proton range is 14 cm, with a LET of 1.07 keV/micron. 
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* From private communications with Dr Trevor Ackerly, chief physicist at the William 
Buckland Radiotherapy Centre, Alfred Hospital, Australia.  
2.3 Results  
The results for varying AuNPs concentrations (1, 2 and 3 % w/w) and sizes (1.9, 
5 and 15 nm) are presented below and are divided into four sections based on the 
irradiation type used; kV X-rays (Section 2.3.1), MV X-rays (Section 2.3.2), electrons 
(Section 2.3.3) and protons (Section 2.3.4). The DE values are also presented, and a 
final comparison between the AuNP size effects in Section 2.3.5. Levels of DE were 
determined as the difference in signal amplitude to that of the control (containing no 
AuNPs) at the same nominal dose, for instance, a 55 % variation between the amplitude 
of the alanine control signal to that of the AuNP/alanine composite at a given dose, 
indicates a 55 % DE caused by the generation of secondary electrons.
Two separate irradiations were completed for X-rays (kV and MV) and 
electrons examining AuNP/alanine composites containing 1, 2 and 3 % AuNPs (w/w) 
of 1.9, 5 and 15 nm sizes, as this size range is not well represented in the literature 
(Section 2.1.2). Whilst only one set of measurements were completed for proton 
irradiations as this work was carried out in Japan with limited funding and beam time 
available.   
2.3.1  X-rays: kV ranges 
The DE for AuNPs of all sizes and concentrations irradiated with kV X-rays is 
clearly evident in the results below. Comparisons between the control alanine EPR 
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signal and the AuNP/alanine composites shows a large response, with the smallest 
AuNP size used (1.9 nm) yielding the largest DE levels.  
2.3.1.1  1.9 nm AuNPs 
The EPR response of the 1.9 nm AuNP/alanine composites (3 to 1 % v/w) and 
control L-alanine are shown in Figure 2-14 a & b. All irradiated samples gave linear 
responses with regression values ranging between 0.995 to 0.997 (Figure 2-14 a) and 
0.995 to 0.999 (Figure 2-14 b). 
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Figure 2-14 a & b. The EPR signal amplitude obtained from alanine and alanine/ 
AuNP (1.9 nm) composites; 3 to 1 % w/w after exposure to various doses of 80 kV X-
rays, sample set 1 (a) and 2 (b).
The level of DE presented in Table 2- 4 a & b shows a range of 113 to 147 % 
for 3% AuNP composites over the doses investigated, 99 to 129 % for the 2 % 
composites and 63 to 77 % for the 1 % composites. 
Table 2-4 a & b. The levels of DE (%) determined for the first (a) and second (b) set of 
AuNP (1.9 nm)/alanine pellets (3 to 1 %) irradiated with kV X-rays.
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2.3.1.2  5 nm AuNPs 
The EPR response of the 5 nm AuNP/alanine composites (3 to 1 % v/w) and 
control L-alanine are shown in Figure 2-15 a & b. Both sets of 3 to 1 % AuNP/alanine 
composites irradiated with kV X-rays gave linear responses with high regression values 
ranging between 0.981 to 0.990 (Figure 2-15 a) and 0.992 to 0.997 (Figure 2-15 b). 
Figure 2-15 a & b. The EPR signal amplitude obtained from alanine and alanine/ 
AuNP (5 nm) composites; 3-1 % w/w after exposure to various doses of 80 kV X-rays, 
sample set 1 (a) and 2 (b).
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DE levels obtained (Table 2-5 a & b) show a 35 to 55 % enhancement for 3% 
AuNP composites over the dose range investigated, which decreased to 19 to 29 % for 
the 2 % composites and to 4 to 15 % for the 1 % composites. 
Table 2-5 a & b. The levels of DE (%) determined for the first (a) and second (b) set of 
AuNP (5 nm)/alanine pellets (3 to 1 %) irradiated with kV X-rays.
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2.3.1.3  15 nm AuNPs 
The EPR response of the 15 nm AuNP/alanine composites (3 to 1 % v/w) and 
control L-alanine are shown in Figure 2-16 a & b. Both sets of 3 to 1 % AuNP/alanine 
composites irradiated produced linear responses and regression values ranging between 
0.990 to 0.994 (Figure 2-16 a) and 0.993 to 0.996 (Figure 2-16 b). 
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Figure 2-16 a & b. The EPR signal amplitude obtained from alanine and alanine/ 
AuNP (15 nm) composites; 3 to 1 % w/w after exposure to various doses of 80 kV X-
rays, sample set 1 (a) and 2 (b).
Table 2-6 a & b show a DE of 50 to 75 % for 3 % AuNP composites, which 
decreased to 31 to 52 % for the 2 % composites and 14 to 37 % for the 1 % composites. 
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Table 2-6 a & b. The levels of DE (%) determined for the first (a) and second (b) set of 
AuNP (15 nm)/alanine pellets (3 to 1 %) irradiated with kV X-rays.
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2.3.2  X-rays: MV ranges 
Overall irradiations with 6 MV X-rays for all the AuNP sizes and concentrations 
investigated gave lower DE levels compared with the kV X-ray irradiations. Whilst the 
effects of increasing concentration are evident and yielded higher DE levels (Section 
2.3.1), as for the kV X-ray irradiations, this was not so clear for AuNP size. However, 
the smaller sized 1.9 nm AuNPs did give slightly higher DE values, followed by the 15 
nm AuNPs, and the 5 nm AuNPs. 
2.3.2.1  1.9 nm AuNPs 
Figure 2-17 a & b show a linear response for all concentrations investigated 
with regression values ranging between 0.940 to 0.979 (Figure 2-17 a) and 0.976 to 
0.983 (Figure 2-17 b). 
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Figure 2-17 a & b. The EPR signal amplitude obtained from alanine and alanine/ 
AuNP (1.9 nm) composites; 3 to 1 % w/w after exposure to various doses of 6 MV X-
rays, sample set 1 (a) and 2 (b).
DE values ranged from 16 to 31 % for 3 % AuNP composites across all doses 
investigated (Table 2-7 a & b), and 10 to 24 % DE for 2 % AuNP composites, which 
decreased to 1 to 8 % for the 1 % composites. 
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Table 2-7 a & b. The levels of DE (%) determined for the first (a) and second (b) set of 
AuNP (1.9 nm)/alanine pellets (3 to 1 %) irradiated with 6 MV X-rays.
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2.3.2.2  5 nm AuNPs 
All AuNP concentration (1 to 3 %) gave a linear response (Figure 2-18 a & b) 
with regression values ranging between 0.992 to 0.996 (Figure 2-18 a) and 0.977 to 
0.981 (Figure 2-18 b). 
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Figure 2-18 a & b. The EPR signal amplitude obtained from alanine and alanine/ 
AuNP (5 nm) composites; 3 to 1 % w/w after exposure to various doses of 6 MV X-
rays, sample set 1 (a) and 2 (b).
Over the doses investigated the 3 % AuNP composites gave a DE range of 11 to 
24 % (Table 2-8 a & b), 5 to 17 % DE for the 2 % AuNP composites, and 0 to 11 % for 
the 1 % composites. 
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Table 2-8 a & b. The levels of DE (%) determined for the first (a) and second (b) set of 
AuNP (5 nm)/alanine pellets (3 to 1 %) irradiated with 6 MV X-rays.
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2.3.2.3  15 nm AuNPs 
Figure 2-19 a & b shows a linear response for all concentrations investigated 
with regression values ranging between 0.988 to 0.994 (Figure 2-19 a) and 0.988 to 
0.993 (Figure 2-19 b). 
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Figure 2-19 a & b. The EPR signal amplitude obtained from alanine and alanine/ 
AuNP (15 nm) composites; 3 to 1 % w/w after exposure to various doses of 6 MV X-
rays, sample set 1 (a) and 2 (b).
DE levels ranged from 17 to 29 % for the 3 % AuNP composites across all 
doses investigated (Table 2-9 a & b), and 14 to 20 % DE for the 2 % AuNP 
composites, which decreased to 9 to 14 % for the 1 % composites. 
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Table 2-9 a & b. The levels of DE (%) determined for the first (a) and second (b) set of 
AuNP (15nm)/alanine pellets (3 to 1 %) irradiated with 6 MV X-rays.
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2.3.3 Electrons 
DE was low for all AuNP sizes and concentrations examined ( 9 %) when 
irradiated with a 6 MeV electron beam. 
2.3.3.1  1.9 nm AuNPs 
Figure 2-20 a & b shows a linear response for all concentrations investigated 
with regression values ranging between 0.987 to 0.989 (Figure 2-20a) and 0.993 to 
0.995 (Figure 2-20 b). 
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Figure 2-20 a & b. The EPR signal amplitude obtained from alanine and alanine/ 
AuNP (1.9 nm) composites; 3 to 1 % w/w exposed to various doses of 6 MeV electrons, 
sample set 1 (a) and 2 (b).
The DE values observed over the doses investigated ranged from 3 to 9 % for 3 
% AuNP composites, 2 to 6 % DE for the 2 % AuNP composites, and 2 to 4 % for the 1 
% composites (Table 2-10 a & b). 
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Table 2-10 a & b. The levels of DE (%) determined for the first (a) and second (b) set 
of AuNP (1.9 nm)/alanine pellets (3 to 1 %) irradiated with 6 MeV electrons.
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2.3.3.2  5 nm AuNPs 
There was minimal variation in the dose (≤ 8 %) as measured by the control 
alanine and the AuNP/alanine samples when irradiated with a 6 MeV electron beam for 
both sets of experiments Figure 2-21 a & b. Regression values ranged between 0.986 
to 0.991 (Figure 2-21 a) and 0.992 to 0.993 (Figure 2-21 b). 
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Figure 2-21 a & b. The EPR signal amplitude obtained from alanine and alanine/ 
AuNP (5 nm) composites; 3 to 1 % w/w exposed to various doses of 6 MeV electrons, 
sample set 1 (a) and 2 (b).
Table 2-11 a & b shows the DE values, which ranged from 2 to 8 % for 3 % 
AuNP composites, 0 to 4 % and 1 to 4 % DE for 2 % and 1 % composites respectively.  
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Tables 2-11 a & b. The levels of DE (%) determined for the first (a) and second (b) set 
of AuNP (5nm)/alanine pellets (3 to 1 %) irradiated with electrons.
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2.3.3.3  15 nm AuNPs 
Figure 2-2a & b shows a linear response for all concentrations investigated 
with regression values ranging between 0.987 to 0.991 (Figure 2-22a) and 0.982 to 
0.985 (Figure 2-22 b). 
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Figure 2-22 a & b. The EPR signal amplitude obtained from alanine and alanine/ 
AuNP (15 nm) composites; 3 to 1 % w/w exposed to various doses of 6 MeV electrons, 
sample set 1 (a) and 2 (b).
DE values ranged from 4 to 7 % for 3 % AuNP composites across all doses 
investigated (Table 2-12a & b), and 3 to 6 % DE for both the 2 % and 1 % AuNP 
composites. 
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Table 2-12 a & b. The levels of DE (%) determined for the first (a) and second (b) set 
of AuNP (15 nm)/alanine pellets (3 to 1 %) irradiated with 6 MeV electrons.
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2.3.4 Protons 
Lastly, the response of the alanine/AuNP composites was examined for proton 
beam irradiations, as this was a large focus of this work, given the discrepancies in past 
studies using computer simulations and animal/cell models (Section 2.1.3). 
The suitability of the alanine-wax dosimeters to characterise the proton beam is 
illustrated by longitudinal measurements of a stack of alanine-wax pellets (Figure 2-
23). The path length through each pellet is 1 cm, this providing the spatial resolution for 
measurement of the depth dependence of the delivered dose. The Bragg peak is marked 
by the sharp drop in the alanine radical yield (Figure 2-23). This approach to 
determination of the depth-dose curve is simple and has a spatial resolution limited by 
the minimum size of the alanine composites needed to give a well-defined EPR signal. 
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Figure 2-23. EPR signal amplitude (divided by 100,000) against depth, representing the 
spread Bragg peak of 150 MeV proton beam.
To confirm the validity of the result for the higher energy proton beam used in 
this study the linearity of the response for the alanine-wax composite materials used 
with the ion-chamber calibrated dose was examined for exposures well above the usual 
clinical dose (20 Gy) for the 150 MeV proton beam (Figure 2-24). 
Figure 2-24. The linearity of alanine dose response over a wide range of proton doses.
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All AuNP/alanine composites irradiated with protons (150 MeV, SOBP) showed 
no dependence on the AuNP size or concentration and consistently yielded DE levels of 
 5 %.  
2.3.4.1  1.9 nm AuNPs 
Alanine composites containing 1.9 nm AuNPs irradiated with 150 MeV protons 
(SOBP) gave linear responses with regression values ranging from 0.977 to 0.982 
(Figure 2-25).  
Figure 2-25. EPR signals of alanine-wax pellets with and without AuNPs (1.9 nm) 
showing the levels of DE following exposure to 150 MeV proton beam. 
Radiation DE levels of  5% was observed for all composites (3, 2 and 1 %) and are 
presented in Table 2-13.  
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Table 2-13. The levels of DE (%) determined for AuNP (1.9 nm)/alanine pellets (3 to 1 
%) irradiated with 150 MeV protons.
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2.3.4.2  5 nm AuNPs 
Alanine composites containing 5nm AuNPs irradiated with 150 MeV protons 
(SOBP) gave linear responses with regression values ranging from 0.978 to 0.984 
(Figure 2-26).  
Figure 2-26. EPR signals of alanine-wax pellets with and without 5 nm AuNPs 
showing DE following exposure to a 150 MeV proton beam.
DE levels of  4 % was observed for all composites (3, 2 and 1 %) and are shown in 
Table 2-14.  
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Table 2-14. The levels of DE (%) determined for AuNP (5 nm)/alanine pellets (3 to 1 
%) irradiated with 150 MeV protons.
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2.3.4.3  15 nm AuNPs 
Alanine composites containing 15nm AuNPs irradiated with 150 MeV protons 
(SOBP) gave linear responses with regression values ranging from 0.982 to 0.983 
(Figure 2-27).  
Figure 2-27. EPR signals of alanine-wax pellets with and without 15 nm AuNPs 
showing DE following exposure to a 150 MeV proton beam.
For all composites (3, 2 and 1 %) investigated, DE levels of  5 % was observed (Table 
2-15).  
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Table 2-15. The levels of DE (%) determined for AuNP (15 nm)/alanine pellets (3 to 1 
%) irradiated with 150 MeV protons.
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2.3.5. Summary of the results based on AuNP size, concentration and 
beam quality 
The DE achieved for the different beam types used to irradiate the 
AuNP/alanine composites containing different AuNP sizes and concentrations are 
summarized in Table 2-16. 
Table 2-16. The levels of DE (%) determined for all AuNP /alanine composites 
examined when irradiated with different beam types.
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The effects of AuNP concentration on DE are evident for both kV and MV X-
ray irradiations; however the effects of AuNP size are clearer for the kV results 
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compared to the MV results, showing a preference for the 1.9 nm particles, followed by 
15 nm and lastly the 5 nm AuNPs (Figure 2-28). Neither electron nor proton 
irradiations showed a DE dependence on the AuNP concentration or size. 
Figure 2-28.  The influence of AuNP size and levels of DE as measured for kV X-rays.  
2.4 Discussion  
The effects of AuNP size and concentration upon the levels of DE achieved when 
irradiated with different quality beams are discussed below, with the results for kV and 
MV X-ray irradiations presented first, followed by irradiations with electrons and 
protons. The results are also compared with other recent studies reported, and the 
results, particularly for proton irradiations, are important because of the discrepancies in 
DE levels achieved when irradiating AuNPs in cell and animal models compared with 
computer simulations.  
2.4.1 X-rays: kV and MV ranges 
2.4.1.1  AuNP concentration 
The higher DE values achieved for the kV X-rays compared to MV X-ray 
irradiations for the same sized AuNPs and concentrations is consistent with literature 
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reports for energies below 100 keV, and the increased DE due to the dominance of the 
photoelectric effect [24, 41]. Whilst for MV energy ranges (6 to 10 MV) the 
photoelectric effect is replaced by the Compton effect as the dominant interaction. 
These results (both kV and MV X-rays) show a linear increase in DE when 
increasing AuNP doping levels (Sections 2.3.1 and 2.3.2), with 3% AuNP/alanine 
composites producing the largest DE for all sizes examined, followed by 2 % 
AuNP/alanine, and 1 % AuNP/alanine composites yielding the lowest DE levels, which 
is in agreement with simulations for both kV and MV X-ray irradiations of AuNPs [92, 
98, 99]. 
2.4.1.2  AuNP size 
For kV X-ray irradiations DE was greatest for the 1.9 nm AuNPs; 113 to 147 % 
(3 % composites) (Table 2-4 a & b), followed by the 15 nm AuNPs: 50 to 75 % (3 % 
composites) (Table 2-6 a & b), and lastly the 5 nm AuNPs: 35 to 55 % (3 % 
composites), which consistently gave the lowest levels of DE for all concentrations 
examined (Table 2-5 a & b). These results agree with the computer simulations by 
Lechtman et al [99] and Hossain and Su [101], which reported higher DE levels for 
smaller sized AuNPs when irradiated with kV energy X-rays, and is known to occur 
because of the larger surface-to-volume ratio of smaller sized nanoparticles [62]. 
However, it is not clear why the 15 nm AuNPs gave a higher DE response than 
the 5 nm, and could be due to the AuNPs polymeric capping reabsorbing the ejected 
electrons, and causing a decrease in the DE levels measured. Further analysis is needed 
to determine the possibility of this occurring, and larger sized AuNPs to conclude this 
part of the study. 
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The dependence on AuNP size and DE levels was not as evident for MV X-ray 
irradiations (Tables 2-7 to 2-9), although a similar size preference as seen for the kV X-
ray results was evident; with 1.9 nm AuNPs yielding a 16 to 31 % increase (3 % 
composites) (Table 2-7 a & b), closely followed by 15 nm; 17 to 29 % (3 % 
composites) (Table 2-9 a & b) and lastly 5 nm; 11 to 24 % (3 % composites) (Table 2-
8 a & b). These results agree with MV X-ray irradiation simulations by Mesbahi et al
[92] who reported a clear relationship between increasing AuNP concentration and 
increasing DE, but not so for the different AuNP sizes investigated. Similarly, Hwang et 
al [98] found that decreasing MetNP size afforded only a modest increase in DE levels 
when irradiating with MV X-ray, whilst increasing MetNP concentrations yielded a 
much greater DE response. The influence of AuNP size for both kV and MV X-rays is 
summarized in Figure 2-28. 
2.4.2 Electrons and protons  
2.4.2.1  AuNP concentration and size 
AuNP size and concentration showed no clear effect on DE levels measured 
when irradiated with electrons or protons Sections 2.3.3 and 2.3.4. The levels of DE for 
electrons was  9 % (for all AuNP sizes and concentrations investigated, Tables 2-10 to 
2-12), and is in agreement with documented results for the same beams as measured 
using cells in culture study (about 4 %) [24], and is further supported by in vivo
measurements by Chang et al [102] who reported 5 to 10 % DE in tumour bearing mice 
containing AuNPs, when irradiated with electrons. The small increase in radical 
generation for the AuNP/alanine composites is most likely due to the increase in the 
physical density in the case of Alanine/AuNP, leading to an increase in the probability 
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of collision and Bremsstrahlung electron interactions, and an increase in the number of 
free radicals generated.  
Significant radiation DE (ca. 20 %) of 45 MeV proton beams caused by 14 nm 
AuNPs was reported in in vivo studies by Kim et al [80]. The high level of DE relative 
to the difference in cross section is surprising and may be associated with secondary 
processes such as the release of Auger electrons. Since the dose response of the alanine 
dosimeter relates to the yield of radical species, the DE of alanine/AuNP in wax pellets 
provides a direct means of assessing the relative contribution of a radical based 
mechanism for the enhanced efficacy of combined AuNP proton beam irradiation. The 
small DE (ca. 5 %, Tables 2-13 to 2-15) is larger than the difference in density of the 
AuNP doped and undoped alanine-wax pellets and is consistent with the increase in 
radical yield for a given proton beam dose being linked to the absorption cross-section 
of the dosimeter with only a small enhancement due to secondary processes associated 
with the AuNPs. The results obtained align very well with the Monte Carlo simulation 
data recently reported by Jeynes et al [81] and Walzlein et al [79] simulated the proton 
beam DE at various distances away from the AuNP core and showed almost no DE is 
predicted at distance further than ca. 1 mm from the AuNP. 
Furthermore, the results suggest that the large DE for mouse tumours reported 
by Kim et al [80] is not due to enhanced radical generation, and when taking into 
account the differences between the two studies; beam quality, AuNP size, and 
concentration, the difference in DE may be partially attributed to the generation of ROS 
in aqueous media, which alanine is unable to detect. Misawa and Takahashi [90] 
reported the yield of ROS is significantly enhanced by the presence of AuNPs and 
identified the production of hydroxyl radicals (OH-) and superoxide anion (O-2) as well 
as other free radicals. Recent work by Davidson and Guo [108] used highly water-
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soluble (approximately 100 nm diameter), and irradiated with kV X-rays, after 
accounting for the average physical enhancements due to other sources, such as; 
nanoscale physical enhancement, chemical enhancement, and anti-enhancement, the 
largest enhancement was obtained for AuNPs present in water, with a 4.5-fold increase 
in DE due to the generation of ROS. As well, a recent study by Yao et al [109] showed 
that AuNPs also act, via strong binding to the target DNA, to chemically increase the 
radiosensitivity of the surrounding biomolecules.  
These results highlight the importance of biological and chemical effects that 
increase the radiosensitization of cells; such as ROS in animal and cell studies [104-
106]. Furthermore, this suggests a greater need for understanding of the DE processes 
occurring within cells, and their potential inclusion in future radiotherapy models [107]. 
2.5 Conclusions 
The amount of radiation DE caused by different concentrations and sizes of 
AuNPs irradiated with varying quality beams; X-ray (kV and MV) electrons and 
protons, was investigated using AuNP/alanine composites in wax. The response of the 
alanine dosimeters reflects the radical yield following irradiation and in all experiments 
this mirrors the differences in absorption cross section, with some modification 
associated with secondary processes. 
Low energy (80 kV) X-rays yielded the highest DE values and was linearly 
dependent on the AuNP concentration (3, 2 and 1 %). The higher AuNP content 
resulted in higher DE, which agrees with literature results along with an increased 
photoelectric cross section. The smallest sized AuNPs (1.9 nm) gave the highest DE 
overall, which also agrees with recent Monte Carlo simulations. For MV X-ray 
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irradiations DE was not as large as for kV X-rays, and is consistent with the literature 
and the dominance of Compton interactions at this energy range. Whilst a dependence 
on AuNP concentration was observed it was small in comparison to kV X-ray 
irradiations and the effect of AuNP size was only slightly evident. These results are in 
agreement with recent Monte Carlo computer simulations and the effects seen for 
AuNPs interacting with kV and MV X-rays. 
The results for electron irradiations agree well with published cell studies using 
electron beams, as well as with proton simulation data. No such dependence on AuNP 
concentration or size was observed for both electron or proton irradiations and DE 
levels were  9 % and  5 % respectively. These results suggest that the much larger 
than expected DE resulting from proton irradiation of AuNP loaded tumours does not 
result from an increase in the yield of radical species. The increased efficacy is more 
likely due to the presence of AuNPs in biological systems catalysing other chemical 
processes (such as ROS), which occur when irradiated with high LET beams, and 
would account for the greater radiosensitization observed in cell/animal studies. 
Therefore, for high-energy proton beams the recent Monte Carlo simulations provide a 
good estimate of the enhanced radical yield following addition of AuNPs to alanine. 
In conclusion, alanine dispersed in wax can be used as a phantom and dosimeter 
for dose distribution measurements delivered by all radiation types used in radiotherapy 
including protons. This work was able to show for the first time radiation DE using 
alanine impregnated with AuNPs for proton beams. This study is extended further in the 
next chapter of the thesis, by the examination of a new material as a possible 
radiotherapy dosimeter, and investigates its responses to different quality beams, 
particularly protons. 
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Chapter 3: Examination of the novel 
dosimeter IRGANOX®1076 
The majority of contents from this chapter has been published. Refer to Appendices iii 
for permission to reproduce published materials.
3.1 Introduction 
As the primary aim of radiotherapy is to deposit a highly tailored dose to 
cancerous targets, whilst minimizing damage to healthy surrounding tissues [3, 24], it is 
vital to reliably measure the radiation dose delivered using tissue equivalent dosimeters. 
Tissue equivalent dosimeters are preferred, as non-tissue equivalent dosimeters require 
approximations and hence have associated errors. As stated in Section 1.3 the most 
commonly used dosimeters in radiotherapy are ionisation chambers, TLDs and diodes, 
which are not tissue equivalent.  More recently, EPR dosimeters, and in particular 
alanine, have been investigated as an alternative for radiotherapy dosimetry. Reasons 
for the interest in alanine are discussed in Section 1.3.2.2, and include the fact that it is 
a tissue-equivalent dosimeter. However, alanine is currently limited by its poor 
sensitivity at low doses (< 5 Gy) [38, 39, 50] [40], as are commonly used in 
radiotherapy applications. Recent attempts to extend the usable range of alanine to 
approximately 1 Gy have been discussed in Section 1.3.2.2, as well as practical 
limitations of the methods trialled. 
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Further issues with alanine dosimeters include the complicated EPR spectrum 
due to a mixture of radicals with a dependence of the intensity of the central EPR signal 
on the rotational orientation of the sample in the cavity. The extent of this variation was 
determined by Dolo and Garcia [110] and shown to range between 9 to 40 % for 
commercially available powders, and 2 to 10 % for commercial pellets. As alanine is 
highly hygroscopic [111], the variation in band profile has been attributed to differing 
water content of the alanine sample [49], which may be due to relaxation effects or 
changes to the radical composition post-irradiation, however, these effects are not fully 
understood [110]. The angular dependence of the EPR spectrum of alanine does not 
preclude use of the material for dosimetric applications provided that the reported signal 
is the average of measurements obtained for a range of angles [48, 53, 112, 113]. 
Despite the many desirable features of alanine as a radiotherapy dosimeter [25], 
issues related to the hygroscopic nature of the material and attendant complications with 
signal measurement provide significant barriers to its more widespread use. These 
problems can be avoided by selection of a material with a composition similar to 
alanine (hence keeping its advantages) but being hydrophobic and giving a single stable 
radical when irradiated, i.e. reducing its limitations. For applications in radiotherapy the 
properties a dosimeter should ideally possess are discussed in Section 1.3.1 but briefly 
include; small in size, malleable (so custom geometrical forms could be made so that 
full scatter conditions are maintained when in contact with non-planar surfaces), 
sensitive to low doses (1 to 2 Gy), tissue equivalent (for more reliable dose estimation), 
stable post-irradiation, inexpensive (making it disposable), and easy to read/interpret 
[25]. The experiments reported herein demonstrate that IRGANOX®1076 has the 
characteristics of a more adequate radiotherapy dosimeter. 
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3.1.1 IRGANOX®1076 
IRGANOX®1076 (Figure 3-1) is a 1, 3, 5 trisubstituted phenol compound, 
which when irradiated gives a radical stabilised by the aromatic ring. The bulky alkyl 
groups at the reactive ortho and para sites (Figure 3-2) prevent further reactions [114] 
thus making the radical highly stable. The radical may result from simple ionisation 
with formation of a phenol radical cation characterised by a doublet EPR signal, due to 
electron coupling with the phenol proton, or may result from loss of a hydrogen atom 
giving a phenoxyl radical characterised by a singlet in the EPR.  The EPR spectrum of 
solid solutions of IRGANOX®1076 in wax, post irradiation consists of a single peak, 
which is easy to measure and quantify, and is consistent with the phenoxyl radical [115-
118] (Figure 3-3).  
Figure 3-1. Chemical structure of IRGANOX®1076, showing sterical hindrance at the 
ortho and para positions. 
Chapter 3: Examination of the novel dosimeter IRGANOX®1076 
101 
Figure 3-2. The resonance structures of the phenoxy radical, showing increased 
reactivity at the ortho (structures 2 and 4) and para (structure 3) positions.
Figure 3-3. The typical EPR signal for IRGANOX®1076 phenoxyl radical.  
IRGANOX®1076 is inexpensive, readily available, approved by the US Food 
and Drug Administration (FDA) [119] and has a mass energy absorption coefficient 
value that is comparable to water and tissue [120], which are all desirable properties for 
radiotherapy based dosimeters. Initial work by Marrale et al. [120] of suspensions of 
IRGANOX®1076 in wax binder irradiated with 60Co photons found good linearity over 
a dose range of 12 to 60 Gy, and signal stability of up to 30 days post-irradiation. 
Interestingly the EPR spectrum reported in these studies has the form of a doublet, 
indicating a phenol radical cation. Later Marrale et al. [27] extended this to studying the 
signal enhancement for IRGANOX®1076 containing 5 % (w/w) gadolinium oxide 
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(Gd2O3) when irradiated with  neutrons and gamma photons. For neutrons signal 
enhancement was increased approximately ten times but no such increase was observed 
for gamma photons. 
These results suggest a broader applicability of IRGANOX®1076 as a potential 
dosimeter for other routinely used radiotherapy beams, in particular protons, which are 
gaining popularity in clinical use. Wax pellets containing a higher 
WAX:IRGANOX®1076 ratio (70:30) were manufacture, which improved the 
malleability of the material, and as well, this composition yielded a solid solution – that 
is, the IRGANOX®1076 dissolves in warmed wax, which on cooling, gives solid 
containing wax-solvated solute molecules. 
The response of the IRGANOX®1076 wax solid state (IWSS) pellets to 
different nominal doses of 2, 5, 10, 15 and 20 Gy using X-rays (kV and MV) and 
charged particles (protons and electrons) was examined, and EPR reproducibility and 
orientation dependence assessed. Finally the EPR signal response for alanine-wax 
pellets containing the same mass (w/w) of dosimeter material (30 mg) were compared 
for the same nominal doses (2 to 20 Gy) and irradiation beams.  
3.2  Methods 
3.2.1 Preparation of IRGANOX®1076 wax solid state (IWSS) pellets 
IRGANOX®1076, Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate, 
(99 %) was purchased from Sigma Aldrich and used without further purification. 
Paraffin wax was obtained from Leica Biosystems as Paraplast Tissue Embedding 
Medium (mp: 56 to 57 °C). 
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Rectangular moulds constructed of silica measuring 10 x 5 x 5 mm were 
warmed and approximately two drops of molten paraffin wax was added to the bottom 
of the mould. IRGANOX®1076 (30 mg) was added to the molten wax and allowed to 
dissolve, forming the upwards face as illustrated in Figure 3-4. An additional 3 to 4 
drops of molten wax was then added over the solid to fill the mould.  
The mould was then cooled and the wax pellet removed, excess wax was 
trimmed to yield uniform wax pellets (measuring 10 x 5 x 5 mm) with a homogenous 
layer of wax and IRGANOX®1076 of approximately 2 to 3 mm depth.
Figure 3-4. The formation of the IRGANOX®1076 (approximately 30 %) wax solid 
state (IWSS) pellet. 
3.2.2  Sample irradiation 
IWSS pellets were placed within a silica holder of the same dimensions, such 
that there were no air gaps between the pellet and mould (Figure 2-9). The pellet 
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surface containing the homogenous mixture of wax and IRGANOX®1076 was placed 
upwards within the mould for irradiation as shown in Figure 3-5. For MV X-rays the 
dose delivered was to the surface of the silica holder containing the wax pellets, which 
was positioned at a depth beyond the point of maximum dose where the LINAC (Varian 
Novalis) was calibrated to 1 cGy/monitor unit (MU). For proton irradiation the samples 
were positioned within the centre of the spread out Bragg peak (SOBP). After receiving 
the required dose, the IWSS pellets were removed and replaced with ‘dummy’ wax 
pellets. 
  
Figure 3-5. Showing the orientation of the IWSS pellet when irradiated. 
3.2.3  Irradiation conditions, standards and uncertainty  
The standards and uncertainties for all beam types used in this investigation 
have been described previously in Section 2.2.8. The X-ray (kV and MV), electron and 
proton irradiations were conducted as described in Section 2.2.5. The IWSS pellets
were placed on top of the back-scatter medium and irradiated using different types of 
radiations (Table 3-1). 
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For dose response measurements, all samples received nominal doses of 2, 5, 
10, 15 and 20 Gy, and is detailed in Table 2-2. For angular response measurements, all 
samples received 30 Gy (6 MV X-rays).  
Table 3-1. The types of radiations to which IWSS pellets were exposed, and the 
conditions used.
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3.2.4  EPR scanning conditions 
The EPR spectra of the irradiated samples were obtained using the conditions 
described in Section 2.2.7, and five repeat scans recorded. The standard spectrometer 
settings for all measurements were: 340 mT centre field, 2.00 mW microwave power, 
10.28 s sweep time, 2.0 mT sweep width, 0.4 mT modulation amplitude, 10.24 ms time 
constant, 100 kHz modulation frequency and 75 dB receiver gain. 
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3.2.5  EPR angular response  
All angular response measurements were conducted using the standard settings 
but with a longer sweep time (21.05 s) and time constant (82 ms).  A goniometer was 
used to determine the angle of measurement and the sample manually rotated to the new 
position. 
3.2.6  Sample storage 
After irradiation, all samples were stored in a sealed container and the 
temperature and humidity was monitored using a digital thermal/hygrometer gauge. The 
temperature was maintained at, or below 24 °C and the relative humidity remained 
below 50 %. 
3.2.7  EPR measurements 
The response of IWSS pellets to the nominal doses delivered by X-ray sources, 
electron and the proton beams is quantified by the concentration of phenoxyl radicals  
generated (Figures 3-2 and 3-3). The uncertainty in the determination of the EPR signal 
amplitude depends on the signal intensity, which is estimated to be between 1.5 % and 
4 % for alanine dosimetry [53], this being consistent with repeated measurements from 
the same sample. The errors associated with the data presented in this chapter represent 
the average of at least three independent samples. 
Chapter 3: Examination of the novel dosimeter IRGANOX®1076 
107 
3.3 Results 
3.3.1 Phase dependence of the EPR signal of IRGANOX®1076 
following irradiation
The EPR signal produced by the radical species formed after irradiation of the 
IWSS pellets and solid IRGANOX®1076 is shown in Figure 3-6 a &c. Irradiation of 
the IWSS pellets (IRGANOX®1076 in solution) results in loss of the hydrogen radical 
(H·) and an EPR singlet, whilst for the crystalline matrix; loss of an electron produces 
the phenol cation and an EPR doublet. Partial dissolution in wax (10 %) gives a mixture 
of the singlet and doublet EPR signals (Figure 3-6 b). The singlet peak’s amplitude 
(peak to peak) was used for all EPR measurements within this study, and was greater 
than the amplitude for the doublet signal (irradiated under same conditions; energy, 
dose, weight of sample), providing better quantification and signal to noise (S/N) ratio 
compared to the doublet. 
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Figure 3-6. The EPR signal for  the phenoxyl radical formed after irradiation of IWSS 
pellets (a) and when present in approximately 10 % wax (b), and lastly the doublet 
signal formed after irradiation of solid IRGANOX®1076 (c) (Note: different irradiation 
& EPR conditions were used to generate c).
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3.3.2 Linear response and LET dependence 
The response of IWSS pellets to different radiation beams, for the nominal 
doses delivered (after ion chamber calibration), is shown in Table 3-2 and Figure 3-7. 
The error bars on the plot correspond to the standard deviation between three 
independent measurements at each nominal dose, and were fitted with a linear function 
with intercept set at origin. The nominal dose values (x-axis) used was determined by 
calibrated ionisation chamber measurements. 
Figure 3-7. Overlay of the radiation types measured (kV & 6 MV X-rays, electrons and 
protons), showing the energy independence of IRGANOX® 1076 as IWSS pellets 
(each dose measured represents the average of at least 3 independent samples).
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Table 3-2.The average EPR signal amplitude for IWSS pellets (each average represents 
at least three separate wax pellets measured) after irradiation with different quality 
beams and doses.
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The relative response of the IWSS pellets (Figure 3-7) shows that the linearity 
of the response of the dosimeter for radiation doses from 2 to 20 Gy with correlation 
coefficients ranging from 0.979 to 0.993. The results show the samples are independent 
of the radiation type but that the sensitivity of the dosimeter is less for kV X-rays than 
for the MV X-rays, electrons and protons. Consequently, the same calibration can be 
used for the different forms of LET radiation. 
3.3.3 Dependence of the EPR signal response over the MV X-ray 
energy range 
The energy independence for MV X-rays was further examined by irradiating 
IWSS pellets with 6, 10 and 18 MV X-rays. Table 3-3 shows the average and standard 
deviation values for the EPR signal measured for three to five pellets irradiated at each 
nominal dose, and the averages are plotted in Figure 3-8 with a standard deviation 
(range of 0.009 to 0.512) corresponding to the error bars. As for the LET response, 
IWSS pellets show an independent response to different MV energies.  
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Table 3-3. The average EPR signal amplitude for IWSS pellets (each average 
represents between three to five separate wax pellets measured) after irradiation with 
different MV energy beams and doses.
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Figure 3-8. Comparison of the average EPR signal for amplitude measured for IWSS 
pellets after irradiation with different energy MV X-rays (6, 10 and 18 MV), at the 
same nominal doses (which represents the average of at least 3 independent samples).
3.3.4 Stability of EPR signal post-irradiation 
The stability of the IRGANOX®1076 EPR signal post-irradiation with protons 
was monitored by repeated measurements of a set of samples over an extended period; 
4 to 466 days (Figure 3-9, Table 3-4). In all cases up until 77 days the change in the 
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signal intensity was less than the measured uncertainty (Table 3-5). While the 
difference in signal is less than the error of the individual measurements the observation 
that in all cases there was a reduction in signal with time may suggest some fading of 
the signal; however this is clearly a minor effect.  
Table 3-4. The average EPR signal amplitude for IWSS pellets (each average 
represents three separate wax pellets measured) after irradiation with protons at 
different nominal doses, and the signal stability over time.
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Figure 3-9. Stability of IRGANOX®1076 EPR signal measured over 466 days post-
irradiation with 150 MeV protons (each measurement represents the average of at least 
3 independent samples).
Table 3-5. Comparison of EPR signal intensity at 4 and 77 days post-irradiation.
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Clearly, after 466 days changes in the signal intensity are noticeable (Table 3-6), with 
fading >10 %, which is larger than the errors associated with each individual 
measurements. 
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Table 3-6. Comparison of EPR signal intensity at 4 and 466 days post-irradiation.
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3.3.5 EPR cavity angular response  
The sensitivity of the amplitude EPR signal to a rotation about the cylindrical 
axis of the sample in the EPR cavity was investigated using a set of five IWSS pellets 
irradiated with a 30 Gy dose of 6 MV X-rays. Measurements were completed three days 
post irradiation, and included spectra recorded at 45° increments covering the range 0 to 
360°. These experiments showed only minor variations (< 2 %) in signal intensity to a 
rotation of the sample in the microwave cavity of the EPR (Figure 3-10). The 
variations in signal amplitude were cyclical and of a low magnitude, and are most likely 
due to a small eucentricity of the rotation axis (slight deviations), which cause a relative 
change in the position of the sample in the microwave cavity. An alternate explanation, 
that the signal intensity is due to instability of the spectrometer, can be dismissed based 
on the reproducibility of the EPR intensity for samples rotated by 360° (Table 3-7). 
These observations are consistent with the homogeneous character of a solid solution 
and the formation of a single dominant radical following irradiation and contrasts with 
the more complex, sample-dependent, orientation-dependent EPR spectra obtained from 
L-alanine [110]. 
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Figure 3-10. The angular response of IWSS pellets as rotated within the EPR cavity. 
Table 3-7. Comparison of the IWSS pellets EPR signal intensity at the starting angle 
(0°) and after one-full rotation was completed (360°).
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As expected for a homogenous sample there was no significant variation of the 
measured signal.  
3.3.6  Comparison with alanine  
A comparison with the amplitude of the EPR signal produced when irradiating 
wax pellets containing the same weight of alanine, which were manufactured and 
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described in Section 2.2.4, were made. The results for kV and MV irradiations are 
shown in Table 3-8, and the EPR signal intensity for three samples per dose plotted in 
Figures 3-11 and 3-12. For irradiation with electrons and protons the results are shown 
in Table 3-9, and plotted in Figures 3-13 and 3-14.  
Table 3-8. Comparison of the EPR signal intensity for IWSS and alanine-wax pellets 
irradiated with kV and MV X-rays.
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Figure 3-11. The EPR response of IWSS and alanine-wax pellet samples irradiated 
with kV X-rays (where each dose measured represents the average of at least 3 
independent samples).
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Figure 3-12. The EPR response of IWSS and alanine-wax pellet samples irradiated 
with MV X-rays (where each dose measured represents the average of at least 3 
independent samples).
Table 3-9. Comparison of the EPR signal intensity for IWSS and alanine-wax pellets 
irradiated with electrons and protons.
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Figure 3-13. The EPR response of IWSS and alanine-wax pellet samples irradiated 
with electrons (where each dose measured represents the average of at least 3 
independent samples).
Figure 3-14. The EPR response of IWSS and alanine-wax pellet samples irradiated 
with protons (where each dose measured represents the average of at least 3 
independent samples).
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Irradiations with MV X-rays, electrons and protons show a similar EPR signal 
response between the IWSS pellets and the alanine-wax pellets. Whilst the IWSS 
pellets do yield slightly higher R2 values; there are little differences in the results 
Figures 3-12 to 3-14. However, for kV X-ray irradiation (Figure 3-11) the IWSS 
pellets show a lower response compared to the alanine-wax pellets. 
3.4 Discussion 
The results for the novel dosimeter of IRGANOX® 1076 are discussed below, 
and focus on the two different radical species formed when irradiating IRGANOX® 
1076 as a crystalline solid and when present as a solid solution in wax. The linear 
response of the material to different LET beams, the good EPR signal stability post-
irradiation, and how it compares with alanine are also reviewed
3.4.1 Examination of the IRGANOX®1076 radical obtained following 
irradiation 
The observed difference in EPR signal produced after irradiation of 
IRGANOX®1076 for crystalline samples and for solid solutions in wax points to 
distinctly different products for the photoionised molecule depending on the local 
environment of the absorbing molecule. The difference is particularly surprising given 
the long-chain para substituents on the phenol ring of IRGANOX® 1076. The 
observation of a doublet EPR signal for irradiated crystalline IRGANOX®1076 
indicates strong coupling with a single proton and this can only be explained in terms of 
a predominant resonance structure corresponding to the oxygen (O) protonated form of 
structure 1 in Figure 3-2. This corresponds to simple photoionisation of the neutral 
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molecule. Clearly, the radical corresponding to structure 1 of Figure 3-2 would give a 
single resonance and this would be formed by net loss of H˙ from the parent molecule. 
This may also be achieved by one-electron oxidation of the phenoxy anion [116, 121] 
or, as observed in this study, for solid solutions of IRGANOX®1076 in wax. In earlier 
work Marrale and co-workers [120] reported the EPR spectrum of “un-irradiated” and 
suspensions of crystalline IRGANOX®1076 in wax (90:10) and in both cases observed 
a doubled signal consistent with Figure 3-6c.  
The sample of IRGANOX®1076 used in these studies did not give an 
observable EPR signal prior to irradiation. It is our contention that the sample of 
IRGANOX®1076 used by Marrale had previously been exposed to radiation, most 
likely in the course of customs or security checks. This observation highlights the long 
lifetime of the radical formed from irradiation of IRGANOX®1076. It also follows that 
suspensions of IRGANOX®1076 in wax will actually comprise a mixture of crystalline 
and dissolved sample and this will give a composite singlet:doublet signal according to 
the composition of the sample. We have conducted measurements of samples 
containing intermediate ratios of IRGANOX®1076 and wax and the resultant signal is 
a mixture of overlapping singlet and doublet band profiles. Under these circumstances 
the reproducibility of the dosimeter is greatest if the sample is in a single form. If wax is 
the medium for supporting the IRGANOX®1076 then a single form is only achieved by 
the use of solid solutions, as employed in this study. It is also noted that there is a small 
increase in signal to noise (√2) when estimating the EPR signal using the peak height of 
the singlet as opposed to the doublet.  
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3.4.2 Linear response and LET independence 
The linear response of IRGANOX®1076 to dose is shown in Figure 3-7. The 
dose range extends up to 20 Gy with correlation coefficients ranging from 0.979 to 
0.993. The EPR signal obtained for IRGANOX®1076 dosimeters following irradiation 
with different energy MV X-rays, electrons and protons (Figures 3- 7 and 3-8) was 
found to be independent of radiation type and LET as it displays the same signal 
amplitude for all three forms of radiation i.e. the same signal is observed for high LET 
protons as for low LET MV X-rays and electrons for the same dose.  Our MV X-ray 
results agree well with those reported by [120], and extend the possible uses of 
IRGANOX®1076 to now include kV X-rays, electrons and protons.  
 For irradiation with 80 kV X-rays IRGANOX®1076 shows a reduced linear 
response to dose (Figure 3-7) when compared to that of MV X-rays, electrons and 
protons. The same reduction in sensitivity to dose when irradiated with lower energy 
photons is also observed with alanine dosimeters [41, 51, 122]. At energies below 100 
keV a reduction in EPR signal of approximately 40 % (compared to 60Co gamma 
irradiation) occurs [41]. For this reason alanine is not used in diagnostic radiology 
where low energy (20 to 60 keV) photons are typically used. Further investigation of 
the response by IRGANOX®1076 to low energy photons is needed to establish its 
application range.   
In summary, with the current EPR measurement protocols IWSS pellets can be 
successfully used to quantify doses of approximately 2 Gy and higher. Further 
optimization of the EPR protocol used to measure the spectra may well extend this limit 
to 1 Gy, which would further extend the application of IRGANOX®1076 clinical 
radiotherapy contexts. 
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3.4.3 EPR stability post-irradiation 
Since a key focus of this research is to assess the applicability of 
IRGANOX®1076 dosimeters to proton dosimetry it is important to consider the 
stability of the EPR signal after proton irradiation (Figure 3-9). The pellets were stored 
within the laboratory at standard conditions in a darkened environment, whilst humidity 
was not controlled; hygrometer measurements suggest that the relative humidity did not 
exceed 50 %. 
The IWSS pellets were repeatedly measured post-irradiation starting from 4 
days post to 466 days. The measurements show good reproducibility of the signal up 
until 77 days (Table 3-4), and signal fading over this period ranged from 1.6 % (5 Gy) 
to 3.8 % (10 Gy), (Table 3-5) this being comparable to experimental uncertainties. 
After 466 days changes in the signal fading was noticeable and ranged from 10.9 to 
14.0 %, (Table 3-6). Overall, these measurements suggest that the IWSS pellets have 
high levels of stability when stored within a standard laboratory conditions for up to 
three months, however signal fading after more than one year is observable. 
3.4.4 Comparison to alanine 
Irradiations with MV X-rays, electrons and protons show a similar EPR signal 
response between the IWSS pellets and the alanine-wax pellets. Whilst the IWSS 
pellets do yield slightly higher R2 values; there is little difference in the results Figures 
3-12 to 3-14. However, for kV X-ray irradiation (Figure 3-11) a lowered response for 
the IWSS pellets compared to the alanine-wax pellets is observed. Whilst the alanine-
wax pellets have a slightly higher R2 value; 0.981 compared to the IWSS pellets; 0.979, 
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the reasons for this reduced signal intensity are not known and further measurements 
are needed. As stated earlier (Section 3.4.2) changes in alanine’s dosimetric response 
for kV X-rays is well known, however, not readily explained in the literature. As 
IRGANOX®1076 shows the same decrease in radical yield for kV X-ray irradiations a 
similar response is occurring, and the differences between the kV results for alanine and 
IRGANOX®1076 may be reflective of another process, such as the bond-dissociation 
energy differences needed to form the dosimeter’s radical species  
(-O-H for IRGANOX®1076 compared to -C-H for alanine). However, currently there is 
no such information regarding this in the literature, and further investigation is 
warranted. 
3.5 Conclusions 
IWSS pellets were found to have sufficient sensitivity to allow dose 
quantification over the range 2 Gy to 20 Gy for all radiation beams investigated (kV & 
MV X-rays, electron and protons) further; the signal is energy and LET independent for 
MV X-rays, electrons and protons. The phenoxyl radical formed is highly stable with 
little change in the EPR signal after >2 months post irradiation by protons; however 
signal fading was evident after approximately 15 months. Comparisons between the 
EPR signal intensity with alanine are comparable, whilst the shortcomings associated 
with the use of alanine in dosimeters (sensitivity at low dose, reproducibility of EPR 
spectra, multiple radical species, hydrophilicity, angular dependence of the EPR 
spectra) are either substantially (sensitivity at low dose) or completely eliminated by the 
use of IRGANOX®1076. The hydrophobic character of the material gives greater 
control over the composition and reproducibility of the dosimeters and helps avoid the 
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complexity of product distribution evident for alanine. The results demonstrated that 
wax is an ideal supporting medium provided that the IRGANOX®1076 is completely 
dissolved in the wax. Under these circumstances a single singlet is observed in the EPR 
which, unlike alanine, has an intensity independent on the orientation of the sample. 
Quantification of the EPR signal is relatively straightforward and this leads to an 
extension of the useful dose range to 2 Gy. 
Based on these findings, it suggests that IRGANOX®1076 is superior to 
conventionally used dosimeters, particularly for high LET beams. The advantages of 
IRGANOX®1076 are; it’s simple and easy to interpret EPR spectrum, tissue 
equivalence, low toxicity, low cost and ready availability and high wax solubility, 
allowing a dosimeter of any shape and size to be made, which is useful for in vivo 
dosimetry. Finally, it is believed that by further optimization of EPR settings its dose 
range may be extend to better than 1 Gy. 
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Chapter 4: A comparison of the EPR 
angular response of alanine and 
IRGANOX®1076 
4.1 Introduction 
Whilst alanine dosimeters have clear advantages for clinical radiotherapy; tissue 
equivalence, good stability post-irradiation, can be reused for accumulative dose 
studies, etc. (see Section 1.3.2.2 for more details) they suffer from EPR angular 
response changes, which alters the amplitude of the central alanine peak when the 
sample is rotated within the EPR cavity (Section 3.1). Known as ‘angular response’ 
(and not to be confused with the angular response that occurs during irradiation) it must 
be taken into consideration when performing EPR measurements with alanine. 
Generally, to overcome this problem the sample is rotated and several measurements at 
various angles within the cavity are averaged to yield the reported signal [48, 53, 112, 
113]. 
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The contributing effects of the angular response have been extensively explored 
by Dolo et al. [49, 110, 123]. Dolo and Garcia [110] found by rotating alanine 
commercial pellets and powders in 10° increments 37 times (whereby the first and last 
measurements at 0ι and 360ι are the same position and was used to verify the stability 
of the EPR during the measurement process) and measuring the central peak’s 
amplitude a roughly sinusoidal curve was obtained. The variation between 
measurements performed was greatest for powder and pellet samples containing large 
grain sizes and poor compacting with maximal deviation values ranging from  9 to 40% 
[110]. Whilst, highly compressed commercial alanine pellets with smaller grain sizes 
showed variations of 2 to10 % in signal amplitude [110]. They concluded that the 
averaging of several measurements at different angles did not adequately reflect the 
large variations seen in the results. 
As alanine is highly hygroscopic [111] the differing water content within 
alanine was identified by Dolo and Feaugas [49] as likely causes for the angular 
response and variation in band profile observed. The water within the sample acted to 
alter the EPR signal produced in two ways; firstly, by affecting the resonance within the 
EPR cavity, and secondly, by changing the radical composition formed. This was in 
agreement with previous work by Abu and Otten [111] which had shown that water 
within alanine was either free bound and affects the quality (Q) factor of the EPR cavity 
by absorbing the microwave signal (which lowers the output peak signal) or physically 
bound which causes variations in the quantities of each radical formed.  
Later work by Garcia and Dolo [110] concluded that radicals formed at the 
surface of alanine grains were unstable and readily underwent rearrangement and 
transformations, which altered the amplitude of the central EPR peak. This supported 
their earlier findings [123], showing how key features of the alanine spectrum changed 
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over time (4 to 16 days post-irradiation). Water diffusion, due to air moisture, was 
thought to be largely responsible for the changes occurring, therefore Dolo and Feaugas 
[49] suggested the use of a hydrophobic binder to protect alanine from environmental 
water and reduce its angular response.  
A typical commercial alanine pellet contains approximately 4 to 15 % binder 
(Gamma-Service: 4 %, Harwell: 9 %, NPL: 9 %, FWT: 4 % and AWMesstechnik: 15 
%), which offers little protection of the alanine from environmental water during the 
irradiation and read-out processes. However, commercial pellets use small grain sizes 
and high compacting, which does help to reduce water diffusion occurring [110]. 
Therefore, this chapter examines the use of a binder; paraffin wax, as the bulk 
constituent within the pellet (approximately 90 %) with alanine dispersed within 
(approximately 10 %). The paraffin wax should act to protect the alanine from 
environmental water and diffusion, thus helping to maintain chemical cohesion i.e. 
radical stability and limit relaxation effects within the cavity post-irradiation.  
If successful this method will resolve the issue of angular response and help to 
reduce measurement uncertainty. However, if the angular variation is still observed, 
then this might well be more indicative of the inherent instability of the three alanine 
radicals formed. The angular response of the pellets was measured at 3 and 30 days 
post-irradiation at various angles within the EPR cavity. The protection offered by the 
wax was assessed and compared with the following samples: 
i. Commercial alanine pellets (Synergyhealth containing 4 % binder),  
ii. Alanine powder (fine grain) contained within gelatine capsules,  
iii. IRGANOX®1076 powder (approximately 10 %) dispersed within paraffin 
wax (approximately 90 %). 
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IRGANOX®1076 is a novel dosimeter (Figure 3-1), and was chosen for 
examination in this work as it is both hydrophobic, forms only a single stable radical 
species when present as a solute in wax (IWSS) and exposed to ionising radiation. The 
EPR singlet formed is both easy to quantify and stable (Figure 3-3). The angular 
response of IRGANOX®1076 is of interest as a comparative means to evaluate 
alanine’s response, and may highlight some of the issues inherent within alanine; 
mainly that it is hygroscopic and forms three radical species. 
4.2 Methods 
4.2.1 Preparation of alanine powder in capsules 
L-Alanine ( 98 %) purchased from Sigma Aldrich was ground into a fine 
powder using a mortar and pestle, 60 mg of the powder was added to a cylindrical 
gelatine capsule (size 5, 1.0 x 0.5 cm), as commonly used for pharmaceutical purposes 
(Figure 4-1). The capsules were stored in vacuum sealed containers with silica beads to 
remove air moisture (humidity  40 % and temperature  25°C).  
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Figure 4-1. Alanine (60 mg) was added to a capsule (showing the lower half) prior to 
irradiation.
4.2.2 Preparation of alanine-wax pellets and IWSS pellets 
 The preparation of alanine-wax pellets is described in Section 2.2.4, and the 
IWSS pellets in Section 3.2.1. 
4.2.3 Irradiation of samples 
All irradiations were completed at the William Buckland Radiotherapy Centre, 
Alfred Hospital, Melbourne, Australia, using a Novalis Classic LINAC with 6 MV X-
rays, with the standards and uncertainties described previously in Section 2.2.8. All 
samples were placed on top of 15 cm solid-water as the back-scatter medium, with a 5 
cm solid water build-up, field size of 10 x10 cm2 and source surface distance (SSD) of 
95 cm and received a nominal dose of 30 Gy.  
alanine
capsule
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4.2.3.1  Synergyhealth alanine pellet irradiation setup 
Five pellets were placed within a Perspex sheet (3 mm thickness) containing 
nine fabricated cavities of the same dimensions, such that there were no air gaps 
between the pellets (Figure 4-2). The remaining four cavities were filled with ‘dummy’ 
pellets, which were marked for easy identification and to prevent any air gaps being 
present during irradiation (Figure 4-3).  
Figure 4-2. The irradiation setup used for Synergyhealth alanine pellets, showing the 
customized Perspex sheet and position of the alanine pellets within. 
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Figure 4-3. The placement of alanine pellets within a customized Perspex sheet, 
showing the marked ‘dummy’ pellets (coloured red) used to prevent air gaps being 
present during irradiation.
4.2.3.2  Capsule and wax pellet irradiation setup 
Five samples each of alanine in wax pellets, alanine in capsules and IWSS 
pellets were placed within a silica holder with cut-out cavities of the same dimensions, 
such that there were no air gaps between the sample and mould. The wax pellet surface 
with the alanine or IRGANOX® 1076 was placed upwards for irradiation (Figure 3.5), 
and the remaining cavities were filled with ‘dummy’ pellets, which were marked for 
easy identification (Figure 4-4).  
Dummy 
pellets 
Alanine 
pellets 
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Figure 4-4. The setup for irradiation of alanine and IWSS pellets and capsules 
containing alanine powder (60 mg).
After irradiation all samples were stored in the same conditions as described 
earlier (commercial alanine pellets and alanine powders in capsules in controlled 
conditions, alanine-wax pellets and IWSS pellets at room temperature without humidity 
control) for approximately 72 hours before EPR analysis. 
4.2.4 EPR conditions to determine angular response 
The EPR spectra of the irradiated samples were obtained using the conditions 
described in Section 2.2.7. All wax pellet samples were placed vertically in a quartz 
tube (open ended, internal diameter; 7 mm), whilst the commercial alanine pellets were 
placed flat in the quartz tube. The capsules containing alanine powder were placed 
vertically in an EPR cold-finger liquid nitrogen quartz dewar flask, (Wilmad, 50 mL 
reservoir, internal diameter; 5.4 mm, outer diameter; 10 mm) to prevent capsule 
movement (Figure 4-5). A goniometer was used to determine the angle of measurement 
and the sample manually rotated to the new position. 
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Spectrometer settings were: number of scans, 5; centre field, 3400 G; 
microwave power, 2 mW; sweep time, 21.05 s; sweep width 200 G; modulation 
amplitude, 4.0 G; time constant, 82 ms; modulation frequency, 100 kHz;  receiver gain, 
75 dB.  
Figure 4-5. The cold-finger liquid nitrogen Dewar flask with the gelatine capsule 
containing alanine powder in position.
4.2.5 EPR stability and measurements  
To maintain the simplicity of this study no post processing (manipulation of the 
spectra) of the EPR signal was performed. The angular variation was determined by 
measuring the amplitude of the central alanine peak (Figure 1-16) or single 
Cold-finger quartz 
dewar flask 
EPR collar 
Capsule containing 
alanine powder 
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IRGANOX®1076 peak (Figure 3-3) at 0° (position was chosen at random) (Figure 4-
6). 
Each pellet or capsule was rotated in 45° increments within the cavity, which 
gave eight measurements per sample (45°, 90°, 135°, 180°, 225°, 270°, 315° and 360°), 
so that the first angle (0°) was remeasured after one full rotation (360°) (Figure 4-6). 
The difference between the two values (0° and 360°) was used to determine the 
spectrometer drift as  0.90 % over the course of the measurement process, meaning 
that peak amplitude changes above 0.90 % are due to angular response only. 
Figure 4-6. The position of the sample angles measured for each sample as it was 
rotated within the EPR cavity.
Measurements were completed at 3 and 30 days post-irradiation, which allowed 
for a long-term assessment of the wax pellet samples stability to be made. The resultant 
EPR peak height at 0° was normalized so that deviations at other angles (due to angular 
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response) were evident and comparable between the different sample types 
investigated. Within this work a deviation range is reported for a sample set containing 
five pellets or capsules, and represents the minimum and maximum deviation values 
obtained. Overall, four sample sets were examined; alanine in wax, IWSS pellets, 
commercially available alanine pellets (Synergyhealth) and gelatine capsules containing 
alanine powder.  
4.2.6  Irradiation standards and uncertainty 
The standards and uncertainties for the MV X-ray beam used in this 
investigation have been described previously in Section 2.2.8. The errors associated 
with the data presented in this paper represent the average of at least five samples 
measured. 
4.3 Results 
The angular response for all five sample types investigated; measured at 3 and 
30 days post-irradiation with a nominal dose of 30 Gy (6MV X-rays) are shown in 
Table 4-1 and Figures 4-7 to 4-11.  
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Table 4-1. The maximal deviation ranges determined for all samples investigated at 3 
and 30 days post-irradiation.
&RPSRQHQWV )RUP 'RVLPHWHUPJ

GRVLPHWHU
LQSHOOHW
'HYLDWLRQ
UDQJH
GD\V
SRVW
'HYLDWLRQ
UDQJH
GD\V
SRVW
$ODQLQH
ZD[ SHOOHW  a  
,:66 SHOOHW  a  
$ODQLQH
6\QHUJ\
KHDOWK
&RPPHUFLDO
SHOOHW a a  
$ODQLQH
SRZGHU FDSVXOH  1$  
4.3.1 The EPR angular response for alanine powder in capsules at 3 
and 30 days post irradiation 
Measurements of the alanine central peak’s amplitude were collected at 45° 
increments within the EPR cavity, for 3 and 30 days post-irradiation. For each sample 
the measurement at 0° was selected as the normal, and assigned the value; 1.00, and 
used to normalise all raw measurements determined at other angles (Tables 4-2 and 4-
4). Therefore, the angular response is the deviation from the normalised value (at 0°) for 
each angle investigated within the EPR cavity and was used to plot Figure 4-7, which 
shows the variation in response for alanine powder (Sigma Aldrich) in gelatine capsules 
at 3 and 30 days post-irradiation as it is rotated. The maximal deviation for all five 
samples at 3 days post-irradiation ranged between 3.55 to 4.37 % (samples 2 and 4, 
Table 4-2) and was similar at 30 days post-irradiation; 3.23 to 5.43 % (samples 3 and 5, 
Table 4-3). 
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Spectrometer drift was monitored by comparison of the EPR signal amplitude at 
the starting position (0°) and after one full rotation within the EPR cavity (360°) for 
each sample (Table 4-4), with consistent values and low variation; 0.31 to 0.82 % (3 
days post-irradiation) and 0.31 to 0.85 % (30 days post-irradiation) obtained.  
Table 4-2. The measured EPR signal amplitude and normalised values for five samples 
(1 to 5) at different angles within the EPR cavity, (note 0° and 360° are the same 
position within the cavity). The maximal deviation range is 3.55 (sample 2) to 4.37 % 
(sample 4).                                                                                              
^ŝŐŵĂůĚƌŝĐŚĂůĂŶŝŶĞƉŽǁĚĞƌƐĂŵƉůĞƐ;ϯĚĂǇƐƉŽƐƚͿ
ŶŐůĞ ϭ ϭŶŽƌŵ Ϯ ϮŶŽƌŵ ϯ ϯŶŽƌŵ ϰ ϰŶŽƌŵ ϱ ϱŶŽƌŵ
ϬΣ ϵ͘ϴϮ ϭ͘ϬϬ ϴ͘ϵϭ ϭ͘ϬϬ ϴ͘Ϯϵ ϭ͘ϬϬ ϵ͘ϳϬ ϭ͘ϬϬ ϵ͘Ϯϵ ϭ͘ϬϬ
ϰϱΣ ϭϬ͘ϬϬ ϭ͘ϬϮ ϵ͘Ϯϵ ϭ͘Ϭϰ ϴ͘ϲϯ ϭ͘Ϭϰ ϵ͘ϱϯ Ϭ͘ϵϴ ϴ͘ϲϯ Ϭ͘ϵϯ
ϵϬΣ ϭϬ͘ϮϬ ϭ͘Ϭϰ ϴ͘ϯϲ Ϭ͘ϵϰ ϵ͘ϭϮ ϭ͘ϭϬ ϭϬ͘ϲϭ ϭ͘Ϭϵ ϴ͘ϴϴ Ϭ͘ϵϲ
ϭϯϱΣ ϵ͘ϳϬ Ϭ͘ϵϵ ϴ͘ϴϳ ϭ͘ϬϬ ϴ͘ϱϭ ϭ͘Ϭϯ ϭϬ͘ϰϯ ϭ͘Ϭϴ ϵ͘Ϭϯ Ϭ͘ϵϳ
ϭϴϬΣ ϵ͘ϲϳ Ϭ͘ϵϴ ϴ͘ϳϱ Ϭ͘ϵϴ ϴ͘ϰϬ ϭ͘Ϭϭ ϵ͘ϲϰ Ϭ͘ϵϵ ϵ͘ϯϯ ϭ͘ϬϬ
ϮϮϱΣ ϭϬ͘ϲϱ ϭ͘Ϭϴ ϴ͘ϵϳ ϭ͘Ϭϭ ϵ͘ϭϳ ϭ͘ϭϭ ϵ͘ϲϳ ϭ͘ϬϬ ϵ͘ϱϱ ϭ͘Ϭϯ
ϮϳϬΣ ϵ͘ϵϳ ϭ͘ϬϮ ϴ͘ϯϴ Ϭ͘ϵϰ ϴ͘ϳϱ ϭ͘Ϭϲ ϭϬ͘ϯϬ ϭ͘Ϭϲ ϵ͘ϬϮ Ϭ͘ϵϳ
ϯϭϱΣ ϵ͘ϭϴ Ϭ͘ϵϯ ϴ͘ϲϯ Ϭ͘ϵϳ ϵ͘Ϭϱ ϭ͘Ϭϵ ϭϬ͘ϰϬ ϭ͘Ϭϳ ϵ͘ϴϱ ϭ͘Ϭϲ
ϯϲϬΣ
;ĐŚĞĐŬͿ ϵ͘ϳϱ Ϭ͘ϵϵ ϴ͘ϴϲ Ϭ͘ϵϵ ϴ͘Ϯϴ ϭ͘ϬϬ ϵ͘ϳϴ ϭ͘Ϭϭ ϵ͘Ϯϲ ϭ͘ϬϬ
࢞ഥ ϵ͘ϵϬ ϭ͘Ϭϭ ϴ͘ϳϳ Ϭ͘ϵϴ ϴ͘ϳϰ ϭ͘Ϭϱ ϭϬ͘Ϭϰ ϭ͘Ϭϯ ϵ͘ϮϬ Ϭ͘ϵϵ
ʍ Ϭ͘ϰϯ Ϭ͘Ϭϰ Ϭ͘ϯϭ Ϭ͘Ϭϯ Ϭ͘ϯϰ Ϭ͘Ϭϰ Ϭ͘ϰϰ Ϭ͘Ϭϱ Ϭ͘ϯϵ Ϭ͘Ϭϰ
DĂǆ͘
ĚĞǀ͘й ϰ͘ϯϰ ϰ͘ϯϰ ϯ͘ϱϱ ϯ͘ϱϱ ϯ͘ϴϵ ϯ͘ϴϵ ϰ͘ϯϳ ϰ͘ϯϳ ϰ͘Ϯϯ ϰ͘ϮϮ
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Table 4-3. The measured EPR signal amplitude and normalised values for five samples 
(1 to 5) at different angles within the EPR cavity. The maximal deviation range is 3.23 
(sample 3) to 5.43 % (sample 5).                                                                                             
 ^ŝŐŵĂůĚƌŝĐŚĂůĂŶŝŶĞƉŽǁĚĞƌƐĂŵƉůĞƐ;ϯϬĚĂǇƐƉŽƐƚͿ
ŶŐůĞ ϭ ϭŶŽƌŵ Ϯ ϮŶŽƌŵ ϯ ϯŶŽƌŵ ϰ ϰŶŽƌŵ ϱ ϱŶŽƌŵ
ϬΣ ϵ͘ϱϳ ϭ͘ϬϬ ϴ͘ϵϱ ϭ͘ϬϬ ϵ͘ϰϱ ϭ͘ϬϬ ϵ͘ϰϬ ϭ͘ϬϬ ϵ͘ϭϲ ϭ͘ϬϬ
ϰϱΣ ϭϬ͘ϭϱ ϭ͘Ϭϲ ϵ͘Ϭϵ ϭ͘ϬϮ ϵ͘ϭϴ Ϭ͘ϵϳ ϴ͘ϴϲ Ϭ͘ϵϰ ϵ͘ϲϵ ϭ͘Ϭϲ
ϵϬΣ ϵ͘ϰϳ Ϭ͘ϵϵ ϵ͘Ϯϲ ϭ͘Ϭϯ ϵ͘ϰϬ Ϭ͘ϵϵ ϴ͘ϴϬ Ϭ͘ϵϰ ϭϬ͘ϰϲ ϭ͘ϭϰ
ϭϯϱΣ ϴ͘ϵϰ Ϭ͘ϵϯ ϴ͘ϲϲ Ϭ͘ϵϳ ϵ͘ϴϵ ϭ͘Ϭϱ ϵ͘ϲϲ ϭ͘Ϭϯ ϵ͘ϳϮ ϭ͘Ϭϲ
ϭϴϬΣ ϴ͘ϵϲ Ϭ͘ϵϰ ϵ͘ϯϲ ϭ͘Ϭϱ ϵ͘Ϭϴ Ϭ͘ϵϲ ϵ͘ϱϳ ϭ͘ϬϮ ϴ͘ϴϰ Ϭ͘ϵϳ
ϮϮϱΣ ϵ͘ϴϮ ϭ͘Ϭϯ ϵ͘Ϯϭ ϭ͘Ϭϯ ϵ͘ϵϱ ϭ͘Ϭϱ ϵ͘ϬϬ Ϭ͘ϵϲ ϵ͘Ϭϵ Ϭ͘ϵϵ
ϮϳϬΣ ϵ͘ϯϲ Ϭ͘ϵϴ ϵ͘ϳϭ ϭ͘Ϭϴ ϵ͘ϲϮ ϭ͘ϬϮ ϴ͘ϳϳ Ϭ͘ϵϯ ϵ͘ϲϵ ϭ͘Ϭϲ
ϯϭϱΣ ϵ͘Ϭϴ Ϭ͘ϵϱ ϴ͘ϲϮ Ϭ͘ϵϲ ϵ͘ϱϰ ϭ͘Ϭϭ ϵ͘ϲϯ ϭ͘ϬϮ ϵ͘ϵϭ ϭ͘Ϭϴ
ϯϲϬΣ
;ĐŚĞĐŬͿ ϵ͘ϱϰ ϭ͘ϬϬ ϵ͘ϬϮ ϭ͘Ϭϭ ϵ͘ϯϳ Ϭ͘ϵϵ ϵ͘ϰϴ ϭ͘Ϭϭ ϵ͘Ϯϭ ϭ͘Ϭϭ
࢞ഥ ϵ͘ϰϮ Ϭ͘ϵϴ ϵ͘ϭϭ ϭ͘ϬϮ ϵ͘ϱϭ ϭ͘Ϭϭ ϵ͘Ϯϭ Ϭ͘ϵϴ ϵ͘ϱϳ ϭ͘Ϭϰ
ʍ Ϭ͘ϰϯ Ϭ͘Ϭϰ Ϭ͘ϯϲ Ϭ͘Ϭϰ Ϭ͘ϯϭ Ϭ͘Ϭϯ Ϭ͘ϯϵ Ϭ͘Ϭϰ Ϭ͘ϱϮ Ϭ͘Ϭϲ
DĂǆ͘
ĚĞǀ͘й ϰ͘ϱϰ ϰ͘ϱϰ ϯ͘ϵϵ ϯ͘ϵϵ ϯ͘Ϯϯ ϯ͘Ϯϯ ϰ͘Ϯϱ ϰ͘Ϯϱ ϱ͘ϰϯ ϱ͘ϰϯ

Table 4-4. The drift in the EPR signal at 3 and 30 days post after measurement of all 
angles (0°/ 360° is the same point within the cavity) for L-alanine powder in capsules.
 ϯĂǇƐ ϯϬĂǇƐ
WĞůůĞƚ
η ϬΣ ϯϲϬΣ
ŝĨĨĞƌĞŶĐĞ
;йͿ
ƌŝĨƚ
;йͿ ϬΣ ϯϲϬΣ
ŝĨĨĞƌĞŶĐĞ
;йͿ
ƌŝĨƚ
;йͿ
ϭ ϵ͘ϴϮ ϵ͘ϳϱ ϵϵ͘ϯϭ Ϭ͘ϲϵ ϵ͘ϱϳ ϵ͘ϱϰ ϵϵ͘ϲϵ Ϭ͘ϯϭ
Ϯ ϴ͘ϵϭ ϴ͘ϴϲ ϵϵ͘ϰϮ Ϭ͘ϱϴ ϴ͘ϵϱ ϵ͘ϬϮ ϭϬϬ͘ϳϴ ͲϬ͘ϳϴ
ϯ ϴ͘Ϯϵ ϴ͘Ϯϴ ϵϵ͘ϴϴ Ϭ͘ϭϮ ϵ͘ϰϱ ϵ͘ϯϳ ϵϵ͘ϭϱ Ϭ͘ϴϱ
ϰ ϵ͘ϳϬ ϵ͘ϳϴ ϭϬϬ͘ϴϮ ͲϬ͘ϴϮ ϵ͘ϰϬ ϵ͘ϰϴ ϭϬϬ͘ϴϱ ͲϬ͘ϴϱ
ϱ ϵ͘Ϯϵ ϵ͘Ϯϲ ϵϵ͘ϲϰ Ϭ͘ϯϲ ϵ͘ϭϲ ϵ͘Ϯϭ ϭϬϬ͘ϱϱ ͲϬ͘ϱϱ






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
Figure 4-7. The large variation of the EPR signal produced for Sigma Aldrich alanine 
powder within capsules when rotated within the EPR cavity at 3 days (upper) and 30 
days (lower) post-irradiation.
4.3.2 The EPR angular response for commercial alanine pellets 
(Synergyhealth) at 3 and 30 days post irradiation 
The angular response for the Synergyhealth commercially produced alanine 
pellets at 3 and 30 days post-irradiation was determined for one full roation of the EPR 
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cavity. Raw measurements were collected at 45° increments and normalized (Tables 4-
5 and 4-6) and plotted in Figure 4-8. The maximal deviation for all five samples, 
ranged between 0.95 to 1.91 % at 3 days post-irradiation (samples 4 and 5, Table 4-5), 
and increased to 2.04 to 3.18 % at 30 days post-irradiation (samples 1 and 4, Table 4-
6). Spectrometer drift was low for both sets of measurements; 0.26 to 0.57 % (3 days 
post-irradiation) and 0.09 to 0.89 % (30 days post-irradiation) (Table 4-7).  
Table 4-5. The measured and normalised EPR signal amplitude for five Synergyhealth 
alanine pellets (1 to 5) at different angles within the EPR cavity, (note 0° and 360° are 
the same position within the cavity).  The maximal deviation range is 0.95 (sample 4) to 
1.91 % (sample 5).                                                                                              
^ǇŶĞƌŐǇŚĞĂůƚŚĂůĂŶŝŶĞƉĞůůĞƚƐ;ϯĚĂǇƐƉŽƐƚͿ
ŶŐůĞ ϭ ϭŶŽƌŵ Ϯ ϮŶŽƌŵ ϯ ϯŶŽƌŵ ϰ ϰŶŽƌŵ ϱ ϱŶŽƌŵ
ϬΣ ϭϵ͘ϳϰ ϭ͘ϬϬ ϭϵ͘ϭϲ ϭ͘ϬϬ ϭϵ͘Ϭϳ ϭ͘ϬϬ ϮϬ͘Ϭϳ ϭ͘ϬϬ ϭϵ͘ϱϭ ϭ͘ϬϬ
ϰϱΣ ϭϵ͘Ϯϴ Ϭ͘ϵϴ ϭϵ͘ϭϴ ϭ͘ϬϬ ϭϵ͘Ϯϴ ϭ͘Ϭϭ ϭϵ͘ϱϲ Ϭ͘ϵϳ ϭϵ͘ϲϳ ϭ͘Ϭϭ
ϵϬΣ ϭϵ͘ϯϯ Ϭ͘ϵϴ ϭϴ͘ϵϲ Ϭ͘ϵϵ ϭϵ͘ϯϭ ϭ͘Ϭϭ ϭϵ͘ϵϱ Ϭ͘ϵϵ ϭϵ͘ϳϳ ϭ͘Ϭϭ
ϭϯϱΣ ϭϵ͘ϴϭ ϭ͘ϬϬ ϭϵ͘ϯϯ ϭ͘Ϭϭ ϭϴ͘ϳϲ Ϭ͘ϵϴ ϭϵ͘ϲϱ Ϭ͘ϵϴ ϭϵ͘ϳϭ ϭ͘Ϭϭ
ϭϴϬΣ ϭϵ͘ϳϯ ϭ͘ϬϬ ϭϵ͘ϰϰ ϭ͘Ϭϭ ϭϴ͘ϯϲ Ϭ͘ϵϲ ϭϵ͘ϵϰ Ϭ͘ϵϵ ϭϵ͘ϳϱ ϭ͘Ϭϭ
ϮϮϱΣ ϭϵ͘ϱϴ Ϭ͘ϵϵ ϭϵ͘ϰϰ ϭ͘Ϭϭ ϭϴ͘ϲϱ Ϭ͘ϵϴ ϭϵ͘ϲϳ Ϭ͘ϵϴ ϭϵ͘ϵϬ ϭ͘ϬϮ
ϮϳϬΣ ϭϵ͘ϳϰ ϭ͘ϬϬ ϭϴ͘ϵϮ Ϭ͘ϵϵ ϭϵ͘ϬϬ ϭ͘ϬϬ ϭϵ͘ϵϮ Ϭ͘ϵϵ ϭϵ͘ϰϬ Ϭ͘ϵϵ
ϯϭϱΣ ϭϵ͘ϲϭ Ϭ͘ϵϵ ϭϵ͘Ϯϭ ϭ͘ϬϬ ϭϵ͘ϭϲ ϭ͘ϬϬ ϭϵ͘ϲϱ Ϭ͘ϵϴ ϭϴ͘ϳϭ Ϭ͘ϵϲ
ϯϲϬΣ
;ĐŚĞĐŬͿ ϭϵ͘ϲϴ ϭ͘ϬϬ ϭϵ͘Ϯϳ ϭ͘Ϭϭ ϭϵ͘ϭϱ ϭ͘ϬϬ ϭϵ͘ϵϵ ϭ͘ϬϬ ϭϵ͘ϰϲ ϭ͘ϬϬ
;࢞ഥͿ ϭϵ͘ϲϬ Ϭ͘ϵϵ ϭϵ͘Ϯϭ ϭ͘ϬϬ ϭϴ͘ϵϱ Ϭ͘ϵϵ ϭϵ͘ϴϬ Ϭ͘ϵϵ ϭϵ͘ϱϱ ϭ͘ϬϬ
ʍ Ϭ͘ϮϬ Ϭ͘Ϭϭ Ϭ͘ϮϬ Ϭ͘Ϭϭ Ϭ͘ϯϯ Ϭ͘ϬϮ Ϭ͘ϭϵ Ϭ͘Ϭϭ Ϭ͘ϯϳ Ϭ͘ϬϮ
DĂǆ͘
ĚĞǀ͘й ϭ͘Ϭϭ ϭ͘Ϭϭ ϭ͘ϬϮ ϭ͘ϬϮ ϭ͘ϳϱ ϭ͘ϳϱ Ϭ͘ϵϱ Ϭ͘ϵϱ ϭ͘ϵϭ ϭ͘ϵϭ
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Table 4-6. The measured and normalised EPR signal amplitude for five Synergyhealth 
alanine pellets (1 to 5) at different angles within the EPR cavity. The maximal deviation 
range is 2.04 (sample 1) to 3.18 % (sample 4).                                                                                             
 ^ǇŶĞƌŐǇŚĞĂůƚŚĂůĂŶŝŶĞƉĞůůĞƚƐ;ϯϬĚĂǇƐƉŽƐƚͿ
ŶŐůĞ ϭ ϭŶŽƌŵ Ϯ ϮŶŽƌŵ ϯ ϯŶŽƌŵ ϰ ϰŶŽƌŵ ϱ ϱŶŽƌŵ
0° ϮϮ͘ϵϴ ϭ͘ϬϬ ϮϮ͘ϯϱ ϭ͘ϬϬ Ϯϯ͘ϮϬ ϭ͘ϬϬ Ϯϯ͘ϬϬ ϭ͘ϬϬ Ϯϯ͘ϲϱ ϭ͘ϬϬ
45° ϮϮ͘ϳϰ Ϭ͘ϵϵ Ϯϭ͘ϵϳ Ϭ͘ϵϴ Ϯϯ͘Ϭϯ Ϭ͘ϵϵ ϮϮ͘ϵϬ ϭ͘ϬϬ Ϯϯ͘ϲϮ ϭ͘ϬϬ
90° Ϯϯ͘ϭϯ ϭ͘Ϭϭ ϮϮ͘ϳϰ ϭ͘ϬϮ ϮϮ͘ϱϴ Ϭ͘ϵϳ ϮϮ͘ϯϬ Ϭ͘ϵϳ Ϯϯ͘ϭϲ Ϭ͘ϵϴ
135° Ϯϯ͘ϲϰ ϭ͘Ϭϯ ϮϮ͘ϰϬ ϭ͘ϬϬ ϮϮ͘Ϭϭ Ϭ͘ϵϱ ϮϮ͘ϯϳ Ϭ͘ϵϳ Ϯϯ͘ϳϭ ϭ͘ϬϬ
180° ϮϮ͘ϵϱ ϭ͘ϬϬ ϮϮ͘ϯϱ ϭ͘ϬϬ Ϯϭ͘ϳϰ Ϭ͘ϵϰ ϮϮ͘Ϯϯ Ϭ͘ϵϳ Ϯϯ͘Ϯϭ Ϭ͘ϵϴ
225° ϮϮ͘ϰϯ Ϭ͘ϵϴ Ϯϭ͘ϭϬ Ϭ͘ϵϰ ϮϮ͘ϵϲ Ϭ͘ϵϵ Ϯϭ͘ϲϯ Ϭ͘ϵϰ ϮϮ͘ϭϱ Ϭ͘ϵϰ
270° ϮϮ͘ϭϭ Ϭ͘ϵϲ Ϯϭ͘ϮϮ Ϭ͘ϵϱ Ϯϯ͘Ϭϲ Ϭ͘ϵϵ ϮϬ͘ϴϬ Ϭ͘ϵϬ ϮϮ͘ϳϲ Ϭ͘ϵϲ
315° Ϯϯ͘ϭϯ ϭ͘Ϭϭ ϮϮ͘ϴϯ ϭ͘ϬϮ Ϯϯ͘Ϭϱ Ϭ͘ϵϵ ϮϮ͘ϬϮ Ϭ͘ϵϲ ϮϮ͘ϱϯ Ϭ͘ϵϱ
360Σ
(check) ϮϮ͘ϴϮ Ϭ͘ϵϵ ϮϮ͘ϭϱ Ϭ͘ϵϵ Ϯϯ͘ϮϮ ϭ͘ϬϬ Ϯϯ͘ϭϭ ϭ͘ϬϬ Ϯϯ͘ϰϰ Ϭ͘ϵϵ
࢞ഥ ϮϮ͘ϴϵ ϭ͘ϬϬ ϮϮ͘ϭϮ Ϭ͘ϵϵ ϮϮ͘ϳϬ Ϭ͘ϵϴ ϮϮ͘ϭϲ Ϭ͘ϵϲ Ϯϯ͘ϭϬ Ϭ͘ϵϴ
ʍ Ϭ͘ϰϳ Ϭ͘ϬϮ Ϭ͘ϲϱ Ϭ͘Ϭϯ Ϭ͘ϱϱ Ϭ͘ϬϮ Ϭ͘ϳϬ Ϭ͘Ϭϯ Ϭ͘ϱϳ Ϭ͘ϬϮ
DĂǆ͘
ĚĞǀ͘й Ϯ͘Ϭϰ Ϯ͘Ϭϰ Ϯ͘ϵϯ Ϯ͘ϵϯ Ϯ͘ϰϭ Ϯ͘ϰϭ ϯ͘ϭϴ ϯ͘ϭϴ Ϯ͘ϰϴ Ϯ͘ϰϴ
Table 4-7. The drift in the EPR signal at 3 and 30 days post after measurement of all 
angles (0°/ 360° is the same point within the cavity) for Synergyhealth alanine pellets.
 ϯĚĂǇƐ ϯϬĚĂǇƐ
WĞůůĞƚ
η ϬΣ ϯϲϬΣ
ŝĨĨĞƌĞŶĐĞ
;йͿ ƌŝĨƚ;йͿ ϬΣ ϯϲϬΣ
ŝĨĨĞƌĞŶĐĞ
;йͿ ƌŝĨƚ;йͿ
ϭ ϭϵ͘ϳϰ ϭϵ͘ϲϴ ϵϵ͘ϳϬ Ϭ͘ϯϬ ϮϮ͘ϵϴ ϮϮ͘ϴϮ ϵϵ͘ϯϬ Ϭ͘ϳϬ
Ϯ ϭϵ͘ϭϲ ϭϵ͘Ϯϳ ϭϬϬ͘ϱϳ ͲϬ͘ϱϳ ϮϮ͘ϯϱ ϮϮ͘ϭϱ ϵϵ͘ϭϭ Ϭ͘ϴϵ
ϯ ϭϵ͘Ϭϳ ϭϵ͘ϭϱ ϭϬϬ͘ϰϮ ͲϬ͘ϰϮ Ϯϯ͘Ϯ Ϯϯ͘ϮϮ ϭϬϬ͘Ϭϵ ͲϬ͘Ϭϵ
ϰ ϮϬ͘Ϭϳ ϭϵ͘ϵϵ ϵϵ͘ϲϬ Ϭ͘ϰϬ Ϯϯ Ϯϯ͘ϭϭ ϭϬϬ͘ϰϴ ͲϬ͘ϰϴ
ϱ ϭϵ͘ϱϭ ϭϵ͘ϰϲ ϵϵ͘ϳϰ Ϭ͘Ϯϲ Ϯϯ͘ϲϱ Ϯϯ͘ϰϰ ϵϵ͘ϭϭ Ϭ͘ϴϵ



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

Figure 4-8. The angular variation for commercial alanine pellets manufactured by 
Synergyhealth as rotated within the EPR cavity at 3 days (upper) and 30 days (lower) post-
irradiation.
4.3.3 The EPR angular response for alanine-wax pellets at 3 and 30 
days post irradiation 
The angular response for samples of alanine powder dispersed in wax when 
rotated in 45° increments within the EPR cavity was determined at 3 and 30 days post-
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irradiation. The maximal deviation for each angle was determined (Tables 4-8 and 4-9) 
and plotted in Figure 4-9 to show the deviation from the normal (1.00), which ranged 
between 1.14 to 2.06 % (samples 4 and 3, Table 4-8) at 3 days post-irradiation, and 
remained stable at 30 days post-irradiation; 1.56 to 1.93 % (samples 4 and 3, Table 4-
9). Spectrometer drift was low and gave consistent results for both sets of 
measurements; 0.00 to 0.75 % (3 days post-irradiation) and 0.20 to 0.90 % (30 days 
post-irradiation) (Table 4-10).  
Table 4-8. The measured and normalised EPR signal amplitude for five alanine- wax 
pellets (1 to 5) at different angles within the EPR cavity, (note 0° and 360° are the same 
position within the cavity).  The maximal deviation range is 1.14 (sample 4) to 2.06 % 
(sample 3).                                                                                              
ůĂŶŝŶĞͲǁĂǆƉĞůůĞƚƐ;ϯĚĂǇƐƉŽƐƚͿ
ŶŐůĞ ϭ ϭŶŽƌŵ Ϯ ϮŶŽƌŵ ϯ ϯŶŽƌŵ ϰ ϰŶŽƌŵ ϱ ϱŶŽƌŵ
ϬΣ ϭϬ͘ϱϬ ϭ͘ϬϬ ϭϬ͘ϱϬ ϭ͘ϬϬ ϭϭ͘ϬϬ ϭ͘ϬϬ ϭϬ͘ϳϬ ϭ͘ϬϬ ϭϬ͘ϲϲ ϭ͘ϬϬ
ϰϱΣ ϭϬ͘ϱϬ ϭ͘ϬϬ ϭϬ͘ϳϬ ϭ͘ϬϮ ϭϬ͘ϳϬ Ϭ͘ϵϳ ϭϭ͘ϬϬ ϭ͘Ϭϯ ϭϬ͘ϳϬ ϭ͘ϬϬ
ϵϬΣ ϭϬ͘ϭϱ Ϭ͘ϵϳ ϭϬ͘ϱϬ ϭ͘ϬϬ ϭϬ͘ϯϰ Ϭ͘ϵϰ ϭϬ͘ϵϬ ϭ͘ϬϮ ϭϬ͘ϱϲ Ϭ͘ϵϵ
ϭϯϱΣ ϭϬ͘ϱϳ ϭ͘Ϭϭ ϭϬ͘ϲϬ ϭ͘Ϭϭ ϭϬ͘ϲϬ Ϭ͘ϵϲ ϭϭ͘ϭϬ ϭ͘Ϭϰ ϭϬ͘ϱϬ Ϭ͘ϵϴ
ϭϴϬΣ ϭϬ͘ϮϬ Ϭ͘ϵϳ ϭϬ͘ϱϬ ϭ͘ϬϬ ϭϬ͘ϴϬ Ϭ͘ϵϴ ϭϬ͘ϵϬ ϭ͘ϬϮ ϭϬ͘ϱϱ Ϭ͘ϵϵ
ϮϮϱΣ ϭϬ͘ϮϮ Ϭ͘ϵϳ ϭϬ͘ϴϬ ϭ͘Ϭϯ ϭϬ͘ϰϱ Ϭ͘ϵϱ ϭϬ͘ϴϬ ϭ͘Ϭϭ ϭϬ͘ϴϴ ϭ͘ϬϮ
ϮϳϬΣ ϭϬ͘ϮϬ Ϭ͘ϵϳ ϭϬ͘ϴϬ ϭ͘Ϭϯ ϭϬ͘ϰϭ Ϭ͘ϵϱ ϭϭ͘ϬϬ ϭ͘Ϭϯ ϭϬ͘ϵϴ ϭ͘Ϭϯ
ϯϭϱΣ ϭϬ͘ϲϮ ϭ͘Ϭϭ ϭϬ͘ϴϲ ϭ͘Ϭϯ ϭϬ͘ϲϱ Ϭ͘ϵϳ ϭϬ͘ϵϬ ϭ͘ϬϮ ϭϬ͘ϳϲ ϭ͘Ϭϭ
ϯϲϬΣ
;ĐŚĞĐŬͿ ϭϬ͘ϱϱ ϭ͘ϬϬ ϭϬ͘ϱϱ ϭ͘ϬϬ ϭϭ͘ϬϬ ϭ͘ϬϬ ϭϬ͘ϲϮ Ϭ͘ϵϵ ϭϬ͘ϳϭ ϭ͘ϬϬ
;࢞ഥͿ ϭϬ͘ϯϳ Ϭ͘ϵϵ ϭϬ͘ϲϲ ϭ͘ϬϮ ϭϬ͘ϲϮ Ϭ͘ϵϳ ϭϬ͘ϵϭ ϭ͘ϬϮ ϭϬ͘ϳϬ ϭ͘ϬϬ
ʍ Ϭ͘ϭϵ Ϭ͘ϬϮ Ϭ͘ϭϱ Ϭ͘Ϭϭ Ϭ͘ϮϮ Ϭ͘ϬϮ Ϭ͘ϭϮ Ϭ͘Ϭϭ Ϭ͘ϭϳ Ϭ͘ϬϮ
DĂǆ͘
ĚĞǀ͘й ϭ͘ϴϳ ϭ͘ϴϳ ϭ͘ϰϮ ϭ͘ϰϮ Ϯ͘Ϭϲ Ϯ͘Ϭϲ ϭ͘ϭϰ ϭ͘ϭϰ ϭ͘ϱϳ ϭ͘ϱϳ


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Table 4-9. The measured and normalised EPR signal amplitude for five alanine-wax 
pellets (1 to 5) at different angles within the EPR cavity. The maximal deviation range 
is 1.56 (sample 4) to 1.93 % (sample 3).                                                                                              
ůĂŶŝŶĞͲǁĂǆƉĞůůĞƚƐ;ϯϬĚĂǇƐƉŽƐƚͿ
ŶŐůĞ ϭ ϭŶŽƌŵ Ϯ ϮŶŽƌŵ ϯ ϯŶŽƌŵ ϰ ϰŶŽƌŵ ϱ ϱŶŽƌŵ
ϬΣ ϵ͘ϰϬ ϭ͘ϬϬ ϵ͘ϳϴ ϭ͘ϬϬ ϭϬ͘ϬϬ ϭ͘ϬϬ ϵ͘ϲϳ ϭ ϵ͘ϱϰ ϭ
ϰϱΣ ϵ͘ϱϯ ϭ͘Ϭϭ ϵ͘ϰϵ Ϭ͘ϵϳ ϵ͘ϴϵ Ϭ͘ϵϵ ϵ͘ϱϳ Ϭ͘ϵϵ ϵ͘ϲϲ ϭ͘Ϭϭ
ϵϬΣ ϵ͘ϲϱ ϭ͘Ϭϯ ϵ͘ϯϱ Ϭ͘ϵϲ ϵ͘ϱϳ Ϭ͘ϵϲ ϵ͘ϲϰ ϭ͘ϬϬ ϵ͘ϴϭ ϭ͘Ϭϯ
ϭϯϱΣ ϵ͘ϴϯ ϭ͘Ϭϱ ϵ͘ϳϮ Ϭ͘ϵϵ ϵ͘ϵϰ Ϭ͘ϵϵ ϭϬ͘ϬϬ ϭ͘Ϭϯ ϵ͘ϵϱ ϭ͘Ϭϰ
ϭϴϬΣ ϵ͘ϲϳ ϭ͘Ϭϯ ϵ͘ϴϭ ϭ͘ϬϬ ϭϬ͘ϬϮ ϭ͘ϬϬ ϵ͘ϳϭ ϭ͘ϬϬ ϭϬ͘ϬϬ ϭ͘Ϭϱ
ϮϮϱΣ ϵ͘ϴϮ ϭ͘Ϭϰ ϵ͘ϲϳ Ϭ͘ϵϵ ϵ͘ϱϱ Ϭ͘ϵϲ ϵ͘ϲϲ ϭ͘ϬϬ ϵ͘ϴϰ ϭ͘Ϭϯ
ϮϳϬΣ ϵ͘ϴϬ ϭ͘Ϭϰ ϵ͘ϱϬ Ϭ͘ϵϳ ϵ͘ϲϲ Ϭ͘ϵϳ ϵ͘ϲϱ ϭ͘ϬϬ ϵ͘ϲϵ ϭ͘ϬϮ
ϯϭϱΣ ϵ͘ϱϵ ϭ͘ϬϮ ϵ͘ϱϯ Ϭ͘ϵϳ ϵ͘ϳϴ Ϭ͘ϵϴ ϵ͘ϵϯ ϭ͘Ϭϯ ϵ͘ϲϭ ϭ͘Ϭϭ
ϯϲϬΣ
;ĐŚĞĐŬͿ ϵ͘ϰϰ ϭ͘ϬϬ ϵ͘ϴϬ ϭ͘ϬϬ ϵ͘ϵϭ Ϭ͘ϵϵ ϵ͘ϲϮ Ϭ͘ϵϵ ϵ͘ϱϮ ϭ͘ϬϬ
࢞ഥ ϵ͘ϲϲ ϭ͘Ϭϯ ϵ͘ϲϭ Ϭ͘ϵϴ ϵ͘ϴϬ Ϭ͘ϵϴ ϵ͘ϳϯ ϭ͘Ϭϭ ϵ͘ϳϲ ϭ͘ϬϮ
ʍ Ϭ͘ϭϱ Ϭ͘ϬϮ Ϭ͘ϭϲ Ϭ͘ϬϮ Ϭ͘ϭϵ Ϭ͘ϬϮ Ϭ͘ϭϱ Ϭ͘ϬϮ Ϭ͘ϭϲ Ϭ͘ϬϮ
DĂǆ͘
ĚĞǀ͘й ϭ͘ϱϴ ϭ͘ϱϴ ϭ͘ϲϵ ϭ͘ϲϵ ϭ͘ϵϯ ϭ͘ϵϯ ϭ͘ϱϲ ϭ͘ϱϲ ϭ͘ϲϴ ϭ͘ϲϴ

Table 4-10. The drift in the EPR signal at 3 and 30 days post after measurement of all 
angles (0°/ 360° is the same point within the cavity) for alanine-wax pellets.
 ϯĚĂǇƐ ϯϬĚĂǇƐ
WĞůůĞƚ
η ϬΣ ϯϲϬΣ
ŝĨĨĞƌĞŶĐĞ
;йͿ
ƌŝĨƚ
;йͿ ϬΣ ϯϲϬΣ
ŝĨĨĞƌĞŶĐĞ
;йͿ
ƌŝĨƚ
;йͿ
ϭ ϭϬ͘ϱϬ ϭϬ͘ϱϱ ϭϬϬ͘ϰϴ ͲϬ͘ϰϴ ϵ͘ϰϬ ϵ͘ϰϰ ϭϬϬ͘ϰϲ ͲϬ͘ϰϲ
Ϯ ϭϬ͘ϱϬ ϭϬ͘ϱϱ ϭϬϬ͘ϰϴ ͲϬ͘ϰϴ ϵ͘ϳϴ ϵ͘ϴϬ ϭϬϬ͘ϮϬ ͲϬ͘ϮϬ
ϯ ϭϭ͘ϬϬ ϭϭ͘ϬϬ ϭϬϬ͘ϬϬ Ϭ͘ϬϬ ϭϬ͘ϬϬ ϵ͘ϵϭ ϵϵ͘ϭϬ Ϭ͘ϵϬ
ϰ ϭϬ͘ϳϬ ϭϬ͘ϲϮ ϵϵ͘Ϯϱ Ϭ͘ϳϱ ϵ͘ϲϳ ϵ͘ϲϮ ϵϵ͘ϰϴ Ϭ͘ϱϮ
ϱ ϭϬ͘ϲϲ ϭϬ͘ϳϭ ϭϬϬ͘ϰϳ ͲϬ͘ϰϳ ϵ͘ϱϰ ϵ͘ϱϮ ϵϵ͘ϳϵ Ϭ͘Ϯϭ

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Figure 4-9. The EPR amplitude changes for samples containing alanine encased in wax 
when rotated within the EPR cavity at 3 days (upper) and 30 days (lower) post-
irradiation. 
4.3.4 The EPR angular response for alanine-wax pellets at 3 days post 
irradiation manufactured > 8 months prior to irradiation  
The angular response for alanine powder dispersed in wax was determined for 
pellets made more than eight months prior to irradiation, and not stored under 
0.85
0.95
1.05
1.15
0° 45° 90° 135° 180° 225° 270° 315°
EP
R
 In
te
ns
ity
 (a
.u
)
Cavity Angle (°)
Alanine-wax pellets: 3 days post 
EPR angular response
0.85
0.95
1.05
1.15
0° 45° 90° 135° 180° 225° 270° 315°
EP
R
 In
te
ns
ity
 (a
.u
)
Cavity Angle (°)
Alanine-wax pellets: 30 days post
EPR angular response
Chapter 4: A comparison of the EPR angular response of alanine and IRGANOX®1076 
146 
controlled conditions (temperature and humidity was not monitored). Raw 
measurements were collected at 45° increments within the EPR cavity, and normalized 
(Table 4-11). The angular response for all angles investigated at 3 days post-irradiation 
is shown in Figure 4-10. The maximal deviation for each angle was determined and 
plotted to show the deviation from the normal (1.00), which ranged between 5.60 to 
8.60 % at 3 days post-irradiation.  
Table 4-11. The measured and normalised EPR signal amplitude for five alanine-wax 
pellets (1 to 5) at different angles within the EPR cavity, (note 0° and 360° are the same 
position within the cavity). The maximal deviation range is 5.60 (sample 1) to 8.60 % 
(sample 5).                                                                                             
ůĂŶŝŶĞͲǁĂǆƉĞůůĞƚƐ;хϴŵŽŶƚŚƐͿ
ŶŐůĞ ϭ ϭŶŽƌŵ Ϯ ϮŶŽƌŵ ϯ ϯŶŽƌŵ ϰ ϰŶŽƌŵ ϱ ϱŶŽƌŵ
ϬΣ ϭϬ͘ϵϮ ϭ͘ϬϬ ϴ͘ϳϳ ϭ͘ϬϬ ϵ͘ϵϴ ϭ͘ϬϬ ϭϭ͘ϲϬ ϭ͘ϬϬ ϭϭ͘ϭϬ ϭ͘ϬϬ
ϰϱΣ ϵ͘ϱϰ Ϭ͘ϴϳ ϵ͘Ϯϵ ϭ͘Ϭϲ ϭϬ͘ϯϬ ϭ͘Ϭϯ ϭϭ͘ϰϬ Ϭ͘ϵϴ ϭϬ͘ϰϬ Ϭ͘ϵϰ
ϵϬΣ ϭϬ͘ϰϬ Ϭ͘ϵϱ ϵ͘ϴϱ ϭ͘ϭϮ ϴ͘ϲϭ Ϭ͘ϴϲ ϵ͘ϲϬ Ϭ͘ϴϯ ϴ͘ϵϳ Ϭ͘ϴϭ
ϭϯϱΣ ϭϭ͘ϮϬ ϭ͘Ϭϯ ϴ͘ϱϱ Ϭ͘ϵϳ ϴ͘ϴϰ Ϭ͘ϴϵ ϭϬ͘ϰϬ Ϭ͘ϵϬ ϭϭ͘ϭϬ ϭ͘ϬϬ
ϭϴϬΣ ϭϭ͘ϭϰ ϭ͘ϬϮ ϴ͘ϰϳ Ϭ͘ϵϳ ϵ͘ϵϮ Ϭ͘ϵϵ ϭϭ͘ϯϬ Ϭ͘ϵϳ ϭϭ͘ϴϬ ϭ͘Ϭϲ
ϮϮϱΣ ϵ͘ϵϮ Ϭ͘ϵϭ ϵ͘ϲϮ ϭ͘ϭϬ ϭϬ͘Ϭϴ ϭ͘Ϭϭ ϭϭ͘ϬϬ Ϭ͘ϵϱ ϭϬ͘ϵϬ Ϭ͘ϵϴ
ϮϳϬΣ ϭϬ͘ϲϵ Ϭ͘ϵϴ ϵ͘ϯϱ ϭ͘Ϭϳ ϴ͘ϵϯ Ϭ͘ϴϵ ϵ͘ϲϰ Ϭ͘ϴϯ ϵ͘ϲϯ Ϭ͘ϴϳ
ϯϭϱΣ ϭϬ͘ϴϳ ϭ͘ϬϬ ϴ͘ϳϯ ϭ͘ϬϬ ϴ͘ϳϮ Ϭ͘ϴϳ ϵ͘ϴϰ Ϭ͘ϴϱ ϭϭ͘ϬϬ Ϭ͘ϵϵ
ϯϲϬ°
;ĐŚĞĐŬͿ ϭϬ͘ϱϴ Ϭ͘ϵϳ ϴ͘ϱϰ Ϭ͘ϵϴ ϵ͘ϳϭ ϭ͘ϭϭ ϭϭ͘ϬϬ Ϭ͘ϵϱ ϭϭ͘ϬϬ Ϭ͘ϵϵ
࢞ഥ ϭϬ͘ϱϵ Ϭ͘ϵϳ ϵ͘Ϭϴ ϭ͘Ϭϰ ϵ͘ϰϮ Ϭ͘ϵϰ ϭϬ͘ϲϬ Ϭ͘ϵϭ ϭϬ͘ϲϭ Ϭ͘ϵϲ
ʍ Ϭ͘ϱϵ Ϭ͘Ϭϱ Ϭ͘ϱϮ Ϭ͘Ϭϲ Ϭ͘ϳϭ Ϭ͘Ϭϳ Ϭ͘ϴϯ Ϭ͘Ϭϳ Ϭ͘ϵϭ Ϭ͘Ϭϴ
DĂǆ͘
Ğǀ͘й ϱ͘ϲϬ ϱ͘ϲϬ ϱ͘ϳϬ ϱ͘ϳϬ ϳ͘ϱϬ ϳ͘ϱϬ ϳ͘ϴϰ ϳ͘ϴϰ ϴ͘ϲϬ ϴ͘ϲϬ

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Figure 4-10. The EPR angular response for old alanine-wax pellets as rotated within 
the EPR cavity at 3 days post irradiation.
4.3.5 The EPR angular response for IWSS pellets at 3 and 30 days 
post irradiation 
The angular response for IWSS pellets was determined by collecting raw 
measurements at 45° increments within the EPR cavity, measurements were normalized 
at 3 and 30 days post-irradiation (Tables 4-12 and 4-13) and are shown in Figure 4-11. 
The maximal deviation for each angle was determined as ranging between 0.99 to 1.50 
% (samples 2 and 3, Table 4-12) at 3 days post-irradiation, which remained stable at 30 
days post-irradiation; 0.82 to 1.58 % (samples 3 and 2, Table 4-13). Spectrometer drift 
was also low for both sets of results; 0.04 to 0.37 % (3 days post-irradiation) and 0.12 to 
0.71 % (30 days post-irradiation) (Table 4-14).  
0.70
0.90
1.10
1.30
0° 45° 90° 135° 180° 225° 270° 315°
EP
R
 In
te
ns
ity
 (a
.u
)
Cavity angle (Σ)
Alanine-wax pellets (>8 months)
3 days post EPR angular response
Chapter 4: A comparison of the EPR angular response of alanine and IRGANOX®1076 
148 
Table 4-12. The measured and normalised EPR signal amplitude for five IWSS pellets 
(1 to 5) at different angles within the EPR cavity, (note 0° and 360° are the same 
position within the cavity). The maximal deviation range is 0.99 (sample 2) to 1.50 % 
(sample 3).                                                                                              
/t^^ƉĞůůĞƚƐ;ϯĚĂǇƐƉŽƐƚͿ
ŶŐůĞ ϭ ϭŶŽƌŵ Ϯ ϮŶŽƌŵ ϯ ϯŶŽƌŵ ϰ ϰŶŽƌŵ ϱ ϱŶŽƌŵ
ϬΣ ϵ͘ϯϮ ϭ͘ϬϬ ϵ͘ϯϳ ϭ͘ϬϬ ϵ͘ϭϲ ϭ͘ϬϬ ϵ͘ϱϰ ϭ͘ϬϬ ϵ͘Ϯϳ ϭ͘ϬϬ
ϰϱΣ ϵ͘ϯϮ ϭ͘ϬϬ ϵ͘ϯϰ ϭ͘ϬϬ ϵ͘ϯϱ ϭ͘ϬϮ ϵ͘ϲϬ ϭ͘Ϭϭ ϵ͘ϭϱ Ϭ͘ϵϵ
ϵϬΣ ϵ͘ϱϰ ϭ͘ϬϮ ϵ͘ϮϮ Ϭ͘ϵϴ ϵ͘ϰϳ ϭ͘Ϭϯ ϵ͘ϰϮ Ϭ͘ϵϵ ϵ͘ϯϭ ϭ͘ϬϬ
ϭϯϱΣ ϵ͘ϲϰ ϭ͘Ϭϯ ϵ͘ϭϰ Ϭ͘ϵϴ ϵ͘ϱϱ ϭ͘Ϭϰ ϵ͘ϯϳ Ϭ͘ϵϴ ϵ͘ϰϮ ϭ͘ϬϮ
ϭϴϬΣ ϵ͘ϲϯ ϭ͘Ϭϯ ϵ͘ϭϴ Ϭ͘ϵϴ ϵ͘ϱϮ ϭ͘Ϭϰ ϵ͘ϯϴ Ϭ͘ϵϴ ϵ͘Ϯϭ Ϭ͘ϵϵ
ϮϮϱΣ ϵ͘ϰϯ ϭ͘Ϭϭ ϵ͘Ϯϲ Ϭ͘ϵϵ ϵ͘ϰϰ ϭ͘Ϭϯ ϵ͘ϲϬ ϭ͘Ϭϭ ϵ͘ϭϳ Ϭ͘ϵϵ
ϮϳϬΣ ϵ͘ϲϰ ϭ͘Ϭϯ ϵ͘ϰϬ ϭ͘ϬϬ ϵ͘ϱϴ ϭ͘Ϭϱ ϵ͘ϳϯ ϭ͘ϬϮ ϵ͘Ϯϯ ϭ͘ϬϬ
ϯϭϱΣ ϵ͘ϰϴ ϭ͘ϬϮ ϵ͘Ϯϵ Ϭ͘ϵϵ ϵ͘ϯϮ ϭ͘ϬϮ ϵ͘ϰϴ Ϭ͘ϵϵ ϵ͘Ϭϳ Ϭ͘ϵϴ
ϯϲϬΣ
;ĐŚĞĐŬͿ ϵ͘ϯϮ ϭ͘ϬϬ ϵ͘ϯϯ ϭ͘ϬϬ ϵ͘ϭϳ ϭ͘ϬϬ ϵ͘ϱϭ ϭ͘ϬϬ ϵ͘Ϯϰ ϭ͘ϬϬ
࢞ഥ ϵ͘ϱϬ ϭ͘ϬϮ ϵ͘Ϯϳ Ϭ͘ϵϵ ϵ͘ϰϮ ϭ͘Ϭϯ ϵ͘ϱϭ ϭ͘ϬϬ ϵ͘Ϯϯ ϭ͘ϬϬ
ʍ Ϭ͘ϭϰ Ϭ͘Ϭϭ Ϭ͘Ϭϵ Ϭ͘Ϭϭ Ϭ͘ϭϰ Ϭ͘ϬϮ Ϭ͘ϭϯ Ϭ͘Ϭϭ Ϭ͘ϭϭ Ϭ͘Ϭϭ
DĂǆ͘
ĚĞǀ͘й ϭ͘ϰϯ ϭ͘ϰϯ Ϭ͘ϵϵ Ϭ͘ϵϵ ϭ͘ϱϬ ϭ͘ϱϬ ϭ͘ϯϯ ϭ͘ϯϯ ϭ͘ϭϲ ϭ͘ϭϲ
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Table 4-13. The measured and normalised EPR signal amplitude for five IWSS pellets 
(1 to 5) at different angles within the EPR cavity. The maximal deviation range is 0.82 
(sample 3) to 1.58 % (sample 2).                                                                                              
 /t^^ƉĞůůĞƚƐ;ϯϬĚĂǇƐƉŽƐƚͿ
ŶŐůĞ ϭ ϭŶŽƌŵ Ϯ ϮŶŽƌŵ ϯ ϯŶŽƌŵ ϰ ϰŶŽƌŵ ϱ ϱŶŽƌŵ
ϬΣ ϴ͘ϲϵ ϭ͘ϬϬ ϴ͘ϰϰ ϭ͘ϬϬ ϴ͘ϯϭ ϭ͘ϬϬ ϴ͘ϱϬ ϭ͘ϬϬ ϴ͘ϯϬ ϭ͘ϬϬ
ϰϱΣ ϴ͘ϰϮ Ϭ͘ϵϳ ϴ͘ϱϴ ϭ͘ϬϮ ϴ͘Ϯϵ ϭ͘ϬϬ ϴ͘ϰϵ ϭ͘ϬϬ ϴ͘ϮϬ Ϭ͘ϵϵ
ϵϬΣ ϴ͘ϱϰ Ϭ͘ϵϴ ϴ͘ϲϬ ϭ͘ϬϮ ϴ͘Ϯϲ Ϭ͘ϵϵ ϴ͘ϲϱ ϭ͘ϬϮ ϴ͘Ϯϵ ϭ͘ϬϬ
ϭϯϱΣ ϴ͘ϳϲ ϭ͘Ϭϭ ϴ͘ϲϮ ϭ͘ϬϮ ϴ͘Ϯϭ Ϭ͘ϵϵ ϴ͘ϲϭ ϭ͘Ϭϭ ϴ͘ϯϳ ϭ͘Ϭϭ
ϭϴϬΣ ϴ͘ϳϮ ϭ͘ϬϬ ϴ͘ϲϵ ϭ͘Ϭϯ ϴ͘ϭϳ Ϭ͘ϵϴ ϴ͘ϰϮ Ϭ͘ϵϵ ϴ͘ϱϱ ϭ͘Ϭϯ
ϮϮϱΣ ϴ͘ϲϴ ϭ͘ϬϬ ϴ͘ϳϲ ϭ͘Ϭϰ ϴ͘ϭϲ Ϭ͘ϵϴ ϴ͘ϯϵ Ϭ͘ϵϵ ϴ͘ϯϵ ϭ͘Ϭϭ
ϮϳϬΣ ϴ͘ϳϲ ϭ͘Ϭϭ ϴ͘ϱϱ ϭ͘Ϭϭ ϴ͘ϭϮ Ϭ͘ϵϴ ϴ͘ϱϲ ϭ͘Ϭϭ ϴ͘ϯϮ ϭ͘ϬϬ
ϯϭϱΣ ϴ͘ϳϳ ϭ͘Ϭϭ ϴ͘ϯϯ Ϭ͘ϵϵ ϴ͘ϭϵ Ϭ͘ϵϵ ϴ͘ϰϭ Ϭ͘ϵϵ ϴ͘ϱϮ ϭ͘Ϭϯ
ϯϲϬΣ
;ĐŚĞĐŬͿ ϴ͘ϳϮ ϭ͘ϬϬ ϴ͘ϱϬ ϭ͘Ϭϭ ϴ͘Ϯϲ Ϭ͘ϵϵ ϴ͘ϱϭ ϭ͘ϬϬ ϴ͘ϯϱ ϭ͘Ϭϭ
࢞ഥ ϴ͘ϲϳ ϭ͘ϬϬ ϴ͘ϱϳ ϭ͘ϬϮ ϴ͘Ϯϭ Ϭ͘ϵϵ ϴ͘ϱϬ ϭ͘ϬϬ ϴ͘ϯϳ ϭ͘Ϭϭ
ʍ Ϭ͘ϭϮ Ϭ͘Ϭϭ Ϭ͘ϭϰ Ϭ͘ϬϮ Ϭ͘Ϭϳ Ϭ͘Ϭϭ Ϭ͘ϭϬ Ϭ͘Ϭϭ Ϭ͘ϭϮ Ϭ͘Ϭϭ
DĂǆ͘
ĚĞǀ͘й ϭ͘ϰϰ ϭ͘ϰϰ ϭ͘ϱϴ ϭ͘ϱϴ Ϭ͘ϴϮ Ϭ͘ϴϮ ϭ͘ϭϯ ϭ͘ϭϯ ϭ͘ϰϭ ϭ͘ϰϭ

Table 4-14. The drift in the EPR signal (3 days post) for each IWSS pellet measured at 
the start (0°) and end (360°).
 ϯĂǇƐ ϯϬĂǇƐ
WĞůůĞƚ
η ϬΣ ϯϲϬΣ
ŝĨĨĞƌĞŶĐĞ
;йͿ
ƌŝĨƚ
;йͿ ϬΣ ϯϲϬΣ
ŝĨĨĞƌĞŶĐĞ
;йͿ
ƌŝĨƚ
;йͿ
ϭ ϵ͘ϯϮ ϵ͘ϯϮ ϭϬϬ͘Ϭϰ ͲϬ͘Ϭϰ ϴ͘ϲϵ ϴ͘ϳϮ ϭϬϬ͘ϯϱ ͲϬ͘ϯϱ
Ϯ ϵ͘ϯϳ ϵ͘ϯϯ ϵϵ͘ϲϯ Ϭ͘ϯϳ ϴ͘ϰϰ ϴ͘ϱϬ ϭϬϬ͘ϳϭ ͲϬ͘ϳϭ
ϯ ϵ͘ϭϲ ϵ͘ϭϳ ϭϬϬ͘ϮϬ ͲϬ͘ϮϬ ϴ͘ϯϭ ϴ͘Ϯϲ ϵϵ͘ϰϬ Ϭ͘ϲϬ
ϰ ϵ͘ϱϰ ϵ͘ϱϭ ϵϵ͘ϲϯ Ϭ͘ϯϳ ϴ͘ϱ ϴ͘ϱϭ ϭϬϬ͘ϭϮ ͲϬ͘ϭϮ
ϱ ϵ͘Ϯϳ ϵ͘Ϯϰ ϵϵ͘ϳϯ Ϭ͘Ϯϳ ϴ͘ϯ ϴ͘ϯϱ ϭϬϬ͘ϲϬ ͲϬ͘ϲϬ
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Figure 4-11. The variation in peak height for five samples of IRGANOX®1076 when 
rotated within the EPR cavity at 3 days (upper) and 30 days (lower) post-irradiation.
4.4 Discussion 
The angular response of commercial alanine pellets and alanine powders was 
previously examined by Dolo et. al [49, 110, 123]. Water diffusion was identified as 
causing changes to alanine water content, which promoted radical transformations and 
resonance issues within the EPR cavity. Together, these effects altered the spectrum 
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profile and an angular dependence was observed [110, 123]. To minimize this effect, 
the average of multiple measurements at different angles within the EPR cavity is 
routinely used for alanine. 
An alternative method was investigated, whereby alanine pellets were 
manufactured consisting of alanine powder present as the minor component 
(approximately 10 %) encased within a protective bulk material (approximately 90 %) 
to limit possible water diffusion. Paraffin wax was chosen as a suitable bulk material as 
it is hydrophobic, commonly used as a binder in commercially manufactured alanine 
pellets (typically  10 %), and does not affect the EPR signal produced.  
To assess the protective ability of the wax pellets measurements at 3 and 30 
days post-irradiation were completed, and compared to other alanine samples and the 
novel dosimeter IRGANOX®1076 also encased within wax. The protective ability 
provided by the wax was further tested post-irradiation as the samples were stored in 
darkened sealed containers without humidity and temperature being controlled 
(however it did not exceed 25 °C and 55 % RH respectively). Whilst, the commercial 
alanine pellets and capsules containing powder were stored in controlled conditions and 
monitored so that humidity was less than 40 % and temperature did not exceed 24 °C.  
4.4.1 Comparison of alanine powders and commercial pellets to 
previous literature reports 
The deviation range for alanine powder supplied by Sigma Aldrich (Figure 4-7) 
was 3.55 to 4.37 % (3 days post) and 3.23 to 5.43 % (30 days post), which is less than 
the 7 to 25 % ranges (at 2 weeks post-irradiation) reported by Dolo and Garcia [110] for 
their Merck and Fluka coarse grain samples. Grounding of the Sigma Aldrich powder 
prior to use may explain the reduced angular response, as low compacting of the 
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powder allows for easier water diffusion through the sample [111], resulting in higher 
angular responses. However, the deviation range is much larger than the approximately 
1 % maximal deviation reported for the Merck fine grain powders [110], thus 
confirming the importance of smaller particle sizes. Placement of the powder within the 
gelatine capsules could account for the good signal stability observed after 30 days 
post-irradiation, as the casing would act to protect the alanine within from external 
water contamination.  
Whilst the deviation range of the Synergyhealth pellets 0.95 to 1.91 % (at 3 days 
post) (Figure 4-8) was much less than the powder in capsule samples as expected, it 
was comparable (although slightly higher) with the approximately 1 % maximal 
deviation for the Gamma-Service and Bruker commercial alanine pellets investigated 
by Dolo and Garcia [110]. The pellets consist of approximately 4 % binder (wax), so 
low angular responses are likely to be due to small grain size and high compacting. 
However, as the alanine is the major component, no protection is provided by the wax 
binder to limit ongoing water interactions, and is evident at 30 days post-irradiation 
(Figure 4-8) as the deviation range had increased to 2.04 to 3.18 %, despite being 
stored in controlled conditions. This result suggests that water contamination is 
occurring and affecting the EPR cavities resonance and alanine’s radical composition. 
4.4.2 The angular response for alanine in wax pellets (3 and 30 days 
post-irradiation) 
The angular responses for the alanine powder dispersed in wax samples are 
shown in Figure 4-9. At 3 days post-irradiation the deviation range was 1.14 to 2.06 % 
which is slightly higher than the Synergyhealth pellets; 0.95 to 1.91 %. Yet after 30  
days the samples show good signal stability, and are relatively unchanged; 1.56 to1.93 
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% despite the samples not being stored in controlled conditions (for temperature and 
humidity), as opposed to the Synergyhealth pellets, whose deviation range nearly 
doubled to 2.04 to 3.18 % after 30 days post-irradiation. These results strongly suggest 
that the encasement of alanine within wax acts to protect it from environmental water 
and increases signal stability over time, thus lowering the observable angular response.  
4.4.3 The effects of time and water diffusion on angular response for 
alanine in wax pellets  
Alanine pellets manufactured more than 8 months prior to irradiation that had 
not been stored under controlled conditions (temperature and humidity was not 
monitored) were irradiated and the angular response determined at 3 days post-
irradiation (Figure 4-10). The deviation was 5.60 to 8.60 %, which is approximately 
four-times higher than the alanine-wax samples irradiated just after manufacture; 1.14 
to 2.06 % (Figure 4-9). These results show that water diffusion through the wax 
encasing has occurred over the time frame between manufacture and irradiation, and 
subsequently affected the EPR signals angular dependence. 
4.4.4 The angular response for IWSS pellets (3 and 30 days post-
irradiation) 
A final comparison with IRGANOX®1076 powder dispersed in wax was also 
made (Figure 4-11), as IRGANOX®1076 is hydrophobic and forms only the phenoxyl 
radical species when solubilised in wax, it was thought that these factors and the 
additional protection offered by the wax surrounding to environmental water would 
yield a lowered angular response. The deviation range at 3 and 30 days post-irradiation 
was; 0.99 to 1.50 % and 0.82 to 1.58 % respectively, which was less than the alanine in 
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wax samples (1.14 to 2.06 % at 3 days post, 1.56 to 1.93 % at 30 days post), however, 
they were not statistically significant (p > 0.05). Further investigations and analysis are 
needed to indicate if the hydrophobic nature of IRGANOX®1076 and that it only forms 
a single radical species are advantageous in lowering the EPR angular dependence. Like 
the alanine in wax samples, the IWSS pellets were largely unchanged at 30 days post-
irradiation, and provide further evidence that the wax when present as a bulk 
component acts to protect the sample within from external influences. 
4.5 Conclusion 
Dispersing alanine powder within wax, such that the wax is the bulk component, 
physically protects the alanine from external water and reduces its EPR angular 
response. At 3 days post-irradiation deviation ranges were low and comparable to the 
commercially manufactured alanine pellets (where alanine is the bulk component). 
However, at 30 days post-irradiation the protection provided by the wax was more 
clear, with the angular deviation ranges remaining largely unchanged, which was in 
sharp contrast to the commercial pellets, whose deviation ranges had nearly doubled, 
despite being stored in controlled conditions. Examination of alanine-wax pellets 
manufactured more than eight months prior to use showed a high angular dependence at 
3 days post-irradiation, suggesting water contamination had occurred and the 
importance of using the samples within a reasonable time frame after manufacture or 
otherwise storing the samples in a controlled environment where humidity and 
temperature are actively monitored. 
Overall, the IWSS pellets had the lowest angular responses; however this was 
not statistically significant. Further studies to determine if this was due to its 
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hydrophobic structure and that it only forms a single radical species when irradiated are 
needed. 
Finally, pellets manufactured in this work would be useful in studies where 
irradiation and read-out are performed over multiple days, such as accumulative dose 
measurements in radiotherapy. The highly stable EPR signal obtained (at 30 days post-
irradiation) and the pellets reduced sensitivity to environmental water would be of great 
benefit. Furthermore, the wax pellet can be moulded into any shape, allowing for highly 
customized patient dosimeters to be made. 
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Chapter 5: Investigation of the novel 
method ‘spiking’ to determine low 
doses (< 2 Gy) using alanine 
dosimeters 
The majority of contents from this chapter has recently been accepted for publication.
5.1 Introduction 
Developments in the application of radiotherapy such as utilisation of alternate 
beam types (MV and kV X-rays, electrons, protons, carbon ions) and treatment plans 
(image guided 4D-CT, PET and MRI) rely on the availability of convenient and reliable 
dosimeters that are sensitive in the dose ranges used for clinical practice. There remains 
the need to develop dosimeters able to quantify low radiation doses ( 2 Gy) and which 
also have the ‘ideal dosimeter properties as described in Section 1.3.1.  
Previous investigations have shown that while dosimeters based on alanine are 
well placed to satisfy these demands for high dose regimes (Section 1.3.2.2), they do 
not have the sensitivity to give reliable measurements for doses of less than 5 Gy. In 
this chapter a protocol for preparation and use of alanine dosimeters that extends their 
useful range down to about 0.5 Gy i.e. extending their low dose dynamic range 
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approximately ten times is presented. This greatly expands the application of dosimeters 
of this sort to clinical application. 
5.1.1 Current dosimeters in radiotherapy 
As discussed in Section 1.3, the dosimeters that dominate current practise in 
radiotherapy are; ionisation chambers (Section 1.3.1.4) which give uniform responses 
over a range of energies, making them useful in calibration, quality assurance and dose 
measurement [124] and solid-state dosimeters such as; TLDs and diodes- for patient in 
vivo dosimetry measurements, and are both discussed in detail in Sections 1.3.1.1 and
1.3.1.2.  
In radiotherapy applications TLDs are favoured due to their small sizes 
(dimensions of 1 mm3), independence to dose direction and dose rate. However, they 
suffer from post-irradiation fading and non-tissue equivalence [25]. Whilst diodes are 
advantageous as they are highly sensitive, physically small, and allow real time read 
outs [25], and for these reasons are often employed in highly specialized dosimetry 
roles, such as modulated beam verification. However, unlike TLDs, they are energy and 
angular dependent, easily damaged by radiation, require recalibrated before use, and 
have a restricted operational temperature range [25]. Finally, both TLDs and diodes 
suffer from non-tissue equivalence, which further complicates their application in 
radiotherapy. This leaves a need for alternative dosimeters with tissue equivalence and 
properties that overcome the limitations stated above, making alanine a potentially 
suitable candidate. 
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5.1.2 Alanine dosimetry in radiotherapy
Exposure of alanine to radiation leads to the generation of several long-lived 
radical species that can be quantified by EPR spectroscopy. The spectrum of irradiated 
alanine consists of five peaks in a 1:4:6:4:1 ratio [47] (Figure 5-1). Traditionally the 
amplitude of the central feature [47] is measured and correlated with dose and is 
considered more reliable than the double integration of the peak [125]. 
Figure 5-1. Typical EPR spectrum of the commercial alanine pellet subjected to ca. 30 
Gy (6MV X-rays). The positive peaks in the differential are designated as shown in the 
figure.  
However, the use of alanine dosimeters in radiotherapy is currently limited by 
their poor sensitivity at doses below 5 Gy [26, 50]. More seriously, baseline distortion 
even for doses between 5 and 10 Gy can impact on the measurement of the central 
peaks’ amplitude [126]. Strategies to overcome this have been implemented, with a 
focus on increasing the sensitivity of alanine dosimeters physically, as well as the EPR 
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protocols utilized in their measurement, and are discussed in Section 1.3.2.2 along with 
their limitations. 
This chapter introduces a new and innovative technique which renders alanine 
dosimeters to be sensitive to 2 Gy and below, and is described below. 
5.1.3 Standard addition or ‘spiking’ 
Standard addition or ‘spiking’ is an analytical chemistry technique used to 
enhance the measurement of weak signals by techniques such as atomic absorption 
spectroscopy (AAS) and gas chromatography (GS). The method involves the addition 
‘spike’ of an analyte with a known large concentration [Y] to an ‘unknown’ analyte of 
low concentration [X] that is unable to be detected reliably by the analytical technique, 
and is shown in equation (5-1). The “spike” increases the unknown’s concentration or 
signal into a range which can be reliably measured by the instrument to give a 
combined signal [Y+X], [127]. Subtraction of the spike signal [Y] leaves the remainder 
to be attributed to the unknown [X]. It is this very method that is examined in this 
chapter; whereby using alanine dosimeters a low dose of radiation will become ‘visible’ 
to the EPR spectrometer by the addition of a larger ‘spike’ dose of radiation, thus 
overcoming the EPR instruments low sensitivity which currently prevents alanine’s 
usage in low dose (൑5 Gy) radiotherapy measurements. 
           (5-1)
            
Another method, which is similar to spiking, is the additive dose method used in 
retrospective dosimetry (archaeological dating and radiation accidents) [128-131]. Here 
a sample of tooth or bone is measured using EPR [132] then irradiated with a series of 
Unknown [X] signal = Unknown + Spike [X+Y] signal – Spike [Y] signal
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known large doses, to produce a dose response curve, which is back-extrapolated to 
determine the original unknown dose received. The additive method has been used in 
radiotherapy by Trompier et al. [133] to determine the over-exposure dose received by 
breast cancer patients at a centre in Poland, in this case measurements were conducted 
using a section of rib bone from the affected patients. While similar in strategy, this 
work differs to the additive dose method in that a single large dose is given to an 
alanine dosimeter prior to exposure to a smaller known dose, and the measured dose is 
obtained without calculation of a dose response curve. Currently, there are no 
precedents for the proposed technique for low dose radiation determination in 
radiotherapy, and the results presented in this chapter show that spiking does allow low 
doses down to 0.5 Gy to be determined by measuring either the height or single 
integration of the central peak in the EPR spectrum for alanine.  
5.2 Methods 
5.2.1  Alanine pellets 
Commercial alanine pellets were purchased from Synergyhealth in Germany; 
each pellet contains 96 % L-alanine and 4 % binder, measuring 4.80 ± 0.1 mm in 
diameter and 3.00 ± 0.3 mm in height, with a recommended dose range from 10 Gy to 
150 kGy. All alanine pellets were stored at room temperature, in vacuum sealed 
containers with silica beads to remove air moisture. Temperature and humidity was 
monitored using a digital thermal/hygrometer gauge and did not exceed 25°C and 40 % 
RH respectively. 
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5.2.2 Irradiation of alanine pellets 
Sample irradiation was completed at the William Buckland Radiotherapy 
Centre, Alfred Hospital, Melbourne, Australia, using a Novalis Classic LINAC with 
6MV X-rays.
During irradiation alanine pellets were housed within a Perspex sheet (3 mm 
thickness) with cavities of the same dimensions as the alanine dosimeters, such that 
there were no air gaps between the pellet and Perspex surrounds (Figure 5-2). During 
irradiation all cavities were filled with blank pellets so as to maintain a homogeneous 
medium.  
Figure 5-2. The replacement of alanine pellets with a blank pellet (coloured red) to 
maintain a homogeneous medium during irradiation.
The Perspex sheet was placed on top of 15 cm solid-water as the back-scatter medium, 
with a 5 cm solid water build-up, field size of 10 x10 cm2 and SSD of 95 cm (Figure 5-
3).  
Dummy 
pellets 
Alanine 
pellets 
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Figure 5-3. The setup used for irradiation of alanine pellets, showing the customized 
Perspex sheet.
After receiving the required dose, the pellets were removed and stored in a 
darkened container under controlled conditions as stated previously. 
Initially pellets were irradiated with two doses administered as follows:  
i. An initial spike dose of 20 Gy was delivered, after which the EPR signal was 
recorded (24 hours post irradiation). A calibration pellet was removed from each 
sample set of 6 pellets and used to account for signal changes over time. 
ii. A second low dose of 0.5, 1.0 or 2.0 Gy was given to the remaining five pellets 
in the set and the EPR spectrum was re-recorded for all pellets (24 hours post 
irradiation). 
A similar strategy was employed for a set of twenty four alanine dosimeters which were 
irradiated with a dose of 30 Gy. Six of these dosimeters were not subject to further 
irradiation and the remaining pellets received doses ranging from 0.5 to 10 Gy. 
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Triplicate measurements were conducted for each dose and are summarized in Table 5-
1. 
Table 5-1. Radiation doses given to all alanine pellets, showing the initial spike (30 
Gy) and second low dose (0.5 to 10.0 Gy). 
1XPEHU
RISHOOHWV
VW'RVH
*\
1XPEHU
RISHOOHWV
QG'RVH
*\
7RWDOGRVH
*\
    
    
    
    
    
    
The calibration pellet (which only received the initial spike of 20 Gy or 30 Gy) was 
remeasured and this value was used to extract the spike values of the other pellets from 
the set. 
5.2.3  EPR signal analysis
All pellets were placed vertically in a quartz tube (internal diameter of 7 mm), 
fitted with an o-ring to ensure the pellet was consistently positioned in the centre of the 
cylindrical cavity. Initial results using a 20 Gy spike were ran with a total of three 
accumulative scans, but this was increased to ten accumulative scans for the second set 
of measurements conducted (Table 1). Data collection settings were as follows; centre 
field, 3400 G; microwave power, 2 mW; sweep time, 21.0 s; sweep width 200 G; 
modulation amplitude, 4.0 G; time constant, 81.92 ms; modulation frequency, 100 
kHz;  receiver gain, 75 dB.
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The amplitude of the central peak and P2 and P3 peaks was measured using 
peak to peak analysis [126], and the single integration of the peaks performed using the 
Bruker Elexsys program, and the integration area used for analysis is shown in Figure 
5-4.  
Figure 5-4. The alanine EPR spectrum showing the amplitude and single integration 
areas as used for the analysis of the P1 peaks. 
The calibration pellet for each sample set accounts for any changes in the EPR signal 
over time. Pellet irradiation and EPR measurement was completed within one week. 
Previous work (Section 4.3.2) had shown that the angular response for 
Synergyhealth pellets to be low (ranging between 0.95 to 1.91 % at 3 days post-
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irradiation), meaning it is stable over the time course of this work. The addition of a 
calibration pellet with each sample set was incorporated to account for any changes in 
the spectrometer over time. All irradiations and measurements were completed within 
one week. 
5.2.4  Measurement limitation
The data presented in this chapter is based on the measurements of the EPR 
signal amplitude, which is related to the alanine radical yield following exposure to set 
nominal doses delivered by X-ray sources. The nominal dose is based on measurements 
using a “parallel plate” ionisation chamber, with a 3 % uncertainty (Section 2.2.8). The 
data presented is an average of at least three measurements from independent samples, 
where the error bars represent the standard deviation between measurements.  
5.3 Results  
5.3.1 EPR measurements of the central alanine peak (P1) 
5.3.1.1  20 Gy dose spike 
Initially, 18 dosimeters received a spike of 20 Gy dose and were divided into 
three sets each containing six pellets. One pellet from each set was kept as a reference, 
and the remaining five pellets irradiated with a specified dose (0.5, 1, 2 Gy), where the 
stochastic uncertainty is estimated by the standard deviation for the five pellets 
subjected to the additional dose. The EPR signal for the calibration pellet was used as 
background to adjust the EPR measurement (spike plus smaller dose) of the other five 
pellets (Tables 5-2 and 5-3), which was then averaged. Table 5-4 summarizes the 
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average EPR signal for both amplitude and single integration of the central peak (P1), 
and are plotted in Figure 5-5. 
Table 5-2. EPR measurements for the P1 peak amplitude, with the calibration pellet ‘a’ 
which only received the 20 Gy spike.
$PSOLWXGHIRU3FHQWUDOSHDN
3HOOHW

6SLNH
*\
QGGRVH
*\
6SLNH
QGGRVH 6SLNH
D  *\  
E    
F    
G    
H    
I    
D  *\  
E    
F    
G    
H    
I    
D  *\  
E    
F    
G    
H    
I    

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Table 5-3. EPR measurements for the single integration of the P1 peak, the calibration 
pellets ‘a’ are highlighted. 
6LQJOHLQWHJRI3FHQWUDOSHDN
3HOOHW

6SLNH
*\
QGGRVH
*\
6SLNH
QGGRVH 6SLNH
D  *\  
E    
F    
G    
H    
I    
D  *\  
E    
F    
G    
H    
I    
D  *\  
E    
F    
G    
H    
I    
Table 5-4. The averages and standard deviations of the EPR signals for each sample set 
(n=5) using the peak amplitude and single integration of the P1 peak. All pellets were 
subjected to a spike dose of 20 Gy.
  $PSOLWXGH3 6LQJOHLQWHJ3
6HW
QG
GRVH
*\
VSLNH
,VDPSOH
,UHIHUHQFH!
ı
,VDPSOH
,UHIHUHQFH
,VDPSOH
,UHIHUHQFH!
ı
,VDPSOH
,UHIHUHQFH
     
     
     
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Whilst the relative error of the 2.0 Gy doses are comparatively small (Figure 5-5), good 
regression values (0.9935 and 0.9997 respectively) are obtained for both methods of 
quantifying the EPR signal, the relative errors for 1.0 and 0.5 Gy doses (both amplitude 
and integration measurements) are large, undermining the use of the approach for 
quantification of doses below ca. 1.5 Gy. The limit of detection was determined by 
calculating the EPR signal value (y) [134], using the equation below (5-2):  
y = mean (for the lowest dose measured: I sample- I reference) + n (number of 
pellets measured in the set) x [standard deviation of the lowest dose].     (5-2) 
Using the equation for the fitted regression line the limit of detection was determined 
as; 2.23 Gy for the amplitude method and 2.01 Gy for the single integration method.
Figure 5-5. Plot of the average EPR signal for the P1 peak amplitude and single 
integration after subtraction of the spike dose (20 Gy) where the error bars represent the 
standard deviation between measurements.
5.3.1.2  The calibration pellet 
The need for a calibration pellet is shown by removal of the calibration pellets 
results; 1a, 2a and 3a from Tables 5-2 and 5-3. Figure 5-6 shows the effect on the 
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averages and standard deviation for the P1 peak’s amplitude and single integration 
(Table 5-5), and that quantification of doses below 2 Gy is no longer possible. 
Table 5-5. The averages and standard deviations of the EPR signals for each sample set 
(n=5) using the peak amplitude and single integration of the P1 peak, without the use of 
a calibration pellet.
 $PSOLWXGH3 6LQJOHLQWHJ3

6HW
QGGRVH
*\
VSLNH
,VDPSOH
,UHIHUHQFH!
ı
,VDPSOH
,UHIHUHQFH
,VDPSOH
,UHIHUHQFH!
ı
,VDPSOH
,UHIHUHQFH
     
     
     
Figure 5-6. Plot of the average EPR signal for the P1 peak amplitude and single 
integration after subtraction of the spike dose (20 Gy), without a calibration pellet. 
5.3.1.3  30 Gy dose spike 
A similar method was employed using a 30 Gy spike (one reference pellet and 
three repeat measurements) with doses of 0.5, 1.0, 1.5, 2.0, 5.0 and 10 Gy. EPR 
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measurements were completed using 10 accumulated scans (Tables 5-6 and 5-7), and 
the averages of the signal are summarized in Table 5-8. Figure 5-7a shows the average 
EPR signal for the amplitude and single integration of P1 versus dose (over the dose 
range 0.5 to 10 Gy). Both plots have good R2 values (0.9895 for amplitude and 0.9890 
for single integration), and doses of 2.0 Gy and below are distinguishable. From Figure 
5-7a the limit of detection was determined as; 1.56 Gy for the amplitude method and 
0.711 Gy for the single integration method.
Figure 5-7b shows the expansion of the region 0.5 to 2.0 Gy doses with the 
alanine EPR signal strength as estimated using the maximum and minimum values of 
dAbs/dH in the P1 region (R2 = 0.7610) or the maximum and minimum values of the 
absorbance plot obtained from integration of dAbs/dHslopes (R2 = 0.9772).
Calculations for the limit of detection are; 1.74 Gy for the amplitude method and 1.03 
Gy for the single integration method.  
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Table 5-6. EPR measurements for P1 amplitude, red values indicate the calibration 
dosimeters ‘a’ from each set, which only received the 30 Gy spike.
$PSOLWXGHRI3FHQWUDOSHDN
3HOOHW

6SLNH
*\
QGGRVH
*\
6SLNH
QGGRVH 6SLNH
D    
E    
F    
G    
D    
E    
F    
G    
D    
E    
F    
G    
D    
E    
F    
G    
D    
E    
F    
G    
D    
E    
F    
G    
*Not used 
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Table 5-7. EPR measurements for the single integration of P1, showing the spike and 
low dose readings.
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FHQWUDOSHDN
3HOOHW
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*\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Table 5-8. The averages and standard deviations for P1 (amplitude and single 
integration) following calibration adjustment and subtraction of the 30 Gy spike.
 $PSOLWXGH3 6LQJOHLQWHJ3
6HW
QG
GRVH
*\
VSLNH
,VDPSOH
,UHIHUHQFH!
ı
,VDPSOH
,UHIHUHQFH
,VDPSOH
,UHIHUHQFH!
ı
,VDPSOH
,UHIHUHQFH
     
     
     
     
     
     
y = 0.2481x
R² = 0.9895
y = 0.2713x
R² = 0.9890
0
1
2
3
0.0 2.0 4.0 6.0 8.0 10.0
E
PR
 in
te
ns
ity
 (a
.u
)
Nominal dose (Gy)
EPR signal using the amplitude & single integration
of the central peak (-spike)
Av. Amp
Av. Single Int.
Chapter 5: Investigation of the novel method ‘spiking’ to determine low doses (< 2 Gy) using 
alanine dosimeters 
174 
Figure 5-7. Averages of the EPR signal for the low doses received, after subtraction of 
the initial spike (30 Gy); (a) shows the dose range 0.5 to 10 Gy and (b) scale 
expansion to highlight the region 0.5 to 2 Gy.
5.3.2 EPR measurements of the alanine peaks P2 and P3  
Using the EPR spectra obtained above (10 accumulative scans and a 30 Gy 
spike dose) the amplitude and single integration of the P2 and P3 peaks of alanine were 
also examined (Tables 5-9 and 5-10). Tables 5-11 and 5-12 summarize the average 
measurements for EPR signals obtained for P2 and P3 after calibration and spike 
subtraction, and Figures 5-8 and 5-9 show the average EPR signal plotted against dose 
respectively. 
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Table 5-9. EPR amplitude measurements for P2 and P3, the red values indicate the 
calibration dosimeter ‘a’ from each set.
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Table 5-10. EPR measurements for the single integration of P2 and P3, with red values 
indicating the calibration dosimeters marked ‘a’.
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Table 5-11. Summary of the averages and standard deviations for and amplitude and 
single integration of the P2 peak after spike subtraction.
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Figure 5-8. Averages of the EPR amplitude measurements for P2 amplitude and single 
integration after subtraction of the initial spike (30 Gy).
Both the P2 and P3 plots (Figures 5-8 and 5-9) show non-linearity and reduced 
R2 values; P2: 0.9388 (amplitude) and 0.9054 (single integration) and P3: 0.9259 
(amplitude) and 0.9198 (single integration), which strongly suggests that neither peak 
could be used for determining doses of  10 Gy. 
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Table 5-12. Summary of the EPR averages for the amplitude and single integration of 
the P3 peak after spike subtraction. 
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Figure 5-9. Average measurements for the P3 peak’s amplitude and single integration 
after subtraction of the initial spike.
5.4 Discussion 
Previous attempts to improve the sensitivity of alanine dosimeters have focused 
on the use of chemical additives to the dosimeter itself and modifications to the EPR 
spectrometer; however both methods are limited in their potential. Using the novel 
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method of spiking; whereby the alanine dosimeter receives a large dose of radiation 
prior to a second low dose, measurements of 2 Gy and below were determined. The 
results are discussed in the sections below, including the importance of the calibration 
pellet used, the effects of varying the spike dose given and changes to some of the EPR 
conditions. As well, the detection limits over the dose ranges used are presented.  
5.4.1 EPR signal analysis and the reference pellet 
Quantification of the EPR signal by single and double integration of the entire 
alanine EPR spectrum was found to give variable results owing to the errors associated 
with background subtraction and for this reason methods based on use of a more 
restricted region of the spectrum were investigated. The central peak (P1) is well-
defined and the intensity of this signal was quantified by single and double integration 
(Figure 5-4), where the more restricted range of field makes the measurement 
comparatively insensitive to small baseline distortions. 
Critical to the success of the spiking method is the reliable correction for the 
effect of the spike dose and is evident in Figures 5-5 (using a calibration pellet) and 
Figure 5-6 (no calibration pellet). In the current investigation a single reference pellet 
was used to quantify this effect. As is evident from Figure 5-7 there can be excellent 
agreement between measurements but systematic deviation from a linear relation 
between the EPR intensity and the nominal dose, as would result from an error in the 
reference signal. These measurements highlight the need to collect sufficient 
measurements of the reference signal to give the statistical basis for reliable 
measurements for nominal doses below 2 Gy. 
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The variation in the calibration pellets EPR signal is clearly seen for the 
amplitude and single integration measurements for P1, P2 and P3 (Tables 5-2, 5-3, 5-6, 
5-7, 5-9 and 5-10). For example, the variation in the P1amplitude measurements for the 
calibration pellet, after a spike dose of 30 Gy (Table 5-6) varies between 0.286 (pellet 
4a) to 0.907 (pellet 2a). This variation in response raises several issues that are the 
subject of continuing investigation; firstly if there is a time dependence issue between 
irradiation and read-out. Samples were stored for at least 24 hours post-irradiation to 
allow signal stabilization of the alanine radical before measurement of the EPR 
spectrum [135]. Logistical reasons associated with the location and access to the EPR 
spectrometer contributed to a variation of the measurement time between 24 to 96 
hours. While examination of the current sets of measurements does not show a clear 
relationship between the measurement time and attenuation of the signal, this element 
of the measurement protocol for EPR measurements requires more systematic 
investigation.  
In this context it is important to note that the storage conditions of the pellets 
requires careful control due to the possible effects of air moisture and water content on 
the pellets EPR signal [53]. Finally, revised protocols require the measurement of 
multiple calibration pellets ( 3) both to allow identification of outlier measurements 
and improve the statistical accuracy of the method. Our current investigations explore 
the impact of these refinements to the protocols on the accuracy and precision of the 
measurements. 
5.4.2 Measurements using a 20 Gy spike 
The results presented in Table 5-4 and Figure 5-5 were completed using a 20 
Gy spike dose and yielded good regression values (0.9935 and 0.9997). While the 2.0 
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Gy doses were clearly defined the 1.0 and 0.5 Gy doses had large standard deviations 
(approximately 0.032 to 0.048), which limited the usefulness of the measurements. The 
calculated limit of detection for both methods were; 2.23 Gy (amplitude) and 2.01 Gy 
(single integration) and suggests that doses of approximately 2 Gy can be reliably 
detected. Whilst, this is an improvement on the current sensitivity of alanine dosimeters 
further means to extend the low-dose detection limit were examined and are discussed 
below. 
5.4.3 Measurements using a 30 Gy spike 
To validate and optimise the accuracy of the spiking method, a larger spike dose 
was applied in conjunction with an increased number of EPR scans and a change in the 
measurement statistics (Table 5-1). While a decrease in the number of repeat 
measurements from five to three will reduce the statistical precision of the result, the 
improved accuracy of the measured spectrum provides an overall improvement in terms 
of reliability of the measurements (Figure 5-7). For the 30 Gy spike and measurement 
protocols there is a clearer distinction between measurements of doses below 2 Gy. A 
decrease in the limit of detection was evident for both methods over the dose range 0.5 
to 10 Gy (Figure 5-7a); 1.56 Gy (amplitude) and 0.711 Gy (single integration) when 
compared the 20 Gy spike samples (amplitude: 2.23 Gy and single integration 2.01 Gy), 
which suggests the increase in accumulative EPR scans is of benefit. However, analysis 
of the dose range 0.5 to 2.0 Gy (Figure 5-7b) shows a decrease in the R2 value for the 
amplitude measurements; 0.9895 (Figure 5-7a) to 0.7610 (Figure 5-7b), which did not 
occur for the single integration results; 0.9890 (Figure 5-7a) to 0.9772 (Figure 5-7b). 
Potentially the reduction in sample number (n= 2 for the 2 Gy dose) may have 
contributed and suggests that a balance between sample number and the number of EPR 
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scans performed is important. The detection limits over the 0.5 to 2.0 Gy dose range 
were determined to be 1.74 Gy (amplitude) and 1.03 Gy (single integration), which is 
lower than those obtained for the 20 Gy spike doses; 2.23 Gy (amplitude) and 2.01 Gy 
(single integration), suggesting that an increase in EPR scans is advantageous.  
Overall, this investigation suggests that half-Gray doses can be achieved by 
optimisation of the spiking method.  
5.4.4 Measurements of P2 and P3 signals 
Lastly the amplitude and single integration of the P2 and P3 (Figure 5-1) 
alanine peaks was examined and summarized in Tables 5-11 and 5-12. Overall the 
measurements for P2 and P3 (both amplitude and single integration) had higher 
standard deviations and reduced linearity when plotted (Figures 5-8 and 5-9), which is 
reflected in the lower regression values for all plots. As well, negative values for all 1.0 
Gy measurements for P2 and P3 amplitude and single integration were found. 
These results are consistent with earlier work by Heydari et. al. [46], who found 
that the P2 and P3 peaks were altered over time due to changes in the alanine radical 
composition. P1 is less susceptible to these effects as it is solely composed of the main-
deaminated radical species. 
5.5 Conclusion 
The spiking method can allow doses  1 Gy to be reliably detected by alanine 
dosimeters, and overcomes the current limitations which hinder its applications in 
radiation fields such as in radiotherapy. The addition of a spike dose increases the 
alanine dosimeters EPR signal making it easily detectable to an X-band EPR 
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instrument. After the addition of a second low dose, the spike signal can be subtracted 
from the total signal (spike + low dose) and reliably determined. Both the amplitude or 
single integration of the central alanine peak P1 can be used, and both are capable of 
quantifying doses of 0.5 Gy. The advantages of the spiking method are that no foreign 
materials are added to the alanine dosimeters, thus tissue equivalence is maintained, the 
EPR signal to noise ratio is improved, and baseline distortions typical at low doses are 
removed due to the large spike dose given. Furthermore no complex post-analysis is 
required and can be performed on any standard X-band EPR spectrometer. This work 
allows for alanine dosimeters to be used in a far wide range of applications in radiation 
dosimetry, particularly for the low doses often relevant for clinical applications.  
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Chapter 6: The formation of 
bimetallic-nanoparticles by neutron 
capture 
Thermal neutron irradiations were undertaken at the Australian Nuclear Science 
and Technology Organisation (ANSTO) at the LE2-2 facility, and funded by the 
Australian Institute of Nuclear Science and Engineering (AINSE) Research Award, ID 
number 11437, 2015. We acknowledge this grant and kindly thank AINSE and 
ANSTO.  
6.1 Introduction 
MetNPs possess unique physical and chemical properties, which are not evident 
in their larger bulk-metal particles, as was discussed in Section 1.4.1. It is well known 
that NPs have larger surface areas to volume, which increases with decreasing particle 
size [62] so that more surface atoms are available to partake in interactions. In 
particular, MetNPs with high atomic numbers (Z) are of interest for use in radiotherapy 
due to the increased probability of photoelectric interactions occurring for kV energy X-
rays, and to a lesser extent MV x-rays, which increases dose deposition at a tumour site 
[24, 39, 63-67, 89].
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As the current understandings of mono-metallic-nanoparticles has increased, 
particularly for AuNPs as possible radiosensitizers (see Section 1.4.1) so too has the 
interest in producing BiMetNPs, (comprising of two different metal nanoparticles), with 
reasons for this described in Section 1.4.2. Current means to produce BiMetNPs 
focuses largely on wet-chemistry methods, which are limited in the combinations of 
producible bi-metals, and usually involve the formation of a single NP containing a 
metal core layered with a secondary metal [73, 136, 137] (Figure 6-1a). This type of 
BiMetNP is synthetically favoured over the alloy type MetNPs (Figure 6-1b) mainly 
because of separation difficulties encounter when isolating the product from reaction 
waste by-products [85] (Section 1.4.2).  
Figure 6-1. The different types of BiMetNPs formed: type (a) consists of a core and 
second metal layer, type (b) is an alloy of the two metals within a single NP (adapted 
from [136]). 
Because of these drawbacks the search for alternative synthetic methods 
continues, which ultimately provides both a more effective means to produce the alloy-
type BiMetNPs, and increases the metallic combinations currently available. In this 
chapter nuclear reactions are investigated as one such alternative method, whereby 
a) Core & layer BiMetNP b) Alloy BiMetNP
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AuNPs undergo neutron activation to form a second metal; mercury, and yield the 
alloy-type BiMetNP product; AuHgNPs.   
6.1.1 Neutron activation of AuNPs and formation of radioactive 198Au
Neutron activation of a target MetNP is the process whereby a target metal 
atomic nuclei absorbs neutrons, and becomes excited i.e. is in an excited energy state. 
To return to the ground state it emits gamma rays, protons or alpha particles to form a 
stable BiMetNP product. AuNPs are a highly suitable target as their interactions with 
neutrons are well known and the unstable gold radioisotope 198Au is well studied and 
employed in recent brachytherapy techniques [68, 69]. The decay scheme of 198Au, via 
gamma and beta emissions is shown in Figure 6-2 and the subsequent formation of the 
stable 198Hg product. 
Figure 6-2. The gamma and beta decay process of the radioactive unstable 198Au 
isotope to the stable 198Hg isotope.
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Following neutron bombardment the stable mercury atom 198Hg formed (Figure 
6-2) would alter the atom packing at the surface of the solid; Au atoms favour the face-
centred-cubic (FCC) packing (Figure 6-3a), whilst Hg atoms favour the rhombohedral 
packing arrangement (Figure 6-3b). The mean coordination number of the Au atoms 
present would also be altered, thus causing changes to the properties of the newly 
synthesized AuHgNPs, and increasing the surface-to-volume ratio, meaning more surface 
atoms are available to partake in a given interaction.
Figure 6-3 a & b. Au atoms arrange in a FCC packing within a solid (a) whilst Hg 
atoms favour rhombohedral packing (b). 
b) Rhombohedral packing
One side of the cube showing the 
arrangement of gold atoms
Gold atoms arranged  
in a cube
a) FCC packing
Mercury atoms arranged 
within a rhombohedral
One side of the rhombus showing the 
arrangement of mercury atoms
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The radioactive isotope 198Au formed after neutron absorption has a half-life of 
2.7 days (Figure 6-2) and was extensively investigated in the 1950’s and 1960’s for the 
treatment of ovarian and prostate cancers. Work by Keettel et al. [138-140] improved 
the five-year survival rate of Stage I and II ovarian cancer patients from 52 % (surgery 
alone) to 86 % when using surgery and 198Au-colloid brachytherapy conjointly. 
Similarly, pioneering work by Flocks et al. [141-143] examined the viability of post-
prostate surgery injections of colloidal 198Au administered to patients over a twenty-five 
year period, which provided a more localised treatment, whilst minimising damage to 
healthy surrounding tissue. A recent review of Flocks’ work [144] found the treatment 
of locally advanced prostate cancer with 198Au yielded statistically significant 
improvements to long and short term patient survival rates compared to the work of 
Flock’s contemporaries at that time. 
More recently, Khan et al. [69] irradiated aqueous solutions of 197Au-dendrimer 
salts and 197Au-nanocomposites in a nuclear reactor to produce positively charged 
poly(198Au0) radioactive gold-dendrimer composite nanodevices ranging in size from 10 
to 29 nm. Single dose injections of the 198Au-nanodevices (74 μCi) directly into 
tumour-bearing mice produced a > 45 % reduction in tumour size, whilst the non-
radioactive analogue yielded no therapeutic benefit. Similarly, Chanda et al. [68] 
produced spherical functionalized 198Au with Gum Arabic glycoprotein (GA) 
nanoparticles (GA-198AuNPs) ranging in size from 12 to 18 nm. A single dose (408 
μCi) injected into severely compromised immuno-deficient (SCID) prostate tumour-
bearing mice, yielded an 82 % reduction in tumour size (harvested 31 days post-
treatment), with no measurable uptake of radioactive materials in non-target organs.  
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Furthermore, Black et al [145] used various 198Au-doped nanostructures (cubic 
cages, spheres, disks and rods) to measure the biodistribution, tumour uptake and intra-
tumoural distribution of the structures within a murine EMT6 breast cancer model, and 
successfully imaged the distributions in vivo using the gamma and beta emissions as the 
unstable isotope decayed. This work successfully demonstrated the ability to use the 
unstable 198Au isotope as a theranostic agent; for targeted brachytherapy and imaging, 
which allowed for real time analysis. Black et al [145] also reported that significantly 
more tumour uptake occurred for nanospheres and disks but was limited to the tumour 
surface, whilst nanorods and cubic cages showed less overall uptake but were more 
dispersed throughout the entire tumour.  
6.1.2 Gold-mercury nanoparticles (AuHgNPs) 
Whilst mercury is highly toxic, the number of mercury atoms generated by gold 
undergoing neutron capture and decaying to mercury is small due to the low cross-
section (reaction probability) and is estimated to be approximately 500 ng per 50 mg of 
AuNP sample used. Williams et al. [146] demonstrated by administering mercuric 
acetate to human KB cells that mercury acts to decrease cell viability by inducing 
oxidative stress (via a series of enzyme activations and inhibitions) to promote DNA 
damage. Other studies have also shown that even low concentrations (10 to 500 ȝM) of 
mercury ions (Hg2+) produce a high percentage of cell deaths by both necrosis and 
apoptosis [147]. Therefore, it is conceivable that if AuHgNPs were administered to a 
tumour site the small amount of mercury atoms present would still induce negative 
chemical and biological affects on the tumour cells.  
The AuHgNPs may also provide a suitable target for radiotherapy, whereby the 
high Z number metals would yield additional DE due to secondary electron emissions. 
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Similarly, if the unstable product containing 198Au was administered to a tumour (after 
neutron capture), the decay process (via gamma and beta emissions) to 198Hg may also 
provide an additional localised dose to the tumour site.  These effects and how they 
could impact on the tumour are illustrated in Figure 6-4.  
Ȗ
Figure 6-4. The decay of radioactive unstable 198Au isotope to the stable 198Hg isotope 
within target tumour cells and the four possible uses of the decay process and stable 
product.
6.2 Methods 
This section describes the materials and thermal neutron irradiation conditions 
to generate BiMetNPs, including sample preparation for ICP-MS analysis and detection 
methods used to measure the emitted radiation during the decay process. 
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6.2.1  Neutron irradiation of AuNPs to form AuHgNPs
Neutron irradiations were conducted at the Open Pool Australian Lightwater 
(OPAL) reactor (20 Megawatt) at the Australian Nuclear Science and Technology 
Organisation (ANSTO) using the LE2-2 facility, position A (Figure 6-5). 
Figure 6-5. Inside the OPAL pool showing the reactor core and placement of samples 
for neutron bombardment.  
AuNP samples were weighed into polyethylene capsules, wrapped in aluminium 
foil and placed within an irradiation canister (Figure 6-6) with a spacer to prevent 
sample movement. For the long irradiation (used to determine the presence of mercury 
by ICP-MS) a single capsule containing 51 mg of sample was irradiated for four hours 
with a neutron flux of approximately 8×1012 cm-2s-1. For the short irradiation (used only 
to measure the gamma-decay from 198Au to 198Hg) five capsules containing 
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approximately 10 mg of sample were irradiated for ten minutes with a neutron flux of 
approximately 2.8×1012 cm-2s-1.
Figure 6-6. The irradiation setup used for neutron bombardment of the AuNPs.
6.2.2  Materials and detectors 
All chemicals used in the irradiation process and analysis by ICP-MS were 
purchased from Sigma Aldrich, of analytical grade, and used without further 
purification; Gold nanopowder (AuNP), <100 nm particle size (99.9 % trace metals 
basis), Mercury standard for AAS and ICP (TraceCERT®, 1000 mg/L Hg in nitric acid), 
Hydrochloric acid (fuming, 37 % for trace analysis) and Nitric acid (redistilled, 70 %, 
99.999 % for trace metal basis).
The gamma-detectors used for the analysis of the AuNPs following short 
neutron irradiation were; two types of Gafchromic films of different sensitivities, TLD 
detectors and OSL nanoDots®. The Gafchromic films self-develop in real time, are near 
tissue equivalent and do not require processing: 
i. RTQA2-1010 (GAFCHROMIC®), dose range 0.02 to 8 Gy, consists of three 
layers; one active layer (17 microns) between two polyester layers (97 microns).  
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ii. EBT3 (GAFCHROMIC®), dose range 1 cGy to > 40 Gy EBT3, consists of three 
layers; one active layer (30 microns) between two polyester layers (50 and 175 
microns).  
Both films were scanned using an EPSOM Perfection V700 scanner in transmission 
mode, and analysis was completed using ImageJ software.  
TLDs (TLD100) were purchased from Thermo Scientific Harshaw. Each TLD 
had the following specifications: dimensions; 3.2 x 3.2 x 0.89 mm, containing; lithium 
fluoride (Li natural) LiF:Mg, dose range; 10 pGy to 10 Gy, and dose accuracy; ±15 (±2 
sigma) %. Approximately 24 hours prior to use all TLDs were annealed at 400 °C for 
one hour and then 100 °C for 4 hours. Measurements were completed using a Harshaw 
QS 5500 TLD reader at the Alfred Hospital, Department of Radiotherapy, Melbourne, 
Australia. 
Single point OSL nanoDots® were purchased from Landauer. Each dosimeter 
had the following specifications: dimensions; 10 mm x 10 mm, thickness 2 mm within a 
plastic covering of 45 mm x 40 mm, containing; aluminium oxide doped with carbon 
(Al2O3:C), dose range for beta (150 keV to 10 MeV); 0.05 mGy to 10 Gy and for 
photons (gamma and X- rays from 5 keV to 40 MeV); 0.05 mGy to 10 Gy, dose 
accuracy; ± 5 % for photons and electrons (5 MeV to 20 MeV), total uncertainty per 
single measurement; +/- 10 %. Approximately 24 hours prior to use all dosimeters were 
annealed by exposure to fluorescent light tubes (for approximately 12 hours), then pre-
scanned using the commercially available microStar® dosimetry reader (Landauer), at 
RMIT University, Melbourne, Australia. 
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6.2.3 Preparation of samples for ICP-MS  
To identify the presence of mercury in the samples following neutron irradiation 
a method called acid digestion was employed. Acid digestion is a well-known means of 
dissolving a solid sample to release the analytes from the product matrix without loss or 
contamination. The resultant solution is then able to be analysed by ICP-MS [148-152]. 
Acid digestion of the samples was completed in a fume hood and all glassware was pre-
washed with hydrochloric acid to remove organic contaminants. The AuHgNP sample 
(approximately 26 mg, following long irradiation) was added to a glass conical flask 
(50 mL), and 10 mL of aqua regia (2 mL HCl: 8 mL HNO3) was slowly added at room 
temperature with gentle stirring. A glass stopper was placed in the top of the flask, so 
that excess gases could escape, whilst preventing contaminants from entering (Figure 
6-7). The mixture was left at room temperature overnight (approximately 16 hours) so 
that complete digestion of the sample occurred, and yielded a dark orange solution 
(Figure 6-7).  
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Figure 6-7. The acid digestion of the irradiated AuNPs over time, showing the solid 
sample digestion (the colour darkens with time). The mercury atoms were released 
from the product matrix and the solution was then analysed by ICP-MS.
Three ICP-MS samples were prepared containing 1 mL, 2 mL and 3 mL of the 
digested sample in solution. All solutions were filtered (Millex®, syringe filter 0.45 ȝm 
pore size) into 15 mL centrifuge screw top tubes (Corning®, PET, sterile) and the 
volume total made up to 10 mL with Milli Q water.  Measurements were completed 
using the Agilent Technologies ICP-MS with laser ablation capability, and ASX-500 
Series Autosampler.  
The ICP-MS detects the ions of interest by the process shown in Figure 6-8 a & 
b. The samples are diluted prior to introduction into the ICP-MS, and then nebulized to 
form an aerosol. A carrier gas takes the aerosol to the high temperature argon plasma 
torch (approximately 6000 to 10000 K) where it is vaporized, atomized, and ionized 
(mainly into singly charged positive ions). The ions are extracted and focused using a 
series of ion lenses, then separated by the quadrupole mass analyser by their 
mass/charge ratio, and detected by an electron multiplier (Figure 6-8b). 
0 hours ~3 hours ~16 hours
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Figure 6-8 a & b. The Agilent Technologies ICP-MS (a) showing the inner workings 
(b) from the induction of the liquid sample through to its detection 
6.2.4 Gamma detection for short-irradiated samples 
 Five vials containing approximately 10 mg of neutron irradiated AuNP (short 
irradiation) were placed on top of two sheets of Gafchromic film; RTQA2-1010 (top 
layer) and EBT3 (bottom layer) (Figure 6-9). This was done as the EBT3 film is more 
sensitive to low-doses (Section 6.2.2), and capable of detecting gamma-emissions 
through the RTQA2-1010 film, thus providing an additional set of measurements for 
the decay process. Two TLDs were placed on either side of the vial and an OSL 
nanoDot® on top (Figure 6-9). 
a.
b.
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Figure 6-9. The sample vial showing the positioning of the OSL nanoDot® (top of vial) 
and two TLDs (sides of vial) and two Gafchromic films (under the vial). 
The TLDs, OSL nanoDot® and films were removed from the sample vials at different 
time points as presented in Table 6-1.  
Table 6-1. Time points that the TLDs, OSL nanoDot® and films were removed 
from sample vials 1 to 5.
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6.3 Results  
The results for the formation of the AuHgNPs after long irradiation with thermal 
neutrons (؄ 0.025 eV)are presented below. The gamma spectrum was taken after 
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containing 
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RTQA2-
1010 film
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sufficient decay time for the sample to be handled (approximately 96 hours, because of 
the high activity following removal from the reactor) and confirms the presence of the 
main 198Au peak at 412 keV due to gamma-decay, and the minor peaks at 676 keV and 
approximately 1088 keV as indicated in Figure 6-10.  Additional peaks in the spectrum 
indicate the presence of contaminant isotopes, mainly silver and iridium, which are 
lower in intensity, and concentration, and have shorter half-lives than the Au peaks of 
interest.  
Figure 6-10. The sample after long irradiation showing the presence of 198Au 
(indicated) which decays via gamma and beta emissions to 198Hg.
6.3.1 ICP-MS and formation of AuHgNPs (long irradiation) 
After thermal neutron bombardment the samples were digested in strong acid to 
release the mercury isotopes from the sample matrix (Section 6.2.3), for detection by 
ICP-MS.  Three samples containing 1, 2 and 3 mL of the digested product were 
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analysed, and the amount of 198Hg isotope present in each sample determined. The 
detection of the naturally more abundant mercury isotope 202Hg was also examined and 
the results are presented in Table 6-2.  
Table 6-2. The results for the three samples of AuHgNP product formed after long 
neutron irradiation of the AuNP starting material, showing the detection of the two 
isotopes 198Hg and 202Hg by ICP-MS.  
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The ratio of the 198Hg isotope and the ICP-MS internal standard (209Bi) in counts 
per second (CPS) are plotted against the concentration (ppb) and shown in Figure 6-11. 
Figure 6-11. Plot showing the increasing concentrations of 198Hg in samples 1 to 3 
(after long thermal neutron irradiation and acid digestion) as detected by ICP-MS 
(mercury standards are at 0 and 50 ppb).
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The non-irradiated AuNP starting material was also analysed for the presence of 
the 198Hg and 202Hg isotopes. From a stock sample solution containing 70 mg of AuNPs 
in 10 mL HNO3, three samples of 1, 2 and 3 mL were removed and made up to 10 mL 
with Milli Q water and analysed, the results are shown in Table 6-3. 
Table 6-3. The results for the starting material AuNP (non-irradiated) samples analysed 
by ICP-MS for the presence of the two isotopes 198Hg and 202Hg.  
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6.3.2 Gamma decay of 198Au to 198Hg (short irradiation) 
 The gamma decay of 198Au to 198 Hg was measured using three different 
dosimetry methods (Figures 6-9); Gafchromic films (RTQA2-1010 and EBT3), TLDs 
and OSL nanoDots®, and the results are presented below.  
6.3.2.1  Gafchromic film Ȗ-decay response 
Films were collected after 2.5, 4, 6, 8 and 10 hours exposure time to the 
activated samples and scanned in transmission mode, and the results are shown in 
Figure 6-12. 
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Figure 6-12. EBT3 (top) and RTQA2-1010 (bottom) Gafchromic film after exposure to 
the irradiated 198Au samples decaying to 198Hg over time (Note: the RTQA2-1010 film 
was positioned under the EBT3 film and has a fainter response).  
The films were analysed using ImageJ software and a plot profile taken over a 
known distance (where darkening of the film had occurred) for each exposure time. 
Using the plot profiles (Figures 6-13 and 6-15), the maximum possible gray-scale value 
(200) was assigned a ‘0 % dose response’ and the minimum gray-scale value (0) a ‘100 
% dose response. A dose-response percentage (%) was then determined for each plot-
profile using the gray-scale value at each peak minima (Figures 6-13) and plotted 
against the exposure time (Figures 6-14 and 6-17). 
2.5 h 4.0 h 6 h 8 h 10 h
RTQA2-1010 
EBT3
4.0 h2.5 h 6 h 8 h 10 h
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Figure 6-13. Analysis of the EBT3 films after exposure to 198Au, showing an increase 
in the dose response value (%) with increasing exposure time to the ࢽ-decay of 198Au.  
Figure 6-14. The dose response (%) determined for EBT3 films versus the length of 
time of exposure to the ࢽ-decay of 198Au. 
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Figure 6-15. Analysis of the RTQA2 films after exposure to 198Au, showing an increase 
in the dose response value (%) with increasing exposure time to the ࢽ-decay of 198Au.  
Figure 6-16. The dose response (%) determined for RTQA2 films versus the length of 
time of exposure to the Ȗ-decay of 198Au. 
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6.3.2.2  OSL nanoDot® gamma decay response 
Results for the OSL nanoDots® were obtained by placing one on each lid of the 
sample vials (Figure 6-9), which were removed after 2.5, 4, 6, 8 and 10 hours exposure 
time, and plotted against the determined dose (mGy) received (Figure 6-17).
Figure 6-17. Plot of the OSL nanoDot® response to the Ȗ-decay of the samples from 
198Au to 198Hg over time.  
6.3.2.3  TLD gamma decay response 
The TLDs were positioned on either side of each sample vial, and the dose 
received determined for each TLD, which was averaged and plotted against the 
exposure time (Figure 6-18).  
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Figure 6-18. Plot of the TLD response to the Ȗ-decay of the samples from 198Au to 
198Hg over time.  
6.4 Discussion 
 In this section, the analysis of both the BiMetNP product and AuNP starting 
material by ICP-MS is examined, and the results for the detection of the gamma-decay 
of the unstable 198Au isotope following neutron capture. 
6.4.1 ICP-MS analysis of AuHgNPs  
The ICP-MS confirmed the presence of the 198Hg isotope (Table 6-2 and Figure 
6-11) following neutron bombardment. The high R2 value; 1.000 is reflective of the 
good linearity between the ratio of CPS for the 198Hg atoms present versus the ICP-MS 
internal standard (209Bi) and the concentration (ppb) of the isotope present in each 
sample. Clearly evident is the increase in 198Hg concentration as the sample volume also 
increases; 19.443 ppb (sample 1, 1 mL) to 142.519 ppb (sample 3, 3 mL) and the CPS 
ratio of 198Hg to standard 209Bi; 0.017 (sample 1) to 0.125 (sample 3).  
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No such increase in the concentration of the naturally more abundant 202Hg 
isotope was evident, with levels remaining consistent (approximately 1 ppb) for all 
three samples (Table 6-2). These results confirm that the higher 198Hg concentrations in 
the product material (AuHgNPs) can only be due to successful neutron capture 
occurring, and not natural occurrences. 
To further confirm that neutron capture had occurred, the un-irradiated AuNP 
starting material was also analysed and the initial amount of 198Hg isotope present in the 
sample determined. The AuNP starting material (70 mg) was dissolved in HNO3 (10 
mL), and three samples of 1, 2 and 3 mL volumes removed and made up to 10 mL with 
Milli-Q water. Despite using a larger mass of the AuNP starting material (70 mg 
compared to 26 mg of the irradiated product) the ICP-MS analysis (Table 6-3) 
confirmed that all three samples contained much lower levels of the  198Hg isotope 
(approximately 0.3 ppb), compared to that detected for the BiMetNP samples 
(approximately 19 to 143 ppb) (Table 6-2). 
Overall the ICP-MS results confirmed the formation of the 198Hg stable atom 
resulting from the decay of 198Au, and that thermal neutron capture had occurred. 
Furthermore, these results support the use of this method as a viable alternative for the 
synthesis of BiMetNPs.  
6.4.2 Gamma decay
 The gamma energy spectrum of the activated AuNPs was measured by a 
germanium/lithium Ge(Li) detector, with a calibrated multi-channel analyser, and a 
typical spectrum is displayed in Figure 6-10. From the spectrum the dominant gamma-
emissions come from the activated 198AuNPs, with some additional smaller contaminant 
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peaks present; mainly silver and iridium. However, these products are of lower intensity 
and concentration, and have shorter half-lives, meaning that their contribution to this 
analysis is low. The gamma decay of 198Au to 198 Hg was measured over time using 
three different dosimetry methods and is discussed below.  
6.4.2.1  Gafchromic film response 
Both films (Figures 6-12) showed a clear darkening over time when exposed to 
the activated samples, indicating gamma-emission detection. Analysis of the films 
yielded plot profiles (Figures 6-13 and 6-15), which gave a dose response (%) for each 
time point investigated, which was plotted against the exposure time (Figures 6-14 and 
6-16). Both films yielded high regression values (R2), with a higher dose response (%) 
evident for the EBT3 film (and more visual darkening) (Figure 6-13) compared to the 
RTQA2-1010 film (Figure 6-15). Interestingly, the RTQA2 film had a slightly higher 
R2 value (0.936) compared to the EBT3 film (0.911) despite emissions having to pass 
through the sample vial container and the EBT3 film above it, and may be indicative of 
its higher sensitivity to low-doses. 
Overall the good agreement between the films highlights that low-level gamma 
emissions are detectable and deliver dose from the decaying 198Au sample. This is 
advantageous for any potential future use of the decay process for either gamma-
imaging or as a brachytherapy type source for additional dose deposition within a 
tumour (numbers 1 and 2 in Figure 6-4). It should be noted that the films used in this 
study are designed for dosimetry and radiotherapy usage, and not imaging, meaning that 
the gamma-emission levels detected were relatively high. Given that the films are not 
energy dependent, other gamma-emitters have also contributed to the measured dose 
determined (Figure 6-11), however their contributions are low. 
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6.4.2.2  OSL nanoDot® response 
Using OSL nanoDots® positioned on the sample lid (Figure 6-9) measurements 
were taken after 2.5, 4, 6, 8 and 10 hours exposure time. A linear response was obtained 
for the dose received (mGy) versus the exposure time, with a R2 value of 0.908 (Figure 
6-17), which is comparable to the EBT3 Gafchromic film (0.911), suggesting that this 
method is also a reliable means of detecting gamma emissions from the decaying 198Au 
sample. 
6.4.2.3  TLD response 
The response of the TLDs (two per sample) (Figure 6-18) showed good 
agreement between the readings for dose received (Gy) versus the exposure time, with a 
high R2 value; 0.911, which is comparable to the film and OSL values. Therefore, TLDs 
are also an adequate means for detecting gamma emissions, with all three methods 
confirming a linear dose response over time.  
6.5 Conclusions 
An alternative method for the production of BiMetNPs was successfully 
completed by thermal neutron bombardment of the starting monometallic-nanoparticles 
(AuNPs) to produce the stable AuHgNPs. This method is advantageous as current wet-
chemistry methods are limited in their ability to produce BiMetNPs consisting of two 
different metals present as an alloy, and therefore, expands on the current means 
available. The presence of the 198Hg isotope in the product material was confirmed by 
ICP-MS, and the decay process of the unstable isotope 198Au to the stable 198Hg (via 
gamma emissions) was successfully measured using three different detection systems; 
Gafchromic films (EBT3 and RTQA2), OSL nanoDots®, and TLDs. All three methods 
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showed good linear responses with high regression values, and highlights the potential 
future use of the decay process of the unstable 198Au isotope as a theranostic agent; 
providing both gamma-emission imaging and brachytherapy dose deposition (i.e. 
therapeutic benefit). As well, the BiMetNP (AuHgNP) product offers an additional 
target for external radiotherapy, and may also act chemically and biologically to 
damage tumour cells. 
210 
Chapter 7: Conclusions and future 
directions 
7.1 Conclusions 
The work undertaken in this thesis and the results generated are both novel and 
innovative, and provide greater insight into key areas of radiotherapy research. This 
thesis has focused on five main areas with the aims and findings summarised below: 
7.1.1 Chapter 2- Dose enhancement due to AuNP size, concentration 
and beam quality 
This chapter focused on the effects of smaller sized AuNP sizes, mainly due to 
the limited amount of current research examining this size range, and the AuNP sizes 
that were available for use and their cost. The effects of AuNP size and concentration 
when irradiated with different beam types (X-ray, protons and electrons) and the DE 
levels achieved were investigated, with a strong emphasis on proton irradiations. The 
use of proton therapy beams has increased worldwide over the last decade and been the 
focus of much research due to the unique energy deposition profile. However, 
conflicting reports on the DE levels obtained when irradiating AuNPs between 
animal/cell studies and computer simulations was of interest, and was the main focus of 
this work. Using an experimental approach, whereby; AuNPs were embedded within 
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the dosimeter alanine, the DE levels were directly related to the amount of alanine 
radicals formed, which was analysed by EPR analysis.  
The main findings of this work were: 
 Low energy X-rays (80 kV) yielded the highest overall DE levels, which were 
linearly dependent on AuNP concentration (3, 2 and 1 %), with the highest AuNP 
concentrations (3 %) yielding the highest DE levels. As well, the smallest AuNP 
size (1.9 nm) yielded the highest DE levels (which is consistent with having a larger 
surface area). All findings were in agreement with recent Monte Carlo simulations 
[89, 99, 101]. However, as only a few sizes were examined, and the 15 nm AuNP 
size gave larger DE levels than the 5 nm AuNP, further investigations using more 
sizes are needed to determine the causes of this result.  
 For MV X-ray irradiations of AuNPs DE levels also showed a clear dependence on 
AuNP concentration, although this was not as high as those observed for kV X-rays 
due to the increased dominance of Compton interactions at this energy range, and 
was in agreement with literature reports. Similar to the kV X-ray irradiations, the 
smallest AuNPs (1.9 nm) yielded the highest DE levels, followed by the 15 nm and 
5 nm AuNPs, however, the responses were not as clear as the effects of AuNP 
concentration, and was in agreement with recent computer simulations [92, 98]. 
 The DE results for electron and proton irradiations of AuNPs showed no 
dependence on AuNP concentration or size, and agreed well with published cell 
studies using electron beams, and proton simulation data [24, 79, 81, 102]. These 
results suggest that the much larger DE results observed for proton irradiation of 
AuNP loaded tumours in cell and animal studies was not mainly due to an increase 
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in the yield of radical species. Therefore, it is likely that other biological and 
chemical processes are occurring, such as, AuNP catalysis and the formation of 
reactive species (including ROS), which are not accounted for in computer 
simulations or the experimental design used in this work. More recently, there has 
been an increase in studies reporting these types of interactions as possible causes 
for the greater radiosensitization observed in cell/animal studies when irradiating 
AuNPs with high LET beams [90, 108, 109]. Therefore, for high-energy proton 
beams the recent Monte Carlo simulations provide a good estimate of the enhanced 
radical yield following addition of AuNPs to alanine. 
 Finally, it can be concluded that alanine dispersed in wax can be used effectively as 
a phantom/dosimeter for all radiation types used in radiotherapy including protons. 
This work also presented a novel means to experimentally determine the DE caused 
by secondary electron emissions from AuNPs by impregnating them within the 
‘reporter’ dosimeter alanine.  
7.1.2 Chapter 3- Examination of the novel dosimeter 
IRGANOX®1076
The work undertaken in this chapter helped to improve the current knowledge 
about the novel EPR-dosimeter IRGANOX®1076 and highlighted some of its 
advantages for potential use in radiotherapy. The manufactured IWSS pellets yielded a 
single EPR peak due to the formation of the phenoxyl radical, and were of sufficient 
sensitivity for dose quantification over the range of 2 Gy to 20 Gy for all radiation 
beams investigated (kV & MV X-rays, electron and protons). Furthermore, the use of 
IRGANOX®1076 is advantageous due to its simple EPR spectrum, good long term 
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post-irradiation signal stability, tissue equivalence, low toxicity, low cost, and high wax 
solubility, meaning it can be moulded to any shape and size dosimeter required.  
The major findings were: 
 The IWSS pellets gave a linear dose response for all types of radiation examined, 
which was LET independent in the MV energy range and for electron and proton 
beams, and energy-dependent in the kV X-ray ranges.
 Irradiations of the IWSS pellets yielded the highly stable phenoxyl radical as an 
EPR singlet, due to complete hydrogen abstraction. Previous work by other groups 
[120] had incorrectly identified the EPR-doublet signal as the phenoxyl radical, 
however, this work conclusively showed that the doublet signal is in fact due to the 
formation of the phenol cation radical, obtained by electron loss following 
irradiation of the crystalline solid. 
 Post-irradiation EPR measurements of the proton irradiated samples, stored in the 
dark and at room temperature, showed good signal stability with minimal signal 
fading (between 1.6 to 3.8 %) up to 77 days post-irradiation. However, after 466 
days post-irradiation, signal fading was apparent, and highlighted the need for 
controlled storage conditions (temperature and humidity) to reduce the effects of 
signal fading for long-term measurements.
 The wax used to manufacture the IWSS pellets was found to be an ideal supporting 
medium in which IRGANOX®1076 completely dissolved. Under these 
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circumstances a single EPR singlet was observed which, unlike alanine, has an 
intensity independent on the orientation of the sample within the EPR cavity. 
 The EPR signal intensity of the IWSS pellets was comparable to alanine-wax pellets 
containing the same amount of dosimeter material (w/w), whilst the shortcomings 
associated with the use of alanine in dosimeters (sensitivity at low dose, 
reproducibility of EPR spectra, multiple radical species, hydrophilicity, angular 
dependence of the EPR spectra) are either substantially or completely eliminated in 
the case of IRGANOX®1076.  
7.1.3 Chapter 4- A Comparison of the EPR angular response of 
alanine and IRGANOX®1076 
As alanine is highly hygroscopic, air moisture can promote post-irradiation 
radical transformations, and consequently alter the resonance within the EPR cavity. 
Both these effects can cause changes in the amplitude of the EPR central peak, and 
influence measurement reliability. Therefore, this work examined the angular response 
of alanine encased within wax as a means to reduce these effects. The alanine-wax 
samples were compared with alanine powder samples (in capsules), commercially 
available alanine pellets and IRGANOX®1076 powder samples also encased within 
wax. All samples were measured over the same time intervals post-irradiation (3 and 30 
days) and multiple measurements at different angles within the EPR cavity taken.  
The major findings of this work were: 
 Dispersing alanine powder within wax, so that the wax is the bulk component of the 
pellet helped to physically protect the alanine from external water and reduce its 
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EPR angular response.  
 At 3 days post-irradiation deviation ranges for the alanine-wax pellets were low, 
and comparable to the values obtained for commercially manufactured alanine 
pellets (where alanine is the bulk component).  
 After 30 days post-irradiation the protection provided by the wax pellets to alanine 
was more evident, with the deviation ranges remaining largely unchanged to that at 
3 days post-irradiation. Conversely, deviation ranges for the commercial pellets had 
nearly doubled, despite being stored in controlled conditions (at reduced 
temperature and humidity).  
 Investigations of the wax pellets containing alanine that were manufactured more 
than eight months prior showed a high angular dependence at 3 days post-
irradiation, suggesting environmental water contamination had occurred. This result 
highlighted the importance of using the samples within a reasonable time frame 
after manufacture and storing the samples in a controlled environment (with 
humidity and temperature controlled). 
 IRGANOX®1076 encased within wax (containing w/w the same amount of 
dosimetric material) yielded the lowest angular responses overall. This low response 
was attributed to the hydrophobic structure and the formation of a single radical 
species when irradiated. 
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7.1.4 Chapter 5- Investigation of the novel method ‘spiking’ to 
determine low doses (< 2 Gy) using alanine dosimeters 
The spiking method detailed in this chapter allows for doses  1 Gy to be 
reliably detected by alanine dosimeters, and overcomes the current limitations that 
hinder its use in radiotherapy. This work allows for alanine dosimeters to be used in a 
far wider range of applications in radiation dosimetry, particularly for the low doses 
often relevant for clinical applications.  
The major findings of this work are: 
 The addition of a spike dose increases the alanine dosimeters EPR signal making it 
easily detectable to an X-band EPR instrument.  
 After the addition of a second low dose, the spike signal can be subtracted from the 
total signal (spike + low dose) and the low-dose reliably determined. Either the 
amplitude or single integration of the central alanine peak P1 can be used for 
quantification, with both capable of quantifying doses of 0.5 Gy.  
 The advantages of the spiking method are that no foreign materials are added to the 
alanine dosimeters, thus tissue equivalence is maintained, the EPR signal to noise 
ratio is improved, and baseline distortions typical at low doses are removed due to 
the large spike dose given.  
 Furthermore no complex EPR post-analysis is required and this method can be 
performed on any standard X-band EPR spectrometer. 
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7.1.5 Chapter 6- The formation of bimetallic-nanoparticles by neutron 
capture 
An alternative nuclear method for the production of alloy-type BiMetNPs was 
successful, whereby, the target product (AuHgNPs) was formed by neutron activation 
of the starting metallic-nanoparticles (AuNPs). The decay of the unstable 198Au isotope 
was successfully monitored over time. 
The major findings of this work were: 
 Thermal neutron activation resulted in the formation of the unstable 198Au isotope. 
 Decay of the unstable 198Au isotope yielded the stable AuHgNP product containing 
the mercury isotope 198Hg, which was confirmed by ICP-MS.  
 An increase in the concentration of the 198Hg isotope was consistent with an 
increase in the sample size analysed by ICP-MS. However, this was not so for the 
naturally more abundant 202Hg isotope, which can only occur due to neutron capture 
during the irradiation process.  
 The gamma decay of 198Au to 198Hg was successfully measured using Gafchromic 
films (EBT3 and RTQA2), OSL nanoDots® and TLDs which yielded linear 
responses over time.  
7.1.6 Summary 
Overall the work undertaken in this thesis adds to the current knowledge of the 
interactions between AuNPs and commonly used radiotherapy beams, and the levels of 
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DE due to the production of secondary electrons. The novel method of neutron 
activation of AuNPs has been shown to occur and the target BiMetNP alloy product 
formed. This provides a viable alternative to the wet-chemistry techniques currently 
used for BiMetNP production. Furthermore, a novel technique (spiking) to improve the 
sensitivity of alanine dosimeters for possible use in radiotherapy (for doses of less than 
5 Gy) was investigated and shows potential to develop the current application of alanine 
dosimeters, as well as, the use of wax-encasement to reduce the EPR angular response 
for alanine samples. Also, the novel dosimeter IRGANOX®1076 shows much promise 
for use in radiotherapy, with good signal stability and response to different quality 
beams within radiotherapy dose ranges. Though limitations in this work due to funding, 
material availability and access to irradiation facilities have prevented more extensive 
studies being carried out, many key findings have been explored, offering an array of 
areas for future investigations, which are discussed below. 
7.2 Future directions 
Based on the results determined in the five key areas of research undertaken, 
possible future directions and areas of extended research are presented below. 
7.2.1 Chapter 2- Dose enhancement due to AuNP size, concentration 
and beam quality 
The use of alanine as a dosimeter embedded with AuNPs in wax provided a 
reliable means to determining the DE levels with varied AuNP size and concentration, 
as well as the irradiation beam type used. However, the AuNP size results for kV and 
MV x-ray irradiations showed a DE level preference for 1.9 nm followed by 15 nm and 
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finally 5 nm. It is not clear why the 15 nm AuNPs gave a higher DE response than the 5 
nm, warranting further investigation. 
Therefore, two studies are proposed for future work to elucidate this anomaly: 
 To extend the AuNP size analysis by examining a larger size range, ideally 
between 1- 80 nm, which may help to further the understanding between 
AuNP size and DE levels for kV and MV X-ray irradiations. 
 Using the same experimental approach (AuNP embedded in alanine) to 
determine the effects of the AuNPs polymeric capping, which may reabsorb 
ejected electrons and subsequently cause a decrease in the resultant alanine 
EPR signal obtained.  
Another area for potential examination is in proton irradiations, where the DE 
levels obtained showed no clear dependence on AuNP concentration or size. These 
findings strongly suggest that the higher DE levels reported in animal and cell studies 
(using AuNP loaded tumours irradiated with protons) was due to other processes. 
Currently it is thought that AuNPs present in biological systems act to promote/catalyse 
other chemical processes (mainly the formation of ROS), which are responsible for the 
higher efficacy reported.   
Therefore future areas of study could include: 
 To examine the effects on ROS concentrations using various cell types when 
AuNPs of different sizes and concentrations are present, with a focus on 
irradiations with high LET beams.  
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 Also, the effects of the AuNP polymeric capping could be investigated, with 
a focus on how the presence of cationic or anionic groups at the NP surface, 
impacts on ROS production, and cell viability.  
7.2.2 Chapter 3- Examination of the novel dosimeter 
IRGANOX®1076
The IWSS pellets manufactured were of sufficient sensitivity for dose 
quantification over the range 2 Gy to 20 Gy for all radiation beams investigated (kV & 
MV X-rays, electron and protons), and were comparable in their response to alanine. 
Therefore, other possible future directions for investigation are:  
 Irradiation measurements using other beam types, particularly high LET 
beams, such as neutrons and carbon ions, would be of interest as these are 
growth areas for future radiotherapy treatments. 
 Further optimization of the EPR settings is needed, as this may further 
extend the dose range below 1 Gy. 
7.2.3 Chapter 4- A Comparison of the EPR angular response of 
alanine and IRGANOX®1076 
Dispersing alanine powder within wax, so that the wax is the bulk component, 
helped protect the alanine from external water diffusion, which also reduced its EPR 
angular response. This work indicated that the alanine-wax pellets could be stored for 
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more than three months post-irradiation in conditions where the humidity and 
temperature were not controlled, without affecting the EPR angular response. 
Further areas of work and investigation include: 
 Investigating the possibility of using commercial alanine pellets coated in a 
layer of wax to see if this helps to reduce the effects of angular response 
post-irradiation. If successful, it would be a quick and reliable means to 
reduce the effects in commercially available alanine pellets and remove the 
need to average several EPR cavity measurements. 
 The lower EPR angular response for IRGANOX® 1076 is possibly due to 
its hydrophobic structure, which reduces its water content, and therefore its 
effects on the resonance within the EPR cavity. Similarly, IRGANOX® 
1076 in wax forms a solid solution, which when irradiated yields a single 
radical species, therefore radical transformations do not occur. These 
properties are not shared by alanine, which is highly hygroscopic and forms 
three radical species, which can undergo transformations post-irradiation. 
Therefore, future work could examine the importance of these properties 
further by analysing the water content of IRGANOX® 1076 and alanine 
samples and how it affects the angular response over time. Repeating this 
work with more samples and measurements may yield a statistically 
significant result in favour of IRGANOX® 1076 over alanine. 
 IRGANOX®1076 showed the same decrease in radical yield for kV X-ray 
irradiations as does alanine, which may be reflective of another process 
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occurring that is not evident in the other irradiations completed. It was 
thought that bond-dissociation energy differences needed to form the 
dosimeter’s radical species; -O-H for IRGANOX®1076 compared to -C-H 
for alanine may be a factor. As there is no literature information regarding 
this further investigation is warranted. 
7.2.4 Chapter 5- Investigation of the novel method ‘spiking’ to 
determine low doses (< 2 Gy) using alanine dosimeters 
The spiking method allowed doses of  2 Gy to be reliably detected using 
alanine dosimeters; the method is advantageous as it is easy to perform, does not 
modify the chemical composition of alanine or require changes to the EPR 
spectrometer.  
Future work to be completed would be: 
 Repeat studies of the method to further validate its use as a reliable protocol. 
 To determine the effects of the spike dose size upon sensitivity. Doses of 20 
Gy and 30 Gy were employed as baseline distortions at less than 10 Gy are 
known to affect measurements of the central alanine peak’s amplitude, 
therefore, the spike size may be of importance and an optimum spike dose 
could be determined.  
 Optimisation of the EPR spectrometer conditions needs investigation, as this 
too could increase the sensitivity and reliability of the method, and help 
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further reduce the lower limits of detection. 
 To further validate the method, the use of more calibration pellets (from 
which an average is used) would improve the statistical strength of the 
method and may also improve the lower limits of detection. 
7.2.5 Chapter 6- The formation of bimetallic-nanoparticles by neutron 
capture 
Using neutron capture the BiMetNP product; AuHgNP was successfully 
produced from the AuNP starting material, and the gamma decay of the unstable 198Au 
isotope to the stable 198Hg successfully measured. 
Future work in this area could focus on the following: 
 To examine and measure the biological effects of AuHgNPs on cells; such 
as cell viability and toxicity measurements. This would be beneficial, 
particularly, as mercury is known to induce oxidative stress on cells. 
 Following neutron capture, the beta and gamma-decay of the 198Au isotope 
to the 198Hg could be used as an imaging agent; therefore further assessment 
is needed. Furthermore, as the decay process also has a therapeutic benefit, 
cell studies to determine the extent of this dose deposition is of interest. 
 Irradiations of AuHgNPs using therapeutic beams and the DE levels 
obtained would also be of interest as the product could provide an additional 
target in treatment.
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